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Abstract 
The use of cardiovascular magnetic resonance (CMR), particularly in the cardiovascular 
research setting, has grown exponentially in the past 20 years. While CMR is increasingly 
used in clinically, it has yet to be incorporated into routine clinical practice and guidelines 
in the majority of conditions. One of the main reasons for this is the relative paucity of 
evidence for its diagnostic and prognostic utility and cost-effectiveness compared to more 
established non-invasive imaging techniques such as echocardiography and nuclear 
imaging. For CMR to become part of routine clinical care, more evidence of its utility is 
required. 
 
The overall aim of this thesis was to demonstrate the clinical utility of CMR by using it to 
examine 5 clinical questions that pose a relevant dilemma to physicians in a cohort of 
patients referred for clinically indicated CMR studies. 
 
CMR has two major advantages over transthoracic echocardiography, the most commonly 
used technique in our centre (and in most worldwide). Firstly, it is the gold standard for 
assessment of left ventricular volumes and function, and secondly, it has the ability to 
characterise the myocardium using specific imaging sequences and intravenous gadolinium 
contrast (known as late gadolinium enhancement ± LGE). The first study in this thesis 
explored the potential benefit of a CMR protocol using these benefits to predict prognosis 
in an unselected cohort of patients. In this study I found that the assessment of myocardial 
function using ejection fraction and deformation imaging (strain) and assessment of the 
presence of fibrosis using LGE had incremental prognostic significance in addition to 
clinical predictors of outcome in all patients, including in those with ejection fractions 
greater than 35% (commonly thought to be patients at lower risk of adverse events). 
 
During scanning of this cohort of patients, it became apparent that CMR imaging of 
myocardial scar in patients with a history of prior myocardial infarction (MI) had the 
ability to identify fat within the infarcted territory, known as lipomatous metaplasia, which 
had been recognised pathologically but is not identified by echocardiography. The tissue 
characterisation ability of CMR has for the first time allowed this to be identified non-
invasively ante-mortem. Pathological studies had suggested that lipomatous metaplasia 
was associated with adverse remodeling, while recent animal studies had suggested that the 
presence of myocardial fat within infarcts was pro-arrhythmogenic. In this study I showed 
that the presence of lipomatous metaplasia was indeed independently associated with 
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mortality and ventricular arrhythmias, suggesting that it perhaps provides an 
arrhythmogenic substrate. 
 
The next study explored the use of LGE in addition to established clinical markers in 
patients undergoing implantable cardioverter-defibrillator (ICD) implantation for 
ischaemic or dilated cardiomyopathy. These patients met the current clinical criteria for 
ICD implantation and also had testing of NT-proBNP, a marker of cardiac strain that is 
associated with adverse prognosis. The patients all underwent pre-implantation CMR. I 
found that the presence of LGE and a high NT-proBNP was associated with a higher risk 
of death and ICD activation, perhaps hinting at a role for CMR in providing further risk 
stratification in this group of patients. 
 
Following on from this, I looked at the diagnostic capabilities of CMR. Characterisation of 
patients with mildly impaired left ventricular systolic function is important as early 
identification of cardiomyopathy can potentially allow early institution of life-saving 
therapies. Mild left ventricular impairment can however also be associated with the normal 
myocardial adaptaWLRQV WR H[HUFLVH NQRZQ DV DWKOHWH¶V KHDUW 7KLV SRVHV D GLDJQRVWLF
dilemma, which may not be easily solved using current imaging techniques. I found that 
the use of a further CMR parameter to characterise tissue, T1 mapping, was able to 
discriminate between patients with early DCM and exercisers with normal physiological 
myocardial adaptation, perhaps providing a solution to this diagnostic challenge. 
 
The final study explored the utility of dobutamine stress CMR (DSCMR) to diagnose 
significant coronary artery disease (CAD) in patients with left bundle branch block 
(LBBB) and clinically suspected CAD. CAD is the most common cause of LBBB, yet 
LBBB causes myocardial abnormalities that can make it difficult diagnose CAD non-
invasively, leading many patients to be referred for invasive coronary angiography (ICA) 
to confirm the diagnosis. Despite this, a substantial proportion of the patients with LBBB 
will not have significant CAD, meaning that ICA would be unnecessary. This study 
compared DSCMR with dobutamine stress echocardiography, with ICA as the gold 
standard. I found that DSCMR was significantly more accurate in diagnosis than 
dobutamine stress echocardiography, perhaps providing a technique that could be used as a 
gatekeeper to ICA. 
 
This thesis shows that CMR can provide important diagnostic and prognostic information 
in a variety of cardiac conditions and can potentially help guide clinical decision-making. 
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Larger studies should be performed to confirm these findings, allowing for determination 
of cost-effectiveness and incorporation of CMR into routine clinical management. 
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

Cardiovascular disease (CVD) is a major health burden in the modern era. Increasingly, 
non-invasive imaging techniques are being used to provide diagnostic and prognostic 
information that can be used clinically to impact patient management. Cardiovascular 
magnetic resonance imaging (CMR) is still a relatively new method of non-invasive 
cardiac investigation, but its value is being increasingly recognised. Nevertheless, it does 
lack some of the levels of evidence that other, more established, methods such as 
echocardiography and nuclear imaging have. In this chapter, I shall provide some 
background to investigation of CVD, before providing more details about CMR. Finally, I 
shall review the current evidence regarding the clinical use of CMR. In the following 
chapters, I aim to use CMR to answer important clinical questions that underline the 
clinical utility of CMR.

²

Cardiovascular disease is a term that covers all disease relating to the heart and vascular 
system and is a major cause of morbidity and mortality throughout the world. Recognised 
as a cause of disease throughout history, including by Leonardo da Vinci and William 
Osler, it has been noted even in the mummified bodies of Egyptian pharaohs (Allam et al., 
2009). The commonest CVD conditions are coronary artery disease (CAD) and stroke. In 
2010, almost 180,000 people in the UK died of CVD, and over 80,000 died of CAD ± the 
biggest single cause of death in the UK (Townsend N, 2012). Despite an improvement in 
the CVD mortality in the UK, death rates still remain high compared to other Western 
European countries. In Scotland, the age-standardised death rate from CVD in 2010 was 
126.7/100,000 for males and 68/100,000 for females.  
 
The commonest causes of CVD morbidity include ischaemic heart disease (IHD) ± 
encompassing myocardial infarction (MI ± 2009 Scottish incidence 255/100,000 in males, 
113/100,000 in females) and angina (48.6/100,000 in males, 37.7/100,000 in females) - 
and heart failure (HF ± 2011 incidence 49/100,000 in males, 29.6/100,000 in females). 
 
CVD encompasses a wide range of conditions, and classification into different types can 
be done in numerous ways, for example, classifying CVD as congenital or acquired, or 
ischaemic and non-ischaemic. Perhaps the most structured but broad method is that 
Chapter 1: Introduction 
 
 21 
proposed by the World Health Organization (WHO) in their International Statistical 
Classification of Diseases and Related Health Problems 10th Revision (ICD-10) which 
essentially divides CVD into 9 categories (table 1.1) (Organization, 2010). 
  
Chapter 1: Introduction 
 
 22 
Table 1-1. WHO ICD-10 Classification of Cardiovascular Disease (IX ± Disorders of 
the Circulatory System) 
 
Code Group Example sub-categories 
I00-I09 Rheumatic diseases Acute rheumatic fever 
Chronic rheumatic heart 
disease 
I10-I15 Hypertensive heart 
disease 
Essential hypertension 
Secondary hypertension 
Hypertensive heart disease 
I20-I25 Ischaemic heart disease Angina pectoris 
Unstable angina 
Acute MI 
Ischaemic cardiomyopathy 
I26-I28 Pulmonary vascular 
disease 
Pulmonary embolism 
Pulmonary hypertension 
I30-I52 Other cardiac disease 
 
 
Pericardial disease 
Endocarditis 
Valvular heart disease (non-
rheumatic) 
Myocarditis 
Cardiomyopathies 
Heart failure 
Arrhythmias 
I60-I69 Cerebrovascular disease Cerebral haemorrhage 
Cerebral infarction 
I70-I79 Arterial/capillary disease Atherosclerosis 
Aortic aneurysm 
Peripheral vascular disease 
I80-I89 Venous disease Deep vein thrombosis 
I95-I99 Other Hypotension 
 
Many of these conditions are encountered by and dealt with by cardiologists. Notably, 
congenital heart conditions are classified separately (with other congenital diseases), 
perhaps reflecting their specialist nature. 
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CVD accounts for a large proportion of all hospital activity. In 2009-2010, over 90,000 
admissions to hospital in Scotland were due to heart disease specifically (Scotland, 2012) 
and total spending on cardiology services was £146 million, a 50% real-terms increase 
since 2002. 
 
Given the burden in mortality and morbidity, as well as the cost of CVD, timely diagnosis 
and intervention is paramount. 
 



 
Following the initial evaluation of the patient by taking a detailed history (identifying the 
SDWLHQW¶VFXUUHQWLVVXHVULVNIDFWRUVHWFDQGH[DPLQDWLRQWKHQH[WVWHSLVXVXDOO\GLUHFWHG
to investigations in order to arrive at a diagnosis and formulate an appropriate management 
plan. Cardiac investigations can be divided into 2 categories ± invasive and non-invasive 
(figure 1-1). 
 
Figure 1-1. Cardiac Investigations 
 
 
In 1992 Fryback and Thornbury described the hierarchical model of diagnostic efficacy 
which defines six levels of evidence to underscore the use of diagnostic techniques as 
follows (Fryback and Thornbury, 1991): 
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1. Technical efficacy: These studies are commonly case reports or small case series 
that describe the methodology of the technique and seek to refine it. 
2. Diagnostic accuracy efficacy: These studies seek to determine the diagnostic 
accuracy of the technique, for example sensitivity and specificity. 
3. Diagnostic thinking efficacy: Studies in this category aim to help the referring 
clinician decide in which patient population the technique might have most benefit, 
for example whether to use the test in a low or high-risk population. 
4. Therapeutic efficacy: These studies simply ask the question: does doing the test 
change patient management? Levels 2-4 can be combined as clinical efficacy 
measures. 
5. Patient outcome efficacy: Do the benefits to the patient of the procedure outweigh 
the risks? Measures can include quality of life and cost. 
6. Societal efficacy: Do the benefits of the procedure outweigh the costs to society? 
 
All of the investigations listed in figure 1-1 have large amounts of evidence to support their 
use, although (as one would expect), the older techniques such as cardiac catheterisation, 
echocardiography and SPECT have the most evidence behind them and numerous studies 
at levels 5 and 6, while newer techniques such as CT, CMR and PET remain at levels 2-4. 
 


The commonest invasive cardiac investigation is cardiac catheterisation. Over 15,000 
procedures are carried out each year in Scotland (Scotland, 2012). Cardiac catheterisation 
was first developed by Forssmann in 1929 who cannulated his antecubital fossa, guided a 
catheter up to his right atrium by fluoroscopy and took an X-ray to confirm the procedure. 
Following refinements to the procedure over the next decade, Forssmann was awarded the 
Nobel Prize for Physiology and Medicine in 1958 (along with Andre Cournand and 
Dickinson Richards) (Heiss, 1992). Cardiac catheterisation is actually two different 
procedures ± left heart catheterisation, commonly carried out to assess the coronary arteries 
by angiography, and right heart catheterisation, which is usually conducted to assess 
cardiopulmonary haemodynamics in the setting of valvular heart disease, pulmonary 
vascular disease or congenital heart disease. Both techniques are carried out using local 
anaesthetic before cannulation of the required vessel ± for left heart catheterisation this an 
artery (radial or femoral artery) while for right heart catheterisation the venous system is 
used (usually via the femoral vein). Catheters are then passed up to the heart using 
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fluoroscopic guidance. In left heart catheterisation the coronary arteries are selectively 
cannulated and contrast injected to identify the presence of significant CAD. Balloons and 
stents can then be introduced during the procedure (known as angioplasty) in order to fix 
flow-limiting stenoses. 
 
Figure 1-2. Invasive Coronary Angiography 
 
Invasive coronary angiogram showing a flow-limiting stenosis in the left anterior 
descending artery (arrow). 
 
A large amount of level 6 evidence exists to support the use of invasive coronary 
angiography (ICA) and it is now a standard recommendation in numerous guidelines 
including in the setting of ST elevation myocardial infarction (Steg et al., 2012), non-ST 
elevation myocardial infarction (Hamm et al., 2011) and stable angina (Montalescot et al., 
2013) amongst others. Adjunctive diagnostic tools can be added to ICA including pressure 
wire assessments (e.g. fractional flow reserve - FFR) to assess the significance of coronary 
stenoses (De Bruyne et al., 2012) and intracoronary imaging such as intravascular 
ultrasound (Parise et al., 2011) and optical coherence tomography (Bezerra et al., 2013). 
 


The ECG is the most basic and widely available non-invasive cardiac investigation. Waller 
recorded the first ECG in 1887, consisting of only 2 leads (Hurst, 1998), and it has been 
refined over the last century to become the standard 12-lead reading that is in widespread 
clinical use today. Various parameters and abnormalities have diagnostic and prognostic 
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value, and the ECG is an essential first part of the evaluation of any cardiac patient (De 
Bacquer et al., 1998a, De Bacquer et al., 1998b) (figure 1-3). 
 
Figure 1-3. A Normal 12-lead ECG 
 
 
 
The ECG can be taken during exercise (exercise tolerance test ± ETT). Changes during 
exercise can be predictive of the presence of ischaemia caused by significant coronary 
stenoses (Ashley et al., 2000), however its diagnostic accuracy is reduced in women and 
patients with resting ECG abnormalities which can make it difficult to know the 
significance of any exercise-induced changes (Montalescot et al., 2013), thus leading to the 
requirement of other investigations. 
 

 
The echocardiogram (echo) is a non-invasive test that uses ultrasound to image the heart. 
Either a transthoracic echo (TTE) or transoesophageal echo (TOE) can be performed, 
although only the TTE is non-invasive. It is cheap, portable and widely available and 
hence it is often the first investigation performed after the ECG. Using various views of the 
heart, cardiac chamber dimensions, volumes and function can be measured and valvular 
heart disease can be quantified (for which echo assessment is the gold-standard (Vahanian 
et al., 2012)). Left ventricular ejection fraction assessment by two-dimensional 
echocardiography has been shown to be an extremely powerful predictor of adverse 
outcome in several groups of patients, including post-MI (Sutton et al., 1994) and in 
idiopathic dilated cardiomyopathy (DCM) (Likoff et al., 1987). 
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Nevertheless, measurement of ejection fraction using two-dimensional TTE does have 
limitations. Firstly, it is not always possible to obtain adequate views of the heart due to 
patient body habitus or the positioning of the heart behind the ribs. Secondly, the 
measurement technique itself is limited as it relies on an approximation of the true shape of 
the heart. The standard technique used for assessment of left ventricular ejection fraction 
/9() LV NQRZQ DV 6LPSVRQ¶V ELSODQH 7KLV XVHV WKH DSLFDO IRXU-chamber and two-
chamber views of the heart to measure end-systolic and end-diastolic volumes to estimate 
the ejection fraction (figure 1-4). This method is subject to limitations such as the difficulty 
in tracing the endocardial borders of the heart, and in patients with arrhythmias such as 
DWULDOILEULOODWLRQ6LPSVRQ¶VELSODQHWHFKQLTXHLVVXEMHFWWRDVWDQGDUGGHYLDWLRQRIDURXQG
8.5% compared to the true ejection fraction (Otterstad et al., 1997), which can make a large 
difference to the management of patients, for example in patients with severe left 
ventricular systolic dysfunction (LVSD) in whom there are strict criteria, based on LVEF, 
for implantation of potentially life-saving therapies such as implantable cardioverter-
defibrillators (ICDs) (McMurray et al., 2012). 
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Figure 1-7KH6LPSVRQ¶V%LSODQH0HWKRGIRU$VVHVVPHQWRI/9() 
 
 
$VVHVVPHQWRI/9()XVLQJ6LPSVRQ¶V%LSODQH7KHHQGRFDUGLDOERUGHUVDUHWUDFHGLQERWK
end-systole and end-diastole in both 4-chamber (A, B) and 2-chamber views (C, D). 
 
Several techniques for improving the accuracy and reproducibility of LVEF measurement 
using echocardiography have been developed including 3-dimensional echocardiography 
(Jenkins et al., 2004), use of contrast (Olszewski et al., 2007) and deformation imaging 
(Marwick, 2006). Nevertheless, these techniques require more specialist expertise, are not 
as widely available as standard two-dimensional echo, and are still subject to some of the 
same image quality issues are basic TTE (Thomas et al., 2009). 
 

 
Nuclear imaging (in cardiology) is most commonly used for myocardial perfusion imaging 
for the assessment of suspected angina, performed using single photon emission 
tomography (SPECT). A radioactive tracer is administered which is taken up by 
myocardium. Under stress (which can be induced by exercise or pharmacologically) any 
areas of myocardium subtended by ischaemic coronary arteries have reduced blood flow in 
comparison to myocardium supplied by healthy coronary arteries and hence a perfusion 
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defect is seen. One disadvantage of this technique is that (dependent on the tracer) the 
patient may have to return several days later for rest imaging due to the half-life of the 
tracer. SPECT has extremely good diagnostic accuracy for diagnosis of significant CAD 
(Elhendy et al., 2002) as well as being of excellent prognostic value (Hachamovitch et al., 
1998). SPECT can also be used to measure LVEF with good accuracy (Tadamura et al., 
1999). SPECT is limited however by its use of radiation, and its less widespread 
availability in the UK. 
 

 
Computed tomographic (CT) techniques have recently been optimised to allow coronary 
angiography assessment, which remains its main application in cardiology. CT has 
excellent spatial resolution allowing for good anatomical definition, although the 64-slice 
CT scanners in routine clinical use are not quite as good as ICA as yet (Piers et al., 2008). 
CT allows for non-invasive visualisation of epicardial coronary artery stenoses using 
contrast. CTCA has excellent diagnostic accuracy for identification of coronary stenoses 
(Budoff et al., 2008, Miller et al., 2008, Meijboom et al., 2008), and potentially may have 
an impact on clinical decision-making by reducing the number of unnecessary invasive 
angiograms, saving money and reducing the risk to patients of an invasive procedure 
(Chow et al., 2009). 
 
CTCA does have some limitations however. The use of ionising radiation potentially 
increases the future risk of cancer, especially in younger women (due to breast tissue) 
(Einstein et al., 2007). This might limit its use in serial assessment of the cardiovascular 
system. Furthermore, the diagnostic accuracy of CTCA decreases with increasing levels of 
calcium within the coronary vasculature. While evaluation of the amount of calcium within 
the coronaries (the calcium score) is a predictor of adverse cardiovascular outcome in itself 
(Hou et al., 2012, Xie et al., 2013), increased levels of calcium make it difficult to 
ascertain the severity and significance of any CAD. For this reason CTCA is only currently 
recommended in patients with a low pre-WHVWSUREDELOLW\ IRU&$'HVVHQWLDOO\DVD³UXOH-
RXW´WHVW(Montalescot et al., 2013, Skinner et al., 2010). The addition of perfusion imaging 
(Ko et al., 2012a) or CT-FFR assessment (Norgaard et al., 2014) might in future widen the 
population in whom CTCA might be used. 

 
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
 

 
CMR refers to the specific use of magnetic resonance imaging (MRI) in the heart. MRI 
uses the phenomenon of nuclear magnetic resonance (NMR), which was first described in 
1938 by Isidor Rabi who was awarded the Nobel Prize for Physics for his work in 1944 
and further developed by Felix Block and Edward Purcell, who were awarded the Nobel 
Prize for Physics in 1952. NMR is refers to the process by which atomic nuclei (the core of 
the atom composed of protons +/- neutrons) absorb and radiate electromagnetic radiation 
when placed within a magnetic field. The first use of MRI was reported by Raymond 
Damadian in 1971 who used NMR in vivo to distinguish between cancerous and healthy 
tissues (Damadian, 1971), while John Mallard developed the first full body MRI scanner in 
Aberdeen during the 1970s. 
 
Any atomic nucleus with an odd number of protons and neutrons (such as hydrogen - 1H, 
carbon - 13C, sodium ± 23Na and phosphorus - 31P) has an intrinsic property known as 
³VSLQ´7KLVFDXVHVHDFKQXFOHXVWRJHQHUDWHDVPDOOPDJQHWLFILHOG,QLVRODWLRQWKLs field is 
negligible, however when put together these can be measured and used in MRI. Due to the 
large amount of hydrogen contained within water and fat in the body, 1H is extremely 
useful for MRI. While these nuclei all spin in different directions normally, when a strong 
external magnetic field is applied, the nuclei align to precess either towards or against the 
magnetic field (given the symbol B0; figure 1.5). A slight majority of the nuclei precess 
towards the direction of the field (known as the net magnetisation, referred to as M0). 
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Figure 1-5. Development of the Net Magnetisation 
 
 
 
The size of M0 is determined by the strength of the magnetic field, measured in Tesla (T). 
The commonest magnetic field strength used in clinical CMR is 1.5T, around 20,000 times 
WKHVWUHQJWKRIWKH(DUWK¶VPDJQHWLFILHOG7KHVWURQJHUWKHPDJQHWLFILHOGWKHJUHDWHUQHt 
magnetisation and subsequent image contrast. 
 

 
The typical MRI scanner consists of 3 main components ± the main magnet which 
generates a constant magnetic field, usually using a superconductor cooled with liquid 
helium; 3 gradient coils which generate a signal along the direction of B0 but can change 
its strength along one of three directions known as the x, y and z axes; and a 
radiofrequency (rf) coil which is closest to the patient and generates a smaller magnetic 
field (B1) that combines with the main magnetic field to create the signal used to form an 
image. A receiver coil is also used in CMR to pick up the signal generated during the 
process. 
 
The generation of an MRI image can be summarised in 5 steps: 
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1. The patient enters the MRI scanner ± all nuclei are exposed to the external 
magnetic field and align along B0 creating a net magnetisation. 
2. This magnetisation is changed away from the direction of the main magnet by 
applying an rf pulse (radiofrequency excitation). The angle of change is known as 
the flip angle. 
3. The magnetisation then returns to its resting (equilibrium) state, known as 
relaxation. The receiver coil collects the signals emitted during relaxation. This 
process is repeated numerous times. 
4. The gradient coils are used to apply various magnetic field gradients to localise the 
signal from the body. 
5. $OO WKH VLJQDOV JHQHUDWHG DUH FROOHFWHG DV GDWD FDOOHG WKH ³N-VSDFH´ DQG FKDQJHG
into an image using a mathematical process called Fourier transformation. 
 
Steps 2 and 3 are summarised in figure 1-6. 
 
Figure 1-6. Generation of the MRI signal using various magnetisations (adapted from 
Ridgway et al. (Ridgway, 2010)) 
 
 
The resting (equilibrium) state is shown in figure 1.6A. This is when the net magnetisation, 
M0 (caused by the main magnet) is directly aligned along the plane of the magnet (B0). If 
an rf pulse of any number of degrees is applied, the net magnetisation vectors aligns along 
that angle. This is known as the flip angle (ĮILJXUH%,IWKHIOLSDQgle is 90°, the net 
magnetisation tips completely into the xy plane (figure 1.6C). The protons continue to 
precess around the z axis at a specific frequency known as the Larmor frequency. This is 
approximately 64MHz at 1.5T. At this point the sequence is said to be fully saturated. This 
pulse is used for spin-echo sequences. A further 180° pulse can be applied can be applied 
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in a spin-echo sequence, known as a refocusing pulse (figure 1.6D). The specific 
advantage of this extra pulse is that it removes any dephasing caused by inhomogeneities 
in the magnetic field, allowing enhanced T2-weighted imaging. A 180° pulse can also be 
applied when the net magnetisation is at equilibrium (figure 1.6E). This sequence is used 
in black-blood imaging. This extra pulse (an inversion pulse) nulls the signal from all 
tissue and blood outwith the slice to be imaged.  There is then a time delay until the spin-
echo pulse sequence is applied (the inversion time; TI). This allows the blood with inverted 
magnetisation to pass into the slice to be imaged, appearing dark. This gives the improved 
contrast seen in black blood imaging. 
 
A slice to be imaged is selected by applying a gradient magnetic field at the same time as 
applying the rf pulse. A phase encoding gradient is applied in which the protons at higher 
magnetic field strength have a higher frequency of precession and those where the gradient 
decreases the field strength have their precession frequency decreased. The gradient is then 
switched off. The protons will then have changed their relative phase by an amount related 
to their position along the gradient. A frequency-encoding gradient is then applied at 90° to 
the phase-encoding gradient, causing the protons to precess at different frequencies 
dependent on their location along the gradient. After the initial rf pulse (figure 1.6C), the 
protons begin to dephase and lose coherence. If a further gradient magnetic field is applied 
in the opposite direction but in the same plane as the original rf pulse, this causes an echo 
to be applied by rephrasing the echo. This causes a reduction in signal decay and increases 
the amplitude of the signal and is known as gradient echo imaging. The time from the 
initial rf pulse to the maximal amplitude of the gradient echo signal is known as the echo 
time (TE). 
 
The signal generated by frequency encoding is analysed using Fourier transformation. 
Fourier transformation can only be used if data is available for several time points, hence 
to analyse the phase-encoding sequence, all 3 sequences (slice selection, phase-encoding 
and frequency-encoding) are repeated at various intervals with the same parameters except 
different phase-encoding gradients. The time interval is known as the repetition time (TR). 
Then Fourier transformation can be applied to phase-encoding as well, allowing image 
generation. 
 
During CMR, all images are synchronised with the ECG. To take a real-time image, the 
TR can be reduced in order to take as many images as possible, however this limits the 
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spatial resolution. Therefore, images are taken either at a particular point in the cardiac 
cycle, or over a number of heartbeats at various points within the cardiac cycle and 
FRPELQHGLQWRRQHWRPDNHLQ³FLQH´LPDJH 
 

 
After the rf pulse, M0 returns to the equilibrium state (B0). This involves 2 processes: 
 
1. Loss of (transverse) phase coherence (T2 relaxation) ± movement out of the xy 
plane. 
2. Recovery of longitudinal magnetisation (T1 relaxation) ± reversion to the z axis. 
 
T1 (longitudinal) relaxation is a (relatively) slow exponential process. T1 times are 
typically 500-1500ms. T2 (transverse) relaxation is typically faster, occurring after less 
that 100ms. T2 relaxation has two components. Firstly, the interactions between the 
protons cause them to lose phase coherence so they do not precess around the xy plane 
together. This is known as T2 relaxation due to spin-spin interaction. Secondly, 
inhomogeneities within the magnetic field, causing differences in the Larmor frequency , 
hence the protons precess at different frequencies and also lose phase coherence. In 
combination with T2 relaxation, this is known as T2* relaxation and is particularly useful 
in situation where there might be a lot of ferromagnetic signal, for example in iron 
overload cardiomyopathy, as these field inhomogeneities are more pronounced. 
 
T1 relaxation is affected by the tissue surrounding the protons. Energy is released from the 
protons as they return to equilibrium, and this is more favourable when the surrounding 
molecules are moving at a rate similar to the Larmor frequency (64MHz). Fat molecules 
move near to this frequency and so has a short T1, while water molecules, being smaller, 
move faster and have a longer T1. Muscle also has a long T1. Intravenous extracellular 
contrast agents such as gadolinium act to shorten the T1 time. 
 
T2 relaxation is mainly due to the size and position of the molecules. As water has small 
molecules that move quickly and are far apart, the opportunities for interaction between the 
molecules are less and so the T2 values are higher than in fat, which has larger molecules. 
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Both T1 and T2-weighted imaging can be performed using spin-echo or gradient-echo. T1-
weighted imaging is produced by using a short TR and short TE. The short TE reduces the 
differences caused by T2 relaxation, ensuring that the difference in contrast is caused by 
T1 relaxation. Fat typically appears bright and fluid dark. T2-weighted imaging parameters 
include a long TR and long TE, reducing T1 signal and emphasizing T2 signal differences. 
Muscle appears dark due to its short T2, while fluid appears bright (figure 1-7). 

Figure 1-7. Parameters for T1 and T2-weighted Imaging (adapted from Ridgway et 
al. (Ridgway, 2010)) 


 
²
 
CMR has two major advantages over other non-invasive imaging modalities. Firstly, it has 
excellent spatial resolution, due to the various sequences used, and has excellent 
anatomical definition. This, combined with the lack of interference by body habitus that 
echocardiography is subject to, make it the current gold-standard for assessment of cardiac 
structure, size and function. Secondly, with the assessment of T1 and T2 signal, CMR is 
able to characterize the myocardium beyond any other non-invasive imaging modality. I 
shall now proceed to review the current clinical use of these advantages in CMR.  
 
 

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
 
The main limitation with the use of CMR in acute myocardial infarction (AMI) is that it is 
a time-consuming test that requires the patient to remain still, breath-hold and also leave 
the monitored environment of the ward or coronary care unit. Even so, there are some data 
to suggest that CMR is safe in the situation of acute MI. In an early study by Plein et al, 72 
patients with a clinical diagnosis of acute non-ST elevation MI (NSTEMI) underwent 
CMR within 72 hours of presentation. 68 patients underwent the test without any adverse 
events occurring while 1 was intolerant of adenosine given during the procedure and 2 
were claustrophobic. One patient was found not to have had an MI and was excluded 
(Plein et al., 2004). The safety of CMR in the acute situation was also demonstrated in 
patients with acute ST elevation MI (STEMI) by Greenwood et al. who evaluated 35 
patients with 2-8 days post-admission without any clinically significant adverse events 
occurring (Greenwood et al., 2007). 
 
These studies also provided evidence of the diagnostic accuracy of CMR in patients with 
AMI. Plein et al found that a comprehensive CMR protocol had a 94% diagnostic accuracy 
for prediction of significant coronary stenoses (i.e. identification of the culprit artery) in 
NSTEMI, while Greenwood et al. reported an 89% diagnostic accuracy in their cohort of 
STEMI patients. The excellent spatial resolution and signal to noise ratio of CMR allows 
confident identification of regional wall motion abnormalities. The use of intravenous 
gadolinium contrast, an extracellular contrast agent, allows identification of myocardial 
damage when T1-weighted imaging is performed 10 minutes after the injection. When the 
images are taken from this sequence, known as late gadolinium enhancement (LGE) 
imaging, normal myocardium appears dark due to the absence of contrast as there is 
minimal extracellular volume (ECV). In areas of myocardial fibrosis there is more ECV 
and so gadolinium is retained, causing shortening of the T1 signal, hence the areas of 
fibrosis appear brighter than the normal myocardium. The presence of LGE has been 
shown to correlate excellently with histological fibrosis in various cardiac conditions 
(Mewton et al., 2011). In a study of 161 patients, a comprehensive CMR examination 
including LGE imaging was found to be a better diagnostic tool than ECG, troponin and a 
clinical risk score (the Thrombosis In Myocardial Infarction score) for identification of 
patients with AMI, with wall motion being the best diagnostic tool (Kwong et al., 2003, 
Eitel et al., 2010). 
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With use of LGE imaging, CMR is able to accurately quantify the extent of myocardial 
damaged caused by the infarct. Both scar size and transmural extent of infarction have both 
been shown to provide prognostic information for prediction of adverse events. CMR is 
also able to specifically characterise the structure of the infarct zone. Hypointense areas 
within the bright area of LGE reflect areas of microvascular obstruction (MVO), thought to 
represent thrombus and haemorrhage into the infarct zone which is often associated with 
percutaneous coronary intervention, and also portend an adverse prognosis (Wu et al., 
1998, Klug et al., 2012). MVO can also be seen during first pass perfusion imaging, where 
images are acquired immediately after the intravenous injection of gadolinium (Wu, 2012, 
Yan et al., 2006a). MVO again appears as a hypointense area using this sequence, where 
the contrast does not immediately penetrate into the infarcted and obstructed area of the 
myocardium due to the impaired blood flow. 
 
One advantage of CMR in the acute setting is in diagnosis of patients with chest pain and 
evidence of myocardial damage (for example elevations of cardiac biomarkers such as 
troponin) but with normal invasive coronary angiograms. CMR is able to provide a 
definitive diagnosis in this group of patients, allowing appropriate management and/or 
reassurance to be offered to the patient. Patients with other conditions such as myocarditis 
or Takotsubo cardiomyopathy can be given a more definitive diagnosis non-invasively, 
while CMR also has the ability to pick up small infarcts caused by embolus or plaque 
rupture, despite normal invasive angiography (Assomull et al., 2007). 
 
The use of T2-weighted imaging allows assessment of areas of increased water content 
(oedema, reflected by high T2 signal), caused by the occluded artery. In the context of 
AMI, this reflects the area-at-risk (AAR) of myocardial infarction. This is useful in both a 
clinical and research context. Myocardial oedema tends to persist for approximately 4 
weeks after the initial injury, hence this can be used to differentiate between acute and 
chronic MI. Abdel-Aty et al. evaluated 73 patients and found that use of T2-weighted 
imaging was able to differentiate between acute and chronic infarcts with 96% sensitivity 
(Abdel-Aty et al., 2004). Areas with high T2 signal but without LGE reflect myocardium 
with reversible damage that would hopefully recover function with appropriate therapy. 
Measurement of the AAR compared to the infarct size (myocardial salvage index = (AAR-
infarct size)/AAR) has been shown to be a good predictor of the likelihood of functional 
recovery and major adverse cardiovascular events (Eitel et al., 2010). Infarct size and 
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myocardial salvage index is now commonly used as an end-point in clinical trials in AMI 
patients (Carrick et al., 2014). 
 

 
CMR has an increasingly invaluable role in the assessment of patients with chronic IHD. 
LVEF is a powerful prognostic indicator in patients with heart failure of any cause 
including those with prior MI (Wong et al., 2004). As the gold-standard non-invasive 
method of measuring LVEF, CMR can be used as a reliable and reproducible means of 
assessment (Grothues et al., 2004). This is especially important in treatment decisions, for 
example the decision to implant lifesaving but expensive defibrillator therapies 
(implantable cardioverter-defibrillators; ICDs), which is in a large part based on the LVEF 
(McMurray et al., 2012). CMR also allows clear assessment of regional function of the 
myocardium due to the excellent contrast definition of the myocardium-blood signal. End-
diastolic wall thickness <6mm has been shown to be diagnostic of infarcted tissue that is 
non-viable (unlikely to recover function even if revascularised) (Schinkel et al., 2005). The 
transmural extent of LGE has been shown to be an even better predictor of viable 
myocardium, as shown in a seminal paper by Kim et al. (figure 1-8) (Kim et al., 2000). A 
meta-analysis by Romero et al. showed that having minimal LGE (<50%) has >90% 
sensitivity for prediction of viable myocardium (Romero et al., 2012). 
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Figure 1-8. Likelihood of Functional Recovery of Infarcted Myocardium Based on 
LGE (adapted from Kim et al (Kim et al., 2000) 
 
 
In this meta-analysis the authors also found that low-dose dobutamine stress CMR 
(DSCMR) was also useful ± segments that showed improvement in function at low-dose 
dobutamine (typically 10 mcg/kg/min) were likely to viable with 91% specificity. Viability 
assessment by nuclear imaging and stress echocardiography has been shown to not 
improve outcomes in a large multi-centre trial, the Surgical Treatment for Ischemic Heart 
Failure (STICH) trial, however the use of a comprehensive CMR protocol has yet to be 
tested in in such a study (Bonow et al., 2011) 
 
Similar to AMI, the presence of LGE has proven to be a predictor of mortality and 
ventricular arrhythmias in patients with chronic IHD, in both patients with a documented 
history of MI (Yokota et al., 2008) and those without (Kwong et al., 2006, Cheong et al., 
2009). The presence of hibernating, viable myocardium assessed by low-dose DSCMR has 
also been shown to be an independent indicator of good prognosis (Kelle et al., 2009). 
 
CMR also provides further infarct tissue characterisation. As well as identifying areas of 
MVO, assessment of the heterogeneity of the infarct has also been shown to be an 
independent prognostic indicator. Commonly, the presence of LGE has been measured in 
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areas that have signal intensity 2-5 standard deviations above remote, non-injured 
myocardium. This area is commonly described as the infarct core. The size of areas of 
myocardium with signal intensity between the core and the remote myocardium, known as 
the grey zone, has been shown to predict ventricular arrhythmias (Roes et al., 2009, Wu et 
al., 2012, Yang et al., 2013). This is thought to be due to aberrant conduction in this area of 
infarcted tissue mixed with healthy myocardium. The use of CMR has also identified areas 
of fatty change within infarct scar, known as lipomatous metaplasia and previously only 
seen in pathological specimens, which might also be associated with arrhythmias (Lucke et 
al., 2010, Pouliopoulos et al., 2013) 
 

 
Stress CMR is now recommended in most guidelines as one of the non-invasive imaging 
tools that can be used to investigate patients with suspected angina. Stress CMR is most 
commonly performed using adenosine (for assessment of perfusion) or dobutamine (for 
assessment of wall motion). 
 
During dobutamine stress CMR (DSCMR), wall motion is assessed at incrementally 
increases of dobutamine (typically 10, 20, 30 and 40 mcg/kg/min). Typically, one would 
see an increase in contractility of an ischaemic segment at low dose and then a decrease in 
contractility at high dose due to decreased coronary flow reserve. In a meta-analysis of 754 
patients, DSCMR had a sensitivity of 83% and a specificity of 86% for identifying patients 
with significant CAD with ICA as the reference standard (Nandalur et al., 2007). The 
addition of assessment of perfusion during stress has also been shown to incrementally 
improve diagnostic performance (Lubbers et al., 2008, Gebker et al., 2008), as has the 
quantitative assessment of wall motion using tagging to analyse myocardial strain and 
deformation (Kuijpers et al., 2003, Korosoglou et al., 2010). 
 
Adenosine perfusion stress CMR has also shown similar diagnostic accuracy. In the same 
meta-analysis by Nandalur et al., the authors found the technique had a sensitivity of 91% 
and a specificity of 81% in 1,516 patients (Nandalur et al., 2007). Clinicians may be more 
comfortable using adenosine rather than dobutamine, as it generally has a lower risk 
profile. Adenosine stress CMR has been evaluated in two large trials. MR-IMPACT 
compared adenosine stress CMR and SPECT against ICA in 241 patients and found that 
CMR performed as well as SPECT, although this was a sub-analysis of a larger trial 
Chapter 1: Introduction 
 
 41 
(Schwitter et al., 2008). This lead to a larger, prospectively designed study, CE-MARC 
(Greenwood et al., 2012). In this study 752 patients underwent adenosine stress CMR and 
SPECT, again with ICA as the diagnostic standard. The results demonstrated the 
superiority of CMR over SPECT in this scenario, with CMR having a sensitivity of 86.5% 
and specificity of 83.4% compared to SPECT which had a sensitivity of 66.5% and a 
specificity of 82.6%. 
 
Both dobutamine and adenosine stress CMR also provide prognostic information. A 
negative stress CMR appears to herald a good prognosis. In a meta-analysis of 11,636 
patients who underwent stress CMR (of either modality), patients with ischaemia had a 
significantly higher risk of cardiovascular death or MI with an annualised event rate of 
4.9% compared to 0.8% in patients with a negative study (Lipinski et al., 2013). 
 

 
Dilated non-ischaemic cardiomyopathy (DCM) is the final common pathway of a number 
of conditions, but its phenotype is characterised by a dilated left ventricle with reduced 
ejection fraction. As with ischaemic cardiomyopathy (ICM), accurate assessment of LVEF 
has an important role in risk stratification (Rayatzadeh et al., 2013, Taylor et al., 2013). In 
up to 50% of cases of DCM the aetiology remains unknown, while patients with ICM may 
also have dilated left ventricles. This often leads to ICA being undertaken which may be 
unnecessary as there is no significant CAD. The use of CMR to identify the presence of the 
typical ischaemic pattern of LGE (subendocardial or transmural) appears to be a good tool 
to act as a gatekeeper to ICA and potentially prevent unnecessary ICA (Assomull et al., 
2011). 
 
Typically, patients with DCM will have either no LGE at all, or a midwall line of LGE 
(McCrohon et al., 2003). The presence of LGE in patients with DCM has been shown to be 
a strong indicator of adverse prognosis in a large cohort (Gulati et al., 2013, Wu et al., 
2008). Novel T1 mapping techniques have recently been developed which are able to 
identify diffuse myocardial fibrosis not picked up by LGE. Patients with DCM appear to 
have higher levels of fibrosis than controls using these techniques, which might have 
additional diagnostic and prognostic value (Dass et al., 2012, Puntmann et al., 2013). 
 
 
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
 
Myocarditis can often be a difficult diagnosis to make clinically. Typically, the patient may 
have a resting ECG with non-specific abnormalities, a mild elevation in troponin, and 
potentially an essentially normal echocardiogram. Often the only way to provide a 
definitive diagnosis would be endomyocardial biopsy (EMB), although of course this is an 
invasive procedure with potential risks (Caforio et al., 2013). It also has inherent 
limitations due to sampling error. CMR has revolutionised the diagnosis of suspected 
myocarditis, using the Lake Louise Criteria (Friedrich et al., 2009). These criteria are: 1. 
Increased signal intensity on T2-weighted imaging suggestive of the presence of 
myocardial oedema; 2. Increased signal intensity on early gadolinium enhancement 
imaging (taken less than 5 minutes after gadolinium injection); and 3. At least one area of 
LGE in a non-ischaemic pattern (this is typically epicardial or midwall). The use of these 
criteria has been shown to have excellent prediction of both suspected (Abdel-Aty et al., 
2005) and biopsy proven myocarditis (Lurz et al., 2012, Francone et al., 2014). The 
different patterns of fibrosis seen using LGE imaging allow differentiation between MI, 
myocarditis and DCM, where traditional non-invasive methods such as echocardiography 
might not provide a definitive diagnosis (figure 1-9).  
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Figure 1-9. Typical Patterns of LGE. 
 
 
LGE imaging from 4 patients: A ± a healthy control patient with no LGE; B ± a patient 
with a prior inferior MI showing the subendocardial pattern of LGE representing 
myocardial fibrosis (arrow); C ± a patient with DCM showing a dilated left ventricle and a 
faint midwall line of LGE (arrow); D ± a patient with myocarditis showing both inferior 
epicardial LGE and septal midwall LGE in a non-coronary distribution (arrows). 
 
More recently, T1 mapping has also been used to evaluate acute myocarditis and might 
perhaps be more accurate than T2-weighted imaging (Ferreira et al., 2013) and may even 
be used to diagnose the myocarditis in patients who are unable to be given contrast 
(Ferreira et al., 2014). The use of CMR may have some ability to predict functional 
recovery in patients with myocarditis (Vermes et al., 2014). 
 

 
While hypertrophic cardiomyopathy (HCM) is still diagnosed by echocardiography, CMR 
has become increasingly important in its evaluation, especially due to its ability to image 
the heart in various planes. Apical HCM can be difficult to diagnose using 
echocardiography, however CMR has proved to be more accurate in its identification 
(Moon et al., 2004a). CMR can also be used to accurately measure myocardial wall 
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thickness and assess for the presence of left ventricular outflow tract obstruction and 
systolic motion of the mitral valve (Maron et al., 2009). CMR can potentially differentiate 
between HCM and other pathologies such as hypertensive heart disease (Puntmann et al., 
2010). Abnormalities of the papillary muscles and mitral valve have also been noted using 
CMR, which may cause symptoms and influence management (Harrigan et al., 2008, 
Kwon et al., 2008).  
 
There has been much interest in the use of LGE in HCM. This has been shown to correlate 
with myocardial fibrosis and scarring and is linked to adverse outcome, leading to calls for 
its use in association with traditional risk factors (Moon et al., 2004b, O'Hanlon et al., 
2010). At present, current clinical risk factors still do not identify all patients at high risk of 
sudden death, and so there has been much research to identify any CMR parameters that 
may add prognostic value. LGE has been shown to predict heart failure hospitalisations in 
HCM patients (Green et al., 2012) and also the presence of ventricular arrhythmia on 
Holter monitoring (Adabag et al., 2008). Despite its link with ventricular arrhythmias on 
monitoring, LGE has shown mixed results for the prediction of sudden death (Green et al., 
2012, Bruder et al., 2010, O'Hanlon et al., 2010, Rubinshtein et al., 2010, Maron et al., 
2008). The presence of oedema and reduced perfusion suggestive of myocardial injury and 
ischaemia has also been seen in HCM, although their prognostic significance has yet to be 
elucidated (Hueper et al., 2012). 
 

 
CMR is becoming an increasing part of the clinical assessment of numerous other cardiac 
conditions, for example in infiltrative cardiomyopathies. Confident non-invasive diagnosis 
of cardiac amyloidosis is now possible for the first time using LGE (Maceira et al., 2005). 
The typical pattern of LGE is of a global circumferential ring of LGE. This pattern has also 
potentially useful as a prognostic marker for prediction of mortality (White et al., 2014). 
Anderson-Fabry disease is an X-linked recessive condition that causes left ventricular 
hypertrophy and can lead to heart failure. A characteristic pattern of LGE in the midwall of 
the basal inferolateral wall of the left ventricle is typical and helps differentiation of the 
condition from HCM and other infiltrative cardiomyopathies (De Cobelli et al., 2009). 
CMR can also be used to assess response to treatment by providing reproducible 
assessment of the level of left ventricular hypertrophy (Imbriaco et al., 2009). 
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One condition in which CMR has particularly proven to be revolutionary is in the 
management of iron overload cardiomyopathy, either in haemochromatosis or transfusion-
related cardiomyopathy (Wood, 2009). Transfusion-related cardiomyopathy is the leading 
cause of death in patients with transfusion-dependent anaemia. The use of T2*-weighted 
imaging, which is affected by iron within the body, has for the first time allowed non-
invasive assessment of myocardial iron content. Anderson et al. showed that the T2* signal 
is inversely correlated to the level of myocardial iron, and directly correlated with LVEF 
(Anderson et al., 2004). In this study, the authors also showed that treatment with iron 
chelation therapy increases T2* time, corresponding to an improvement in LVEF. This 
group then went on to publish data showing that T2* imaging is also provides prognostic 
information on prediction of heart failure and mortality (Kirk et al., 2009). CMR is now an 
integral part of the management of iron overload cardiomyopathy. The level of evidence 
for the use of CMR in this condition (level 6) perhaps provides a model for increasing the 
clinical use of CMR in other conditions. 
 

 
The clinical value of CMR is becoming increasingly recognised. Nevertheless, CMR is a 
relatively new imaging modality, and perhaps does not yet have the same level of evidence 
for its clinical utility as more established modalities such as echocardiography and SPECT, 
particularly in prognostic studies. CMR is limited by its cost, the level of expertise 
required and reduced availability in comparison to other methods. These factors mean that 
it is still not widely used in routine clinical practice. In order for CMR to become more 
utilised, there needs to be more evidence to show that it can change the management of 
patients. 
 
In this thesis, I aim to show the clinical utility of CMR by using it to answer important 
clinical questions that are difficult to answer using other modalities. I will specifically look 
at five questions: 
 
1. Can the use of a comprehensive, multi-parametric CMR protocol using LGE and 
myocardial deformation imaging (strain measured by tagged magnetic resonance) 
in addition to assessment of LVEF provide increased prognostic value for 
prediction of adverse events compared to clinical and LVEF assessment alone? 
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2. In patients with prior MI, infarct characteristics have been shown to be stronger 
predictors of adverse prognosis than the infarct size alone. Does the presence of 
myocardial fat within the infarct territory (lipomatous metaplasia), predict adverse 
events? 
3. Not all heart failure patients requiring ICD therapy require to use their device.  Can 
the structural information provided by pre-implantation CMR be combined with a 
functional assessment (n-terminal pro B-type natriuretic peptide ± nt-proBNP) to 
provide more powerful prognostic information that could be used to help selection 
of patients, allowing avoidance of unnecessary device implantation and potentially 
cost-savings? 
4. The differentiation between with early DCM and myocardial adaptation to exercise 
is not always clear-cut when based on LVEF assessment alone, leading to a 
potential diagnostic dilemma. Could a multi-parametric assessment using CMR 
potentially be used to help diagnose patients with DCM? 
5. In patients with suspected angina, the presence of left bundle branch block (LBBB) 
causes difficulties in the interpretation of commonly used non-invasive techniques 
for evaluation of this presentation. Does the use of multi-parametric stress CMR, 
combining perfusion and wall motion assessment potentially improve diagnosis 
compared to dobutamine stress echocardiography? 
 
By aiming to answer these 5 clinically relevant questions, I hope to add to the evidence 
demonstrating the clinical utility of CMR. 
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2. General Methods 
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

In this section I will describe the CMR and statistical methods used that were common to 
studies in this thesis. Detailed study specific methods are described within the relevant 
chapters. 



All patients underwent CMR examination at the Golden Jubilee National Hospital, 
Clydebank between January 2009 and March 2014 and were scanned using a 1.5 Tesla 
scanner with a 12-element phased array cardiac surface coil (Siemens Magnetom Avanto, 
Erlangen, Germany). All patients had been referred for a clinically indicated scan from 
hospitals throughout the West of Scotland. Patients were selected for various studies 
dependent on the referral indication. All patients who had contraindications to CMR 
examination (severe renal impairment with eGFR <30, metallic implants, 
pacemakers/implantable defibrillators) were excluded from the studies. 
 


All patients underwent a standard protocol, parts of which were adapted dependent on the 
specific clinical question to be answered by the CMR examination. All patients had ECG 
monitoring during the CMR examination. The standard CMR protocol is outlined in figure 
2-1. 
 
Figure 2-1. Standard CMR Protocol 
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The CMR examination began with initial Half-Fourier Acquisition Single-Shot Turbo 
Spin-Echo (HASTE) images, which allow for localisation of various structures within the 
body and accurate anatomical detailing, allowing for planning of the rest of the study. 
Following this, left ventricular mass, volumes and function were assessed with the 
acquisition of cine images using a steady-state free precession (SSFP) technique. Next, 
tissue characterisation sequences were acquired. These included T1- and T2-weighted 
imaging sequences. Tagged magnetic resonance images were obtained using a spatial 
modulation of magnetisation (SPAMM) sequence for assessment of regional myocardial 
function, strain and left ventricular torsion (Axel and Dougherty, 1989). Once native tissue 
characterisation sequences were acquired, gadolinium contrast (0.15 mmol/kg of 
gadoterate meglumine; Dotarem, Guebert S.A., Villepinte, France) was given 
intravenously through a peripheral cannula. Early gadolinium enhancement imaging (EGE) 
was performed 2 minutes post-injection; 10 minutes post-injection, late gadolinium 
enhancement imaging (LGE) was performed using segmented phase-sensitive inversion 
recovery turbo fast low-angle shot sequence (PSIR). Following this, a further (post-
contrast) T1-weighted sequence was carried out. 
 
I shall now proceed to describe each sequence in more detail. 
 


HASTE imaging is used in the initial planning sequences of the CMR examination. These 
out of focus images (figure 2-2) are used to localise the anatomical structures of the body 
and plan the remainder of the examination. HASTE is DOVR NQRZQ DV ³EODFN-blood 
LPDJLQJ´ GXH WR WKH ORZ EORRG VLJQDO +$67( LV DQ XOWUDIDVW VHTXHQFHZKLFK LV RIWHQ
used in CMR as it is less sensitive to movement artifacts, primarily as it is a single-shot 
sequence. This sequence was performed with ECG-triggering and without breath-holding. 
Typical imaging parameters were as follows: TR 800ms, TE 80ms, 2 R-R intervals/23; flip 
angle 160°; effective slice thickness, 5 mm without interslice gaps; matrix size, 158 × 256; 
and spatial resolution, 2.4 × 1.5 mm2. HASTE imaging is also useful for assessment of the 
extracardiac anatomy, including the aorta (Davis et al., 2014), lungs (Vogt et al., 2004), 
liver (Yu et al., 1998) and kidneys (Irwin et al., 2013) (figure 2-2).  
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Figure 2-2. An example of HASTE imaging 
 
 
HASTE imaging in axial (A), sagittal (B) and coronal (C) views. An incidental finding of a 
right lung lesion is noted (arrows). A ± aorta, LA ± left atrium, LL ± left lung, LV ± left 
ventricle, RA ± right atrium, RL ± right lung, RV ± right ventricle. 

6WDWH)UHH3UHFHVVLRQ´&LQHµ,PDJLQJ66)3

Sequences for assessment of left ventricular volumes, global function (e.g. ejection 
fraction) and mass were acquired using an SSFP technique (multi-slice single-shot breath-
hold true fast imaging - trueFISP). Cines of the left ventricle were acquired in 3 long axis 
views (4-chamber, 3-chamber and 2-chamber) and a stack of short axis views (typically 8-
10), allowing for complete visualization of left ventricular myocardial structure and 
motion. Typical sequence parameters were TE 1.2 ms, TR 3.5 ms, flip angle 50q, slice 
thickness 8mm, gap 2mm, FOV 281 x 340. 
 
:HLJKWHG,PDJLQJ´7PDSSLQJµ

T1-weighted imaging was carried out using a Modified Look Locker Inversion-recovery 
sequence (MOLLI), initially described by Messroghli et al (Messroghli et al., 2004). 
Essentially, after the initial inversion pulse, the recovery of longitudinal magnetisation is 
measured. Several TrueFISP sequences are acquired at different inversion times over a 
single breath-KROGDOORZLQJJHQHUDWLRQRID³PDS´VKRZLQJWKHLndividual T1 time of each 
voxel. 3 short-axis views were obtained to represent the base, mid-ventricular and apical 
segments of the heart. Motion correction is then applied to account for cardiac movement. 
Typical parameters were: TE 1.1 ms, initial TI 100 ms; TI increment 80 ms, flip angle 35°, 
matrix 192 x 124 pixels, spatial resolution 2.1 x 1.1 x 8.0 mm, slice thickness 8 mm, scan 
time 17 heartbeats. 
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T1 mapping sequences were obtained both prior to and (on average 7 -10 minutes) after 
injection of gadoOLQLXPFRQWUDVWDOORZLQJIRUDVVHVVPHQWRI³QDWLYH´7DQGSRVW-contrast 
T1 signals. 
 


T2-weighted imaging was carried out using two methods. Firstly, a short-tau inversion-
recovery sequence (STIR) was used (Simonetti et al., 1996). Again, 3 short-axis slices 
were obtained to represent 3 levels of the left ventricle. In this sequence, a pair of 180° 
inversion pulses are applied, followed by a long inversion time. This nulls blood pool 
VLJQDOKHQFHWKLVLVDOVRD³EODFN-EORRG´VHquence. Following this, a further 180° inversion 
pulse is applied, which has the effect of nulling the signal from fat (which has a short TI) 
and enhancing the signal from tissues with a longer T1 time (for example those containing 
water). Typical parameters of this sequence were: TE 63 ms, TR 800 ms, flip angle 180°, 
acquisition time 8 to 13 seconds, matrix 166×256, bandwidth 235 Hz/pixel. The time 
interval between the 180° inversion pulses for STIR was 6.74 ms, voxel size was 
2.2×1.4×8 mm3. Average breath hold for this sequence was 15 seconds. 
 
After this, a second T2-weighted technique was used, allowing for direct quantification of 
T2 time analogous to the T1 mapping technique previously described (Giri et al., 2009). 
Three T2-weighted images were obtained during one breath hold at 0 ms, 24 ms and 55ms, 
allowing generation of the T2 time for each individual voxel. Again, a motion correction 
algorithm was applied to allow for movement artefact. Typical imaging parameters were: 
TE 1.1 ms, TR 260 ms, flip angle 70°, band width ~ 947 Hz/pixel, matrix 160 x 105 pixels, 
spatial resolution 2.6 x 2.1 x 8.0 mm, slice thickness 8 mm. 
 
²

Assessment of regional myocardial function (strain), left ventricular rotation and torsion 
was carried out using a CMR tagging ± spatial modulation of magnetisation (SPAMM) 
(Axel and Dougherty, 1989). Essentially, magnetic resonance tags are applied to the heart, 
allowing tracking of myocardial motion through the cardiac cycle. By doing this, 
assessment of circumferential, radial and longitudinal deformation can be obtained, as well 
as rotation of heart. Tagged images of the left ventricle were acquired in 3 short axis slices 
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and in the 4-chamber long-axis view. Grid tags were applied at the start of the ECG R 
wave and gradient echo cine images acquired to follow myocardial motion using the tags. 
Imaging parameters were as follows: TR 40.1 ms, TE 3.9 ms, flip angle = 14°, slice 
thickness = 6 mm, field of view = 380 mm, grid distance 5 mm, 20 cardiac phases/R-R 
interval on ECG. 
 


Following administration of intravenous gadolinium contrast as described above, early 
gadolinium enhancement imaging was carried out 2 minutes post-injection using a single-
shot SSFP sequence with a non-selective inversion pulse. A full short-axis stack was 
obtained, copied from the cine SSFP sequences. Typical parameters: TE 1.2, TR 2.7, TI 
200-350 ms, slice thickness 8 mm, gap 2 mm. 
 
10 minutes post-injection, late gadolinium enhancement imaging was performed. A full 
short-axis stack and 3 long-axis views (as per SSFP cine imaging) were obtained using a 
PSIR sequence. Typical imaging parameters were: TE 4.4, TR 630, flip angle = 25q, 
matrix 192 x 256, bandwidth 130 Hz/pixel, echo spacing 8.7ms, trigger pulse 2, voxel size 
was 1.7 x 1.2 x 8 mm3. Typical inversion times were 200 to 340 ms, selected to optimally 
null myocardial signal. 
 


Post-processing of all images were analysed using commercially available proprietary 
Siemens software (Argus) based on CMR workstations, except for analysis of CMR 
tagging which was performed using specific tagging analysis software (HARP, Diagnosoft, 
Durham, North Carolina). All image analysis was performed by I.M., unless otherwise 
specified. 
 


Qualitative analysis of left ventricular function was carried by visual assessment of the 
cine SSFP images for global and regional myocardial motion and wall thickening. Resting 
(diastolic) wall thickness was measured in the most basal left ventricular slice, as were 
end-diastolic and end-systolic diameters. 
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To obtain quantitative measurements of left ventricular mass, volumes and ejection 
fraction, all cine images were loaded into Argus. The computer software automatically 
selected end-diastole, while end-systole was manually selected as the image in each slice 
with the smallest area of blood pool. Once selected, the endocardial and epicardial borders 
were manually outlined. Papillary muscles were included as part of the myocardial blood 
pool. Following tracing of the myocardial borders for each slice (typically 8-10 slices 
depending on the size of the heart), an automated calculation was carried out by the Argus 
software to obtain left ventricular mass, end-systolic volume, end-diastolic volume and left 
ventricular ejection fraction using a sum of discs method (figure 2-3). 
 
Figure 2-3. Manual planimetry to obtain left ventricular mass and function using 
SSFP cine imaging. 
 
 
Endocardial (red) and epicardial (green) contours are measured at end-diastole and end-
systole. This process is repeated in every slice, allowing for calculation of left ventricular 
volumes, ejection fraction and mass. 
 


Both T1 (native and post-contrast) and T2 maps were qualitatively assessed for image 
quality and artefacts. It quickly became apparent that apical slices were often subject to 
poor image quality, often due to signal drop-out from the thinner myocardium, causing 
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interference from the myocardial blood pool, and so apical slices were not included in 
quantitative assessment, similarly to other studies (Wong et al., 2012, Moon et al., 2013). 
 
The major advantage of mapping techniques is the ability to perform a fully quantitative 
measurement of T1 and T2 times of any structure. To do this, a region of interest was 
drawn within the interventricular septum, taking care to exclude signal from the 
myocardial blood pool, but ensuring to take as large an area as possible to be truly 
representative. Again, as the lateral wall is often subject to partial volume effects similarly 
to the apex, the septum was chosen as the most robust measure. The T1 and T2 times were 
respectively recorded (figure 2-4). 
 
 
Figure 2-4. T2, native T1 and post-contrast T1 maps in a normal patient. 
 
Typical appearances using T1 and T2 mapping in a healthy control. A region of interest 
can be drawn within the septum to measure T1 and T2 relaxation times (green area). 
 
T2-STIR images were also analysed qualitatively, again primarily for the presence of 
artefacts, often caused by the lengthy breath holds required for this sequence (15-20 
seconds). Relative myocardial signal intensity was assessed by comparison of the signal 
intensity of an area of interest with either a remote area of myocardium or skeletal muscle 
signal intensity (Abdel-Aty et al., 2005).  
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

Tagged images were analysed in a specialist software package (HARP, Diagnosoft, North 
Carolina, USA). 3 short-axis slices were analysed for measurement of circumferential and 
radial strain and rotation. The 4-chamber view was used to measure longitudinal strain. 
 
Endocardial and epicardial contours were drawn on one image (similarly to those drawn in 
Argus on cine images for assessment of LV mass and function); these were automatically 
copied to all other images in the cine sequence by the software and then manually adjusted 
to ensure adequate tracing of myocardial motion. Following this, an automatic calculation 
of circumferential and longitudinal strain were obtained. (figure 2-5). 
 
Figure 2-5. CMR tagging for assessment of circumferential strain in a healthy 
control. 
 
 
Global circumferential strain measured using tagged CMR at the basal (green), mid (red) 
and apical (blue) levels of the left ventricle. 

 
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

Early gadolinium enhancement images were analysed qualitatively for the presence of 
hypointense myocardial regions, typically indicative of microvascular obstruction caused 
by myocardial infarct (causing reduced penetration of gadolinium contrast within that 
area). 
 
Late gadolinium enhancement images were first analysed qualitatively for the presence of 
contrast-enhanced myocardium. If present, quantitative analysis could be carried. Several 
techniques are available for quantification of LGE volumes using the relative signal 
intensity of the contrast-enhanced region compared to normal myocardium (Flett et al., 
2011). For all studies in this thesis, the presence of LGE was defined as any area with a 
signal intensity 5 standard deviations (SD) above that of remote myocardium. This 
technique is commonly used throughout the literature, is robust and has been used in 
prognostic studies (Flett et al., 2011, Beek et al., 2009). 
 
To do this, firstly a region of interest was drawn with in an area that objectively did not 
have any LGE to act as an area of remote myocardium. The mean signal intensity and 
standard deviation in this area was displayed on the workstation. After adjusting the 
³ZLGWK´VHWWLQJRIWKHPRQLWRUWRWKHPHDQVLJQDOLQWHQVLW\DQGWKH³FRQWUDVW´VHWWLQJWR
SD above this, any areas that remained enhanced were contoured and measured. The total 
left ventricular area was also traced, and the percentage of enhanced myocardium 
calculated. This was done in each short-axis slice of the left ventricle (using the same 
slices as for calculation of left ventricular function) in order to calculate the percentage of 
enhancement in the left ventricle. Intra- and inter-observer variability is as previously 
described in our group (Payne et al., 2011b). Figure 2-6 illustrates an example of the 
analysis of LGE imaging. 
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Figure 2-6. Quantification of late gadolinium enhancement imaging. 
 
 
Manual planimetry of an area of LGE (yellow) with signal intensity 5SD above remote 
myocardium. This was repeated in every left ventricular slice and the percentage of 
myocardium affected by LGE calculated ((area of LGE/total myocardial area) x 100). 
 


All statistical analysis was performed using SPSS (version 21.0, IBM, Armonk, NY, 
USA). Continuous variables are presented as mean ± SD while non-continuous variables 
are presented as number with percentage in brackets. Differences between continuous 
variables were compared using a two-tailed t-test, while categorical variables were 
compared using a chi-VTXDUH WHVW&RUUHODWLRQVZHUHDVVHVVHGXVLQJ3HDUVRQ¶VFRUUHODWLRQ
co-efficient. Outcome analysis was performed using Cox logistic regression and time-to-
event curves constructed using the Kaplan-Meier method. Receiver-operator characteristic 
(ROC) curves were formed for assessment of diagnostic accuracy and in order to find best 
cut-off values for prediction of outcomes of various parameters. For all analysis a p value 
<0.05 was deemed to be significant, unless otherwise mentioned. 

 
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

Full ethical approval was obtained for these studies from West of Scotland Research Ethics 
Committee 3, reference 14/WS/1052 (appendix 1). This allowed inclusion of patients into 
the studies within this thesis on the basis that all information was anonymised and 
therefore patients could not be traced, as well as computerised record linkage for follow-
up. Prior analysis that had been performed for clinical reasons (such as left ventricular 
function measurements) could also be used. The protocol for this study allowed for 
inclusion of analysed data (appendix 2). 
 


While the CMR methods are robust, there are some limitations in the methodology used 
within this thesis. 
 
Firstly, measurement of the left ventricular volumes can also be performed by including 
the papillaries as part of the myocardium, which is more accurate. In our unit, volumes are 
calculated excluding the papillaries, so in order to maintain consistency this was kept the 
same. 
 
Secondly, our T1 mapping sequence does not include an error map, which can act as a 
quality control check for the presence of artifacts (Kellman et al., 2013). I was present for 
as many scans as possible in order to try to pick up artifacts in real time and if necessary 
repeat the sequence. 
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3. The Combined Incremental Prognostic Value of 
Left Ventricular Ejection Fraction, Late Gadolinium 
Enhancement and Global Circumferential Strain 
Assessed by Cardiovascular Magnetic Resonance 
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

As discussed in Chapter 1, the primary unique advantages of CMR lie in two main factors 
± its ability to provide accurate and reproducible assessment of ventricular dimensions and 
function, such that it is considered the non-invasive gold standard for measurement of 
LVEF; and secondly, its ability to non-invasively characterise the myocardium using LGE 
imaging to assess the presence of myocardial fibrosis. 
 
The assessment of LVEF has a vital role in the evaluation and management of patients in 
cardiology, providing significant prognostic information and guiding treatment decisions 
(Solomon et al., 2005, Yancy et al., 2013, McMurray et al., 2012). While LVEF is 
commonly evaluated using echocardiography, CMR is becoming increasingly utilised. 
CMR is currently recognised as the non-invasive gold standard for assessment of LVEF 
due to its ability to provide unobstructed views of the heart in any plane and increased 
reproducibility (Hoffmann et al., 2005). 
 
Tissue characterisation using LGE allows the non-invasive visualisation of myocardial 
fibrosis. The presence of fibrosis is seen in numerous conditions and has also been shown 
to have significant prognostic value, independent of LVEF (Kuruvilla et al., 2014, 
Mavrogeni et al., 2013, Gulati et al., 2013). 
 
Despite LVEF assessment by CMR being well validated, LVEF remains an insensitive tool 
for assessment of regional myocardial contractility. LVEF is dependent on other factors 
such as LV loading conditions and dimensions, thus it does not always provide a true index 
of LV systolic function (Buckberg et al., 2008). It is also increasingly understood that early 
changes in myocardial contractility occur which might have a sub-clinical, but important 
impact. The assessment of myocardial contractility, most commonly reported using strain 
as a measure of deformation, can be carried out using tagging sequences during CMR 
(Ibrahim el, 2011). This technique is regarded as the non-invasive gold-standard for 
deformation imaging. The assessment of global circumferential strain (GCS) using tagging 
has been shown to identify myocardial dysfunction in numerous conditions independent of 
LVEF. Recently, GCS has been shown to be an independent prognostic indicator in both 
asymptomatic patients and those with heart failure (Choi et al., 2013, Cho et al., 2009). 
Assessment of GCS may provide extra information to LVEF. 
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As yet, no study has assessed the prognostic value of LVEF, LGE and GCS in a combined 
CMR protocol. The aim of this study was to explore the prognostic value of these 
parameters in addition to baseline clinical risk factors for prediction of major adverse 
cardiovascular events in an unselected cohort of patients with suspected cardiac disease 
referred for clinical assessment. 





570 patients referred for clinically indicated CMR were prospectively screened. All 
patients able to undergo the complete CMR protocol without any contra-indications to the 
use of gadolinium were eligible. Clinical management of the patients was left to the 
discretion of the referring physician. Baseline characteristics were obtained at the time of 
UHIHUUDOXVLQJWKHSDWLHQWV¶FDVHQRWHV 
 


All patients underwent a systematic CMR protocol including cine imaging, tagging and 
LGE as described in Chapter 2. Briefly, cine images were obtained using an SSFP 
sequence in three long axis planes (2-chamber, 3-chamber, 4-chamber) and in short axis 
slices through the left ventricle. Then 3 matched short-axis slices were taken to represent 
the basal, mid and apical levels of the left ventricle using tagged CMR for assessment of 
GCS. Intravenous gadolinium was then given and LGE imaging was performed after 10 
minutes.  
 
All analysis was performed using Argus, other than analysis of tagged CMR images which 
was performed using Diagnosoft HARP as described in Chapter 2.  
 


The combined primary endpoint for this study was incidence of cardiovascular mortality or 
major adverse cardiovascular events (MACE). MACE included heart failure 
hospitalisation, sustained ventricular arrhythmia requiring hospitalisation or defibrillator 
therapy and survived cardiac arrest. 
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All patients were followed up using our computerised record linkage system which allows 
access to patient records, allowing us to identify survival status and hospital admissions 
³&OLQLFDO3RUWDO´,QFDVHRISDWLHQWV¶LQZKRPWKHFRPSXWHULVHGUHFRUGVZHUHQRWXSWR
GDWHWKHSDWLHQW¶VJHQHUDl practitioner was contacted to ensure adequate follow-up status. 
Events were adjudicated by an independent observer unaware of the results (N.T). 



As described in Chapter 2, continuous variables are expressed as mean ± SD and 
categorical variables are expressed as a number and percentage. Comparison between 
continuous variables was carried out using a two-tailed t-test, while categorical variables 
were compared using the chi-square test. Correlation between continuously distributed 
&05 SDUDPHWHUV ZHUH DVVHVVHG XVLQJ 3HDUVRQ¶V FRUUHODWLRQ FRHIILFLHQW ZKLOH QRQ-
SDUDPHWULFFRUUHODWLRQVZHUHDVVHVVHGXVLQJ6SHDUPDQ¶VFRUUHODWLRQ2XWFRPHDQDO\VLVZDV
conducted using Cox proportional hazards, and time-to-event curves were drawn using the 
Kaplan-Meier method. All variables were evaluated using univariate Cox regression 
analysis to ascertain their prognostic power for prediction of the primary outcome. Hazard 
ratio and chi-square were obtained. To evaluate the incremental prognostic value of CMR, 
significant univariable CMR predictors (p<0.05) were then added to the significant 
multivariable clinical predictors, and further multivariable models using each CMR 
parameter created. CMR variables were individually added to the clinical model in a 
forward stepwise selection, to assess their independent prognostic power over and above 
the previous model. Optimal cut-off points for LVEF, GCS and LGE were calculated using 
ROC curves. The chi-square of each model was subsequently calculated. This process was 
WKHQ UHSHDWHG LQ SDWLHQWV ZLWKRXW VHYHUH OHIW YHQWULFXODU V\VWROLF G\VIXQFWLRQ 
5HSURGXFLELOLW\ ZDV DVVHVVHG XVLQJ 3HDUVRQ¶V FRUUHODWLRQ FRHIILFLHQW DQG WKH LQtraclass 
coefficient. 
 
For all analyses a p value <0.05 was considered statistically significant and all p values are 
two-tailed. 
 
 
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



In total 539 patients were included in the final analysis. Of the 31 patients excluded, 8 
were unable to undergo LGE imaging due to renal impairment, 11 patients had inadequate 
image quality due to poor breath-holding ability and 12 had arrhythmias that impaired scan 
quality such as uncontrolled atrial fibrillation. Baseline clinical characteristics of the 539 
patients are shown in table 3-1.  
 
Table 3-1. Baseline Clinical Characteristics. 
 
Variable  
Age (years) 48.1 ± 15.4 
Male (%) 343 (63.6) 
Ischaemic Heart Disease (%) 61 (11.3) 
Diabetes Mellitus (%) 53 (9.8) 
Hypertension (%) 77 (14.3) 
Smoker (%) 58 (10.8) 
ACE inhibitor use (%) 225 (41.7) 
Beta-blocker use (%) 223 (41.4) 
Mineralocorticoid Antagonist Use (%) 136 (25.2) 
Statin use (%) 140 (26.0) 
Aspirin use (%) 159 (29.5) 
ACE ± angiotensin-converting enzyme 
Data are presented as mean ± SD if continuous or number (%) if categorical. 
 
The mean age of the cohort was 48.1 ± 15.4 years. 63.6% were male. The majority of 
patients did not have any clinical risk factors. Reasons for referral for CMR are shown in 
table 3-2. The majority of patients (56.8%) were referred for assessment of left ventricular 
function. 
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Table 3-2. Reasons for Referral for CMR Assessment. 
 
Reason Number (%) 
Presumed dilated non-ischemic 
cardiomyopathy ± assessment of LV function 
199 (36.9) 
Presumed ischemic cardiomyopathy ± 
assessment of LV function 
107 (19.9) 
Left ventricular hypertrophy - 
characterisation 
59 (10.9) 
Presumed myocarditis 64 (11.9) 
Ventricular arrhythmia (specify) 75 (13.9) 
Aortic disease 35 (6.5) 
 
 
Baseline CMR characteristics are shown in table 3-3.  
 
Table 3-3. Baseline CMR Characteristics. 
 
Variable  
Left ventricular ejection fraction (%) 55.9 ± 14.1 
Global circumferential strain (%) -13.4 ± 4.6 
Late gadolinium enhancement present 164 (30.4) 
Late gadolinium enhancement (%) 0 (0-1.22) 
Data are presented as mean ± SD if continuous, median (interquartile range) if non-
parametric or number (%) if categorical. 
 
Mean LVEF measured by CMR was 55.9 ± 14.1% and mean GCS was -13.4 ± 4.6%. 164 
patients had LGE present (30.4%). The mean volume of LGE was 4.1 ± 10.4%. There was 
a strong correlation between all three parameters (correlation between LVEF and LGE 
percentage r = -0.43; between LVEF and GCS r = -0.58; between GCS and LGE 
percentage r = 0.33, p<0.001 for all; figures 3-1 ± 3-3).  
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Figure 3-1. Correlation between LVEF and GCS. 
 
 
r=-0.58, p<0.001. 
 
Figure 3-2. Correlation between LVEF and LGE Percentage. 
 
 
r=-0.38, p<0.001 
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Figure 3-3. Correlation between GCS and LGE Percentage. 
 
 
r=0.31, p<0.001 
 
Mean acquisition time for tagged CMR was 104 ± 22 seconds (1.7 ± 0.37 minutes) while 
mean time for post-processing analysis of tagged CMR was 3.6 ± 0.7 minutes. 


 
The mean follow-up duration was 2.2 ± 1.2 years. The combined primary outcome 
occurred in 58 patients, giving an event rate of 10.8%. There were 16 cardiovascular 
deaths (10 due to heart failure, 4 sudden deaths and 2 due to myocardial infarction), 30 
admissions for heart failure, and 12 ventricular arrhythmias requiring treatment. Age, a 
prior history of ischemic heart disease (IHD), smoking and use of angiotensin converting 
enzyme inhibitors, beta-blockers, aspirin or statins were all significant univariate clinical 
predictors of the primary outcome. In multivariable analysis of the significant clinical 
predictors of the primary outcome only a history of IHD remained a significant predictor 
of the primary outcome (HR 3.76; 95% CI 1.83-7.72, p<0.001), while use of beta-blockers 
showed a trend towards significance (HR 2.21; 95% CI 0.95-5.17, p=0.07) (table 3-4). 
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Table 3-4. Clinical Predictors of the Primary Outcome. 
 
Variable Univariable HR 
(95% CI) 
p value Multivariable 
HR (95% CI) 
p value 
Age (years) 1.04 (1.02-1.06) <0.001 1.02 (1.00-1.05) 0.10 
Male 1.64 (0.91-2.96) 0.10   
Ischemic 
Heart Disease 
6.77 (3.80-12.04) <0.001 3.76 (1.83-7.72) <0.001 
Diabetes 
Mellitus 
1.67 (0.78-3.58) 0.19   
Hypertension 1.36 (0.66-2.80) 0.41   
Smoker 2.09 (1.04-4.19) 0.039 1.50 (0.74-3.05) 0.27 
ACE inhibitor 
use 
5.57 (2.74-10.49) <0.001 1.75 (0.76-4.04) 0.19 
Beta-blocker 
use 
5.38 (2.75-10.51) <0.001 2.21 (0.95-5.17) 0.07 
Statin use 2.54 (1.45-4.44) 0.001 0.62 (0.28-1.34) 0.22 
Aspirin use 3.16 (1.81-5.54) <0.001 1.22 (0.52-2.85) 0.64 
HR ± hazard ratio; CI ± confidence interval 
 


All 3 CMR parameters were significant univariate predictors of the primary outcome 
(LVEF: HR 0.92; 95% CI 0.91-0.94, p<0.001; presence of LGE: HR 5.47; 95% CI 3.16-
9.48, p<0.001; GCS: HR 1.21; 95% CI 1.16-1.27, p<0.001). When individually added to 
significant clinical predictors in multivariable analysis, all 3 CMR parameters remained 
significant (table 3-5).  
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Table 3-5. Multivariable analysis Including CMR Parameters. 
Model 1 (Clinical + LVEF) Model 2 (Clinical + LGE) Model 3 (Clinical + GCS) Model 4 (Clinical + LVEF 
+ LGE) 
Model 5 (Clinical + LVEF 
+ LGE + GCS) 
 HR (95% 
CI) 
p 
value 
 HR 
(95% 
CI) 
p 
value 
 HR 
(95% 
CI) 
p 
value 
 HR 
(95% 
CI) 
p 
value 
 HR 
(95% 
CI) 
p value 
IHD 3.61 
(1.96-
6.65) 
<0.001 IHD 2.73 
(1.44-
5.17) 
0.002 IHD 3.75 
(2.03-
6.91) 
<0.001 IHD 2.58 
(1.22-
5.01) 
0.005 IHD 2.60 
(1.34-
5.07) 
0.005 
BB 1.54 
(0.70-
3.39) 
0.28 BB 2.88 
(1.40-
5.91) 
0.004 BB 1.91 
(0.90-
4.06) 
0.09 BB 1.58 
(0.72-
3.44) 
0.25 BB 1.40 
(0.64-
3.08) 
0.40 
LVEF 0.94 
(0.92-
0.96) 
<0.001 LGE 3.71 
(1.90-
7.25) 
<0.001 GCS 1.20 
(1.12-
1.27) 
<0.001 LVEF 0.95 
(0.93-
0.97) 
<0.001 LVEF 0.97 
(0.94-
0.99) 
0.01 
         LGE 2.29 
(1.10-
4.77) 
0.027 LGE 2.12 
(1.03-
4.37) 
0.041 
            GCS 1.10 
(1.02-
1.20) 
0.019 
BB ± beta blocker; IHD ± ischaemic heart disease; LVEF ± left ventricular ejection fraction; LGE ± late gadolinium enhancement; GCS ± global circumferential strain
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In the final multivariable model, all 3 CMR parameters remained significant predictors of 
the primary outcome (LVEF: HR 0.97; 95% CI 0.94-0.99, p=0.01; presence of LGE: HR 
2.12; 95% CI 1.03-4.37, p=0.041; GCS: HR 1.10; 95% CI 1.02-1.20, p=0.019). The 
addition of both LGE and GCS had incremental prognostic value when added to clinical 
predictors and LVEF (figure 3-4). 
 
Figure 3-4. Incremental Value of CMR Parameters for Prediction of the Primary 
Outcome Shown by Improvement in Chi-Square. 
 
 
 
All 3 CMR parameters had reasonable power for prediction of adverse events. The area 
under the ROC curve for LVEF was 0.834, for LGE 0.699 and for GCS 0.820 (all 
p<0.001). Using ROC analysis, optimal cut-offs for LVEF and GCS were 50.2% and -
12.1% respectively, which provided excellent stratification of risk (figures 3-5 ± 3-7). 
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Figure 3-5. Kaplan-Meier Curve For Survival Based on the Optimal LVEF Cut-Off. 
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Figure 3-6. Kaplan-Meier Curve For Survival Based on the Presence of LGE. 
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Figure 3-7. Kaplan-Meier Curve For Survival Based on the Optimal GCS Cut-Off. 
 
 
 

 
In total there were 474 patients with LVEF RIZKRPH[SHULHQFHG WKHSULPDU\
outcome (7.4%) ± there were 11 deaths, 14 admissions for heart failure and 10 ventricular 
arrhythmias. In this group, both the presence of LGE (HR 3.88; 95% CI 1.86-8.09, 
p<0.001) and GCS (HR 1.09; 95% CI 1.00-1.19, p=0.046) remained significant 
multivariable predictors of the primary outcome when added to LVEF (HR 0.93; 95% CI 
0.90-0.97, p=0.001) (figures 3-8 and 3-9).  
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Figure 3-8. Kaplan-Meier Curve For Survival Based on the Presence of LGE in 
Patients with LVEF  
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Figure 3-9. Kaplan-Meier Curve For Survival Based on the Optimal GCS Cut-Off in 
3DWLHQWVZLWK/9() 
 
 
 
 
Patients with LVEF 35% but GCS <-12.1% and LGE present had similarly poor 
outcomes to patients with LVEF <35% (figure 3.10).

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Figure 3-10. Kaplan-Meier Curve For Survival Based on LVEF, GCS and LGE. 





30 CMR studies were jointly analysed by I.M. and N.T. to assess reproducibility of GCS 
measurements. There was excellent intra-observer variability (r=0.96, p<0.01) and 
interobserver agreement (r=0.94, p<0.01). The intraclass correlation coefficient for 
interobserver agreement was 0.95 (95% CI 0.88-0.98, p<0.001). 
 

 

 
This study identified two important findings: 
 
x For the first time in a large, prospectively evaluated cohort of unselected patients, I 
have shown that the assessment of GCS using CMR tagging has independent and 
incremental value in the prediction of MACE when added to clinical predictors, 
LVEF and LGE as part of a routine CMR protocol.  
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x Importantly, this incremental predictive value of GCS held true in the absence of 
significant left ventricular systolic dysfunction extending its applicability. Indeed, 
in patients with LVEF 35%, a reduced GCS in association with the presence of 
LGE had a similarly poor prognosis as those with LVEF <35%. 
  

 
LVEF has been shown to be a strong predictor of adverse outcome (Solomon et al., 2005, 
Dagres and Hindricks, 2013). The presence of severe left ventricular systolic dysfunction 
(LVSD), defined by an LVEF <35%, is a marker of extremely poor prognosis, and is 
commonly used to guide treatment decisions regarding use of mortality and morbidity 
improving therapies such as defibrillators and cardiac resynchronization therapy 
(McMurray et al., 2012, Yancy et al., 2013). Despite these factors, the use of LVEF alone 
is subject to some limitations. Firstly, it is known that a strict cut-off based on ejection 
fraction may still miss patients at higher risk as patients with an LVEF >35% can still have 
admissions for heart failure and cardiac death (Gorgels et al., 2003, Makikallio et al., 2005, 
Stecker et al., 2006). Secondly, LVEF is not purely a measure of contractility as it is 
affected by volumes, loading conditions, heart rate, and valvular function among other 
factors. This means that patients with a preserved or mildly reduced LVEF may still have 
an adverse prognosis (Gustafsson et al., 2003), whereas some healthy patients may actually 
have reduced LVEF (Abergel et al., 2004). This has lead to the search for other parameters 
that may improve risk stratification. 
 
LGE has emerged as a powerful predictor of adverse outcome in patients with both 
reduced and preserved LVEF (Kwong et al., 2006, Wu et al., 2008, Krittayaphong et al., 
2011, Gulati et al., 2013). Its absence may provide extra reassurance to clinicians in 
patients who might already be at high risk of MACE. The presence of LGE signifies 
myocardial fibrosis, which as well as reducing overall myocardial contractility, might also 
represent a substrate for ventricular arrhythmias which might lead to sudden death (Iles et 
al., 2011, Scott et al., 2011a, Dawson et al., 2013). This study adds to the increasing 
evidence suggesting that the presence of LGE is an adverse prognostic indicator, not only 
in traditionally high-risk patients (LVEF <35%), but also in those who might be thought to 
KDYHDUHGXFHGULVN/9() 
 
 
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
 
The measurement of circumferential strain perhaps aims to resolve some of the problems 
associated with LVEF related to loading conditions. GCS is a less load-dependent measure 
than LVEF, and is thought to better reflect myocardial contractile function (Ibrahim el, 
2011). Strain measured using echocardiography has been shown to be an independent 
marker of adverse prognosis that is potentially stronger than LVEF in a number of studies 
(Cho et al., 2009, Stanton et al., 2009). However, although CMR tagging is accepted as the 
gold standard for non-invasive assessment of strain, only one study has evaluated the 
prognostic value of tagging. A recent study by Choi et al. in the Multi-Ethnic Study of 
Atherosclerosis cohort evaluated 1,768 asymptomatic patients using CMR tagging (Choi et 
al., 2013). The authors found that GCS provided incremental prognostic value when added 
to baseline clinical variables and LVEF. This incremental benefit also persisted in patients 
with preserved LVEF. 
 
This study, on one hand, parallels the results of Choi et al., and on the other extends its 
observations to patients with suspected cardiac disease, underscoring the additional clinical 
value of CMR tagging.  Similar to Choi et al., I also found that GCS was an independent 
predictor of adverse events in a large unselected cohort of patients undergoing CMR 
examination. In addition, I found that the incremental benefit of GCS was also present 
when the presence of LGE was included. This is important as most CMR protocols include 
the use of gadolinium contrast agents and so to have clinical utility it is important that the 
use of tagging has incremental benefit to both LVEF and LGE. 
 
The incremental benefit of GCS may be due to two reasons. Firstly, changes in strain 
might reflect a composite of myocardial fibrosis and contractile dysfunction, which LVEF 
and LGE only measure individually (Buckberg et al., 2008, Rosen et al., 2005). This 
combined assessment using GCS might provide more powerful prognostic information. 
Indeed, GCS is the major contributor to left ventricular stroke volume (Buckberg et al., 
2008). Secondly, LGE is often not able to identify diffuse myocardial fibrosis due to the 
QHHGWRLGHQWLI\DUHDVRI³QXOOHG´KHDOWK\P\RFDUGLXP(Mewton et al., 2011). Assessment 
of GCS may identify areas of reduced contractility caused by diffuse fibrosis not picked up 
by LGE (Dass et al., 2012). This may also explain the incremental prognostic value of 
GCS in patients with moderate and preserved LV function. Interestingly, the presence of 
LGE was a stronger predictor of outcome in this group. This might have implications for 
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the use of defibrillator therapies in this group, as it might suggest that the more common 
cause of adverse outcome in this group is ventricular arrhythmia rather than pump failure. 
The results of this study perhaps point to this being the case. 
 

 
The addition of CMR tagging did not add too much time to the standard CMR protocol of 
cine and LGE imaging. Ultimately, with current the availability of fast acquisition imaging 
hardware as well as user friendly tagging software, assessment of GCS could potentially be 
incorporated into routine CMR examinations and provide incremental prognostic value in 
DGGLWLRQWR/9()DQG/*(7KHLGHQWLILFDWLRQRISDWLHQWVZLWK/9()EXWUHGXFHG
GCS and LGE may identify a group that could benefit from more advanced therapies, 
whereas those impaired LV systolic function but preserved GCS and the absence of LGE 
might have a better prognosis. 
 

 
This study has two inherent limitations, firstly its single-centre nature, and secondly that it 
suffers from an element of referral bias as patients were only included if referred for CMR. 
CMR is not yet a routine part of clinical care (for most conditions), and so this study most 
likely only included patients in whom the clinician wished to have further information and 
may have been more concerned about. Nevertheless, by having very few exclusion criteria, 
and including consecutive patients, the study cohort is still very broad and generalisable to 
routine clinical care. 
 
Only GCS was assessed in this study. The protocol did not include long-axis views for 
assessment of global longitudinal strain (GLS) in this cohort in order to keep scan times to 
a minimum. However, GLS has been shown to be a strong echocardiographic predictor of 
outcome (Stanton et al., 2009). Additionally, strain rate and diastolic deformation 
parameters were not assessed in this study, which may also have prognostic value. 
 
 
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

The assessment of GCS by CMR tagging provides incremental prognostic value for 
prediction of adverse cardiovascular events when added to baseline clinical variables, 
LVEF and LGE in a routine CMR protocol in patients with and without severe LV systolic 
dysfunction. Assessment of myocardial strain may be a useful parameter to include in 
CMR scanning protocols and help identify a group of patients with increased risk despite 
not initially meeting the current guidelines for being high-risk. 
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4. Prevalence and Prognostic Significance of 
Lipomatous Metaplasia in Patients with Prior 
Myocardial Infarction 
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

In the last chapter I showed the incremental prognostic significance of CMR using 
techniques that utilise its 2 main advantages, namely its superior ability (compared to other 
non-invasive techniques) to assess left ventricular function, and its ability to provide 
information on tissue characterisation. 
 
During scanning the cohort of patients for the study in the previous chapter, it became 
apparent that in patients with prior myocardial infarction (MI), the pattern of LGE 
(representing myocardial infarct scar) was not always a confluent area, but in fact 
contained various components that could be characterised further using other CMR 
techniques. 
 
Following MI, numerous changes, known as remodeling occur. Among these, the presence 
and extent of LGE in the injured area is recognised as a strong predictor of adverse 
outcomes by means of providing a substrate for ventricular arrhythmias and sudden cardiac 
death (SCD) (Bello et al., 2005, Klem et al., 2012, Kwon et al., 2009, Scott et al., 2011a). 
It has been recently noted, initially in pathological specimens, that infarcted myocardium 
can be infiltrated by adipose cells, known as lipomatous metaplasia (LM). Pathological 
studies have found a prevalence of LM of between 68% and 84% in patients with a history 
of prior myocardial infarction (Baroldi et al., 1997, Su et al., 2004). It has also been 
suggested that the presence of myocardial fat may interfere with the conduction system of 
the heart, perhaps providing a substrate for SCD (Pantanowitz, 2001). 
 
Recognition of LM in early studies was limited as it is not detected by echocardiography or 
SPECT imaging (Nucifora et al., 2011). Recently, the use of computed tomography (CT) 
and CMR has allowed in-vivo identification of LM (Winer-Muram et al., 2004, Schmitt et 
al., 2007, Wu et al., 2007). Recent studies have aimed to characterise the incidence of LM 
using both CT and CMR, but they have been limited by their small size and/or 
retrospective nature (Ahn et al., 2009, Goldfarb et al., 2009, Ichikawa et al., 2009, Lucke et 
al., 2010). Recently there has been evidence that the development of LM in an ovine model 
of myocardial infarction is associated with an increased of ventricular arrhythmia 
(Pouliopoulos et al., 2013). To date no study has prospectively characterised the 
prevalence, functional characteristics and prognostic relevance of LM post-MI. 
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As well as LGE imaging, acquisition of images 1-2 minutes post-injection of gadolinium 
(known as early gadolinium enhancement imaging ± EGE) allows identification of 
microvascular obstruction within infarcted myocardium, a known marker of adverse 
prognosis post-MI (Wu et al., 1998). Meanwhile, T2-weighted sequences such as black-
blood short-tau inversion recovery (T2-STIR) allow identification of myocardial oedema, 
visualized by areas of increased signal (Simonetti et al., 1996). Oedema develops acutely 
after MI due to the myocyte necrosis, causing release of cellular contents and increased 
myocardial water content.  
 
These sequences also offer an opportunity to identify fat within the myocardium. T2-STIR 
sequences give low intensity in areas occupied by fat, and the removal of the STIR pulse 
will result in signal increase in the corresponding region. In order to identify the present of 
fat within the infarct territory, a pair of T2-weighted spatially matched images with and 
without a fat suppressing STIR pulse (henceforth described as T2-STIR+ and T2±STIR-) 
were added to the CMR protocol.   
 
The aim of this study was to prospectively evaluate the incidence and prognostic 
significance of LM in an unselected cohort of patients with prior MI using the 
aforementioned CMR techniques.  
  




This study included consecutive patients who had a remote history of MI (>6 months), 
referred by for CMR for evaluation of cardiac symptoms such as chest pain or dyspnoea. 
Diagnosis of prior MI was confirmed by review of the clinical notes of the index 
presentation for a combination of typical symptoms (such as typical chest pain, dyspnea, 
autonomic symptoms), a diagnostic rise in cardiac biomarkers (troponin I >0.04ng/ml) and 
electrocardiographic changes consistent with type 1 MI (ST elevation/depression, new T 
wave abnormalities or pathological Q waves) (Thygesen et al., 2012). To corroborate the 
evidence of type 1 MI secondary to obstructive coronary artery disease, all patients had 
undergone either invasive or CT coronary angiography (14+/- 10 days post event). Patients 
with angiographically normal epicardial coronary arteries, stress-related cardiomyopathy 
Chapter 4: The Prognostic Significance of Lipomatous Metaplasia Post-MI 
 
 83 
RUP\RFDUGLWLV ZHUH H[FOXGHG %DVHOLQH FKDUDFWHULVWLFV ZHUH REWDLQHG IURP WKH SDWLHQWV¶
hospital records. 
 


As described in Chapter 2, cine images were obtained for assessment of mass and function 
using an SSFP sequence in long-axis planes and short-axis slices from the mitral valve to 
the apex of the left ventricle. Following this, T2-weighted imaging was conducted in 3 
matched short-axis slices (representing the basal, mid and apical segments) using a STIR 
sequence (T2-STIR+) (Simonetti et al., 1996). The identical underlying black-blood 
sequence was then performed without a third inversion pulse (T2-STIR-). After injection 
of gadolinium, EGE imaging was obtained at 2 and 5 minutes post-injection as described 
previously in our unit (Payne et al., 2011a). 10 minutes after the injection LGE imaging 
was performed using an inversion recovery fast gradient-echo sequence. The CMR 
protocol is summarised in figure 4-1. 
 
Figure 4-1. Summary of the CMR Examination Sequence. 
 
 
 
 
Left ventricular diameter, mass volumes and function were derived from the short-axis 
slices using manual tracing of the endocardial and epicardial contours. The presence of 
LGE was assessed by identification of areas of myocardium with a signal intensity of 
>5SD above remote myocardium. This area was expressed as percentage of the total left 
ventricular area measured in short-axis as described in Chapter 2. 
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The imaging protocol was specifically designed to identify myocardial fat in a 
comprehensive manner and to try to exclude potential confounders that might be mistaken 
for fat. To achieve this, the presence of LM was based on several features:  
 
x )LUVWO\WKHSUHVHQFHRID³FKHPLFDOVKLIWDUWHIDFW´RQ66)3LPDJLQJLQDQDUHDZLWK
a regional wall motion abnormality (RWMA). This artifact is caused by the 
difference in signal intensity between fat and myocardium, and has previously been 
recognised as an indicator of the presence myocardial fat (Lucke et al., 2010).  
x Secondly, the presence of an area of hypointense signal on T2-STIR+ images 
within the areas of myocardial infarct i.e. within the area with the RWMA. Thirdly, 
the same area should appear isointense on T2-STIR- images (any areas that 
remained hypointense on T2-STIR- images could be due to intra-infarct 
hemorrhage which can occur after MI) (Ganame et al., 2009). Also, the absence of 
hyperintense areas using T2-weighted imaging was designed to confirm the 
absence of recent myocardial injury (Wright et al., 2009).  
x Prior myocardial infarction was confirmed by the presence of LGE in a 
subendocardial or transmural pattern in the area with a RWMA.  
x Finally, to further exclude intramyocardial hemorrhage and microvascular 
obstruction, the segment(s) with RWMA had to have no hypointense areas on 
either EGE or LGE imaging, thus excluding the presence of microvascular 
obstruction (Wu, 2012). 
 
To provide further corroboration of the identification of LM using CMR, CMR findings 
were compared with cardiac CT in those patients who underwent both, specifically 
measuring the signal intensity (in Hounsfield units) of those areas where fat was suspected. 
This also allowed exclusion of a final confounder in our CMR diagnosis of LM, namely 
the myocardial infarct calcification which may also cause a low signal that could be 
mistaken for fat using our CMR technique, but causes high signal on CT (Su et al., 2004).  
 


All patients were followed-up using the computerised record linkage system allowing 
identification of all deaths and hospital admissions. In total 12 patients were lost to follow-
up and were not included in the final analysis (figure 4-2).  
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Figure 4-2. Derivation of the Study Cohort. 
 
 
 
The combined primary outcome was all-cause mortality, sustained ventricular arrhythmia 
and heart failure hospitalisation. Cause of death was determined from the case notes, 
UHFRUGVIURPWKHSDWLHQW¶VJHQHUDOSUDFWLWLRQHUDQGSRVW-mortem or death certificate where 
available. Sustained ventricular arrhythmia was documented as survived cardiac arrest, any 
ventricular arrhythmia requiring hospital admission or emergency DC cardioversion for 
haemodymanic instability or any appropriate implantable cardioverter-defibrillator 
activation.  



As described in Chapter 2, continuous variables are reported as mean ± standard deviation 
while categorical variables are reported as numbers with percentage in brackets. 
Comparisons between groups were evaluated using t-WHVWVRUȤ-squared tests as appropriate. 
Logistic regression was used to identify independent predictors of the presence of LM. 
Kaplan-Meier and Cox-proportional hazards methods were used to evaluate the univariable 
prognostic significance of various factors for the prediction of cardiovascular mortality, 
ventricular arrhythmias and HF hospitalizations from the time of CMR examination. To 
determine the independent prognostic significance of the presence of LM, multivariable 
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models were created including statistically significant univariable predictors in a forward 
stepwise selection (including variables with significance p<0.10). Only the most 
significant variables were included to allow one variable for every 10 occurrences of the 
primary endpoint. Multivariable models were created to separately assess the impact of 
clinical factors (model 1), LV remodeling (model 2) and infarct characteristics (model 3) 
before assessing the impact of LM with the strongest overall predictors (model 4). In 
patients in whom 2 different events occurred the time to first event was used. The c-
statistic was calculated for the multivariable model based on the Cox proportional hazards 
model. For all analyses a p value <0.05 was considered statistically significant and all p 
values are two-tailed. 
 




390 consecutive patients referred for CMR were screened for inclusion into the study. Of 
these, 316 patients were eligible and had complete follow-up. Derivation of the cohort is 
summarised above in figure 4-2.  
 
The average age of the cohort was 58.6 ± 10.9 years and the majority were male (75.3%). 
Median time from MI to CMR examination was 4.0 years (IQR 0.75-9.5 years). 217 
patients had undergone invasive coronary angiography (68.7%) and 99 (31.3%) had 
undergone CT coronary angiography to confirm coronary artery disease. The mean LVEF 
was 40.2% ± 15.1% (median 21%, IQR 10-33%) and mean NYHA class 1.97 ± 0.87. 
There was a high prevalence of cardiovascular risk factors (diabetes 26.7%, 
hypercholesterolemia 20.4% and hypertension 34.3%). Median follow-up was 2.9 years 
(IQR 1.7-3.5 years). The majority of patients had LAD territory infarcts (35.0%) while 
25.4% had multi-vessel infarcts. Mean infarct size was 23.33% ± 15.02% (median 21%, 
IQR 10-33%) of the left ventricle and just over half had transmural infarcts (51.8%). 


 
42 patients with LM and 57 without LM underwent coronary CT as well as CMR 
examination. Using this CMR protocol, the diagnosis of LM corresponded very well to 
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hypointense areas seen on CT typical of myocardial fat, rather than peri-infarct 
calcification (figure 4-3). 
 
Figure 4-3. Correlation Between CMR and CT for Identification of LM. 
 
 
A patient with a prior LAD territory myocardial infarct imaged using CT and CMR. 
Coronary CT shows the presence of subendocardial hypointense signal in the 3-chamber 
view (-36 Hounsfield units) in the anterior wall (left; arrow). CMR T2-STIR+ imaging also 
shows the presence of hypointense signal in the same territory as the CT (middle; arrow) 
which appears isointense using T2-STIR- (right). 
 
Overall, the mean signal intensity of the areas of LM in the 42 patients with LM was -32 
+/- 27 Hounsfield units in comparison to normal myocardium which measured 98+/- 38 
Hounsfield units. The addition of EGE imaging also allowed us to exclude the presence of 
myocardial hemorrhage as a cause of hypointense signal on T2-weighted imaging (figures 
4-4 and 4-5). 
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Figure 4-4. CMR Imaging of LM Using The Study Protocol. 
 
 
The presence of LM in the infarcted area (anteroseptal wall) was seen non-invasively 
through the presence of chemical shift artefact using steady state free precession imaging 
(A; arrow). Using T2W+STIR imaging this area appeared hypointense (B; arrows) but 
isointense using T2W-STIR (C). Late gadolinium enhancement imaging confirmed an LAD 
territory infarct with fibrosis in the anterior wall and septum and no central area of 
microvascular obstruction (D; arrow). 
 
Figure 4-5. CMR Imaging of Microvascular Obstruction Using The Study Protocol. 
 
 
An example of the utility of early and late gadolinium enhancement in differentiating 
between LM and microvascular obstruction caused by myocardial haemorrhage. 
SSFP cine imaging reveals the presence of an anterior wall motion abnormality suspicious 
of prior MI (A). There is a hypointense area on T2-STIR+ imaging that was suspicious for 
LM (B; arrow) however this area also appeared hypointense on early gadolinium 
enhancement imaging (C; arrow), suggesting that it was caused by intra-infarct 
myocardial haemorrhage rather than fat. This was corroborated by a similar hypointense 
area within the infarcted myocardium on late gadolinium enhancement imaging 
corresponding to an area of microvascular obstruction caused by haemorrhage (D; 
arrow). 
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

Using the CMR diagnostic criteria for LM, 77 patients from the total 316 (24.4%) had 
evidence of LM (LM+). Clinical and CMR associations with the presence of LM are 
summarized in tables 4-1 and 4-2.  
 
Table 4-1. Baseline Clinical Characteristics. 
 
Variable All Patients 
(n=316) 
LM + (n=77) LM ± 
(n=239) 
p value 
Age (yrs) 58.6 ± 10.9 59.4 ± 9.7 58.4 ± 11.3 0.46 
Male (%) 229 (75.3) 55 (71.4) 174 (76.7) 0.36 
Height (m) 1.69 ± 0.10 1.68 ± 0.09 1.69 ± 0.10 0.26 
Weight (kg) 82.4 ± 17.7 81.5 ± 15.7 82.7 ± 18.4 0.61 
BMI (kg/m2) 28.9 ± 5.2 29.0 ± 4.8 28.8 ± 5.4 0.81 
Diabetes (%) 56 (26.7) 17 (32.7) 39 (24.7) 0.40 
AF (%) 26 (12.3) 9 (17) 17 (10.8) 0.23 
Hypercholesterolemia 
(%) 
43 (20.4) 11 (20.8) 32 (20.3) 0.94 
Chronic Kidney 
Disease (%) 
22 (10.4) 7 (13.2) 15 (9.5) 0.44 
Hypertension (%) 69 (34.3) 18 (34.6) 51 (34.2) 0.96 
Beta-blocker (%) 278 (88.0) 64 (83.1) 214 (89.5) 0.11 
ACEI /ARB (%) 256 (81.0) 63 (81.8) 193 (80.8) 0.91 
MRA (%) 112 (35.4) 30 (39) 82 (34.3) 0.56 
Statin (%) 48 (76.2) 10 (66.7) 38 (79.2) 0.32 
Prior 
Revascularisation 
(%) 
166 (52.5) 35 (45.5) 132 (55.2) 0.15 
Years since MI 6.45 ± 6.62 10.38 ± 7.11 5.19 ± 5.96 <0.001 
Mean NYHA Class 1.97 ± 0.87 2.30 ± 0.82 1.86 ± 0.87 0.001 
ACEI ± angiotensin converting enzyme inhibitor; ARB ± angiotensin II receptor 
antagonist; BMI ± body mass index; AF ± atrial fibrillation; LVEDD ± left ventricular 
end-diastolic diameter; MRA ± mineralocorticoid receptor antagonist 
Data are presented as mean ± SD if continuous or number (%) if categorical. 
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Table 4-2. Baseline CMR Characteristics. 
 
Variable All Patients 
(n=316) 
LM + (n=77) LM ± 
(n=239) 
p value 
LVEF (%) 40.2 ± 15.1 33.1 ± 13.1 42.6 ± 15.0 <0.001 
LVEDVi (ml/m2) 115.3 ± 43.6 136.0 ± 50.2 108.1± 38.7 <0.001 
LVESVi (ml/m2) 75.2 ± 49.8 100.9 ± 66.6 66.5 ± 39.0 <0.001 
LV Mass (g/m2) 87.2 ± 26.3 94.1 ± 29.4 84.8 ± 24.8 0.007 
LVEDD (cm) 6.67 ± 1.03 7.17 ± 1.18 6.49 ± 0.91 <0.001 
LVESD (cm) 5.26 ± 1.34 5.94 ± 1.41 5.02 ± 1.24 <0.001 
Infarct Size (%) 23.33 ± 15.02 31.56 ± 12.08 20.45 ± 14.91 <0.001 
Transmural 
Infarct 
156 (51.8) 66 (85.7) 90 (40.2) <0.001 
Coronary Artery 
Territory 
   0.004 
LAD 106 (35.0) 28 (36.4) 78 (34.5)  
LCx 48 (15.8) 7 (9.1) 41 (18.1)  
RCA 72 (23.8) 12 (15.6) 60 (26.5)  
Multi-vessel 77 (25.4) 30 (39.0) 47 (20.8)  
LV Aneurysm 14 (6.6) 10 (17.5) 4 (2.6) <0.001 
LV Thrombus 10 (4.7) 4 (7) 6 (3.9) 0.46 
LVEF ± left ventricular ejection fraction; LVEDi ± left ventricular end-diastolic volume 
index; LVESVi ± left ventricular end-systolic volume index; LVEDD ± left ventricular end-
diastolic diameter; LVESD ± left ventricular end-systolic diameter; WMSI ± wall motion 
score index; LAD ± left anterior descending artery; LCx ± circumflex artery; RCA ± right 
coronary artery 
Data are presented as mean ± SD if continuous or number (%) if categorical. 
 
LM+ patients had older infarcts (mean infarct age 10.38 ± 7.11 years vs. 5.19 ± 5.96; 
p<0.001), had more extensive infarcts (infarct size 31.56% ± 12.08% vs. 20.45% ± 
14.91%; p<0.001; and more often had transmural infarction (85.7% vs. 40.2%; p<0.001). 
There was no significant difference in the use of beta-blockers, ACE inhibitors or 
mineralocorticoid receptor antagonists between the two groups. LM was not associated 
with any clinical factors such as age, gender, weight, body mass index, diabetes, chronic 
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kidney disease, hypertension, hypercholesterolemia or atrial fibrillation. It was also not 
associated with prior revascularization (by PCI or CABG). 
 
However, LM was associated with greater degrees of adverse remodeling. LM+ patients 
had lower LVEF (33.1% ± 13.1% vs. 42.6% ± 15.0%; p<0.001) and higher left ventricular 
end-diastolic volume index (136.0 ± 50.2 ml/m2 vs. 108.1 ± 38.7ml/m2; p<0.001) and end-
systolic volume index (100.9 ± 66.6ml/m2 vs. 66.5 ± 39.0ml/m2; p<0.001). LM was also 
more likely to be present in patients with aneurysmal left ventricular segments (17.5% vs. 
2.6%; p<0.001). There was no association with the presence of LV thrombus (7% vs. 
3.9%; p=0.46). Using logistic regression, both infarct size measured by LGE (OR 1.03; 
95% CI 1.01-1.06, p=0.003) and LVEF (OR 0.97; 95% CI 0.95-1.00, p=0.022) were 
predictors of the presence of LM. 
 


The primary outcome of all-cause mortality, ventricular arrhythmia and HF hospitalisation 
occurred in 46 patients, 23 LM+ (29.9%) and 23 LM- (9.6%). There were 29 deaths, of 
which 25 were cardiovascular. 2 were related to malignancy and 2 due to end-stage 
respiratory failure. There were 12 arrhythmic events, and 5 heart failure hospitalisations. In 
univariable analysis, LM was a significant predictor of the primary outcome (HR 3.65; 
95% CI 2.04-6.52, p<0.001) (table 4-3 and figure 4-6).  
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Table 4-3. Univariable Predictors of the Primary Outcome. 
 
Variable HR (95% CI) p value Ȥ2 
Age (yrs) 1.01 (0.99-1.04) 0.30 1.09 
Male (%) 0.65 (0.35-1.20) 0.16 1.96 
Weight (kg) 0.99 (0.98-1.01) 0.37 0.82 
Body Mass Index (kg/m2) 0.99 (0.93-1.05) 0.62 0.24 
Diabetes 1.93 (1.06-3.49) 0.03 4.85 
Atrial Fibrillation 3.31 (1.68-6.50) 0.001 13.48 
Hypercholesterolemia 1.16 (0.52-2.60) 0.72 0.13 
Chronic Kidney Disease 1.95 (0.87-4.36) 0.10 2.76 
Hypertension 0.94 (0.48-1.86) 0.87 0.03 
Statin 1.02 (0.57-1.81) 0.96 0.003 
Beta-blocker 0.40 (0.20-0.81) 0.011 6.91 
ACE 
Inhibitors/Angiotensin II 
Receptor Blocker 
0.65 (0.32-1.34) 0.24 1.38 
Mineralocorticoid receptor 
antagonist 
0.97 (0.50-1.87) 0.92 0.01 
NYHA Class 1.57 (1.19-2.25) 0.012 6.39 
LVEF (%) 0.97 (0.95-0.99) 0.003 8.92 
LV Mass (g/m2) 1.00 (0.99-1.01) 0.43 0.61 
LVEDD (cm) 1.36 (1.04-1.79) 0.026 4.93 
LVESD (cm) 1.31 (1.06-1.63) 0.014 6.14 
LVEDVi (ml/m2) 1.01 (1.00-1.01) 0.026 4.92 
LVESVi (ml/m2) 1.00 (1.00-1.01) 0.11 2.59 
LM + 3.65 (2.04-6.52) <0.001 21.79 
Infarct Size (%) 1.02 (1.00-1.04) 0.08 3.17 
Infarct Size (per 10% 
increase) 
1.30 (1.02-1.65) 0.035 4.55 
Multivessel Infarct 2.29 (1.27-4.12) 0.006 8.03 
Transmural Infarct 1.68 (0.92-3.09) 0.09 2.86 
LV Aneurysm 2.61 (1.02-6.65) 0.044 4.36 
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HR ± hazard ratio; LVEF ± left ventricular ejection fraction; LVEF ± left ventricular 
ejection fraction; LVEDD ± left ventricular end-diastolic diameter; LVESD ± left 
ventricular end-systolic diameter; LVEDVi ± left ventricular end-diastolic volume index; 
LVESVi ± left ventricular systolic volume index; LM ± lipomatous metaplasia 
 
Figure 4-6. Kaplan-Meier Survival Curves by LM status for Prediction of the 
Primary Outcome. 
 
 
 
Other univariable predictors of the primary outcome were atrial fibrillation (HR 3.31; 95% 
CI 1.68-6.50, p=0.001), diabetes (HR 1.93; 95% CI 1.06-3.49, p=0.03), LVEF (HR 0.97 
per 1% increase; 95% CI 0.95-0.99, p=0.003), infarct size (HR 1.30 per 10% increase; 
95% CI 1.02-1.65, p=0.035), beta-blocker use (HR 0.40; 95% CI 0.20-0.81, p=0.011) and 
NYHA class (HR 1.57; 95% CI 1.10-2.25, p=0.012). Left ventricular dimensions, 
aneurysms and the presence of multi-vessel infarcts were also significant predictors of the 
primary outcome. The presence of LM remained significant predictor of the primary 
outcome in all multivariable models (table 4-4). The addition of LM to multivariable 
model 4 increased the c-statistic for the prediction of the composite primary outcome from 
0.70 (95% CI 0.62-0.79) to 0.76 (95% CI 0.70-0.82; p=0.15). 
 
  
 


  
    
    
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Table 4-4. Multivariable Predictors of the Primary Outcome. 
 
 Variable HR (95%CI) p value 
Model 1 
(clinical) 
NYHA Class 1.37 (0.92-2.02) 0.12 
Diabetes 1.88 (0.96-3.68) 0.07 
AF 3.51 (1.69-7.32) 0.001 
Beta-blocker use 0.55 (0.25-1.22) 0.55 
LM + 3.84 (1.75-8.43) 0.001 
Model 2 
(remodeling) 
LVEDV (ml/m2) 1.00 (0.99-1.01) 0.65 
LVESD (cm) 0.94 (0.47-1.90) 0.87 
LVEDD (cm) 1.07 (0.47-2.42) 0.87 
LVEF (%) 0.97 (0.94-1.01) 0.09 
 
LM + 3.07 (1.64-5.74) <0.001 
Model 3 
(infarct 
characteristics) 
Infarct size (per 10%) 0.97 (0.71-1.34) 0.87 
Multi-vessel infarct 1.89 (0.98-3.65) 0.06 
Aneurysm 1.63 (0.60-4.39) 0.34 
Transmural infarct 1.00 (0.49-2.03) 0.99 
LM + 2.89 (1.48-5.65) 0.002 
Model 4 
(strongest 
combined) 
AF 2.85 (1.42-5.72) 0.003 
LVEF 0.98 (0.96-1.00) 0.09 
Diabetes 1.93 (1.05-3.56) 0.036 
Multi-vessel infarct 1.38 (0.74-2.58) 0.31 
LM + 2.67 (1.44-4.96) 0.002 
AF ± atrial fibrillation; LVEF ± left ventricular function; LM ± lipomatous metaplasia;  HR ± 
hazard ratio; LVEF ± left ventricular ejection fraction; LVEDD ± left ventricular end-
diastolic diameter; LVESD ± left ventricular end-systolic diameter 
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There were 12 patients who had recorded ventricular arrhythmias over the follow-up 
period, 10 in the LM+ group (12.9%) and 2 in the LM- group (0.8%). The presence of LM 
was the only significant predictor of ventricular arrhythmia (HR 17.65; 95% CI 3.86-
80.76, p<0.001) (figure 4-7). 

Figure 4-7. Kaplan-Meier Survival Curves by LM status for Prediction of 
Ventricular Arrhythmia. 





 

 
This study was the first study to examine the prognostic significance of LM in patients 
with a history of prior MI. The two main findings were that:  
 
x This study confirmed findings from prior studies suggesting that the presence of 
LM is associated with older infarcts, lower LVEF, adverse LV remodeling and 
larger infarct size as measured by LGE in a large cohort.  
 


  
    
    
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x In addition, this study has shown for the first time that the presence of LM is an 
independent predictor of adverse outcome post-MI.  
 

 
Following MI, the heart undergoes a process of remodeling involving numerous 
biochemical pathways which cause inflammation, myocyte hypertrophy and collagen scar 
formation, leading to morphological changes such as left ventricular dilatation and infarct 
expansion (Sutton and Sharpe, 2000, Konstam, 2008). The increased use of CMR and CT 
has provided clinicians with increased ability to characterise tissue, and provide further 
understanding of the changes in the myocardium that occur post-MI beyond left ventricular 
dimensions. 
 
The presence of LM has, until recently, only been able to be identified pathologically, 
inevitably post-mortem. In these pathological studies, it was noted that LM was associated 
with greater degrees of adverse remodeling, suggesting that its presence might be an 
adverse prognostic indicator (Baroldi et al., 1997, Su et al., 2004). Of course the very 
nature of these studies meant that this association could only be postulated. The use of 
CMR has allowed, for the first time, this hypothesis to be tested. 
 
While ACE inhibitors and beta-blockers are a cornerstone of post-MI therapy due to their 
beneficial effects on adverse remodeling of the left ventricle, they have less of an effect on 
infarct scar. Characterisation of infarct scar, including the presence of LM, might provide a 
new therapeutic target to improve outcomes in this group of patients. 
 
²
 
In pathological studies, LM appears to be fairly common in patients with a history of prior 
MI. Baroldi et al were the first to report the presence of LM in MI scar using 
histopathology, with an incidence of 68% (Baroldi et al., 1997). A further study of 
explanted hearts by Su et al reported an incidence of 84% (Su et al., 2004). These figures 
are significantly higher than the incidence reported in this study (24.4%). This might be 
explained by the lower spatial resolution of CMR compared to histological examination, 
which means that CMR may miss very small areas of adipose tissue. Su et al found that 
only 17% of infarcts had adipose >25% of the infarct size ± potentially, this may be the 
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level of adipose tissue which can be identified as LM by CMR. Baroldi et al also reported 
that only 28% of the patients that they identified with LM had adipose tissue greater than 
20%.  
 
The prevalence of LM in this cohort is similar to two large retrospective studies 
investigating the prevalence of LM. Ahn et al reported a prevalence of 22.4% in 161 
patients evaluated by CT, a similar figure to this study (Ahn et al., 2009). The 
identification of intramyocardial fat by its low attenuation (around -30 Hounsfield units) 
on CT has been well described (Ichikawa et al., 2009). Another large study of 315 patients 
using CMR by Lucke et al reported a prevalence of only 11% (Lucke et al., 2010). This 
may have been because the authors included patients 3-6 months post-MI, when perhaps 
they had undergone less remodeling. Based on the knowledge that LM tends to reflect 
adverse remodeling over a duration of time and thus is likely to be linked with older 
infarcts, patients with an MI less than 6 months prior to CMR were excluded from this 
study. By using this cut-off the CMR exam would also be a truer reflection of the impact 
of LM on left ventricular function by allowing more time for any post-infarct myocardial 
stunning to resolve (Bax et al., 2001). 
 

 
In this study, the presence of LM was associated with more adverse remodeling i.e. 
ischaemic cardiomyopathy. LM+ patients had lower LVEF and larger left ventricular 
volumes and diameters. Furthermore, LM was also associated with larger infarcts which 
were more likely to be transmural and aneurysmal. These findings are in keeping with the 
original landmark studies of Baroldi and colleagues who reported that LM+ patients had 
more LV dilatation and more severe left ventricular systolic dysfunction (Baroldi et al., 
1997). Pathophysiologically, adipocytes secrete numerous substances within the body, one 
of which, fatty acid-binding protein is known to depress cardiomyocyte inotropy, perhaps 
contributing to a reduction in LVEF (Lamounier-Zepter et al., 2009). 
 
Infarct age was the only clinical feature I found to be associated with LM suggesting that 
its development is progressive (Ahn et al., 2009, Goldfarb et al., 2009, Ichikawa et al., 
2009, Lucke et al., 2010). Similar to previously published studies investigating the clinical 
significance of LM, we did not find any other clinical associations with LM (Ahn et al., 
2009, Ichikawa et al., 2009, Lucke et al., 2010). The pathogenesis of adipose deposition 
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within myocardial infarcts is not clearly understood as yet, however it is known that areas 
of MI scar display abnormal metabolism with reduced uptake of fatty acids leading to the 
replacement of collagen with adipocytes (Hansen et al., 1995, Baroldi et al., 1997). It is 
postulated that newer medical and reperfusion therapies might reduce the development of 
LM (Su et al., 2004). The prevalence of LM in this study is similar to the earlier 
histopathological studies (allowing for differences in spatial resolution), despite these 
therapeutic advances. 
 
This study is the first to demonstrate the independent prognostic significance of LM for 
prediction of adverse events in a real-world clinical population.  
 
The presence of LM was a stronger predictor than infarct size alone and remained 
significant when added to left ventricular volumes or ejection fraction. There is an 
increasing recognition of the prognostic importance of not just infarct scar size, but also its 
structure (Yan et al., 2006b, Roes et al., 2009, Schmidt et al., 2007). A recent study in a 
ovine model by Pouliopoulos et al found that the presence of LM in sheep with 
experimentally induced myocardial infarcts was associated with more inducible ventricular 
tachycardia (Pouliopoulos et al., 2013). The presence of myocardial fat has also been 
associated with inducible ventricular tachycardia in humans in the right ventricle (Vignaux 
et al., 2002). It may be that adipose tissue predisposes to re-entrant tachycardias and 
impairs myocardial conduction, leading to increased risk of ventricular arrhythmias and 
death (Pouliopoulos et al., 2013). Strategies to reduce LM may translate to a prognostic 
benefit in future. 
 

 
This study has some limitations. The lack of histological examination meant that there was 
no way to pathologically corroborate and validate the CMR findings. This is similar to the 
other studies and case reports in this area, and is probably a reflection of the reduction in 
the amount of post-mortems and endomyocardial biopsies conducted in the modern era. 
The use of CT did however provide some element of confirmation of the CMR techniques. 
There may also be other reasons for the differences in outcome that we did not explore in 
this study, for example the presence of any underlying ischemia. This effect was hopefully 
reduced by selecting consecutive patients. Finally, due to the nature of this study, we are 
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unable to attribute causation between LM and any of our functional findings. Further 
studies are required to investigate this. 
 


LM is a common finding in patients with prior MI assessed by CMR. It is associated with 
older and larger infarcts with greater degrees of adverse LV remodeling and more 
symptomatic heart failure. The presence of LM was an independent predictor of adverse 
cardiovascular outcome. Additionally, LM appears to act as a substrate for malignant 
ventricular arrhythmia that may predispose to sudden cardiac death.  
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5. Late Gadolinium Enhancement and NT-proBNP 
Identify a Population at Low Risk of Death or 
Arrhythmic Events in Patients With Primary 
Prevention Implantable Cardioverter Defibrillators. 
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

In the last chapter I explored the prognostic utility of infarct characteristics in prediction of 
death and arrhythmias in a cohort of patients with previous MI. The presence of LGE was 
a significant predictor of adverse outcome. LGE is also present in patients with out 
infarcts, for example in those with DCM. Both ICM and DCM are common causes of 
severe heart failure (HF), typically defined as LVEF <35%. Current HF guidelines 
recommend the use of implantable cardioverter defibrillators (ICDs) in symptomatic 
patients with severe HF despite optimal medical therapy as these patients are at increased 
risk of lethal ventricular arrhythmias and sudden death (figure 5-1).  
 
Figure 5-1. Summary of the Current ESC Heart Failure Guidelines (2012). 
 
 
Adapted from (McMurray et al., 2012). HF ± heart failure; ACEI ± angiotensin-converting 
enzyme inhibitor; NYHA ± New York Heart Association classification for heart failure 
symptoms; LVEF ± left ventricular ejection fraction. 
 
ICDs and cardiac resynchronization therapy devices with a defibrillator function (CRT-Ds) 
reduce mortality in symptomatic patients with HF who have not had a prior cardiac arrest, 
i.e. as primary prevention (Moss et al., 2002, Bardy et al., 2005). Current criteria as 
Chapter 5: The Combined Prognostic Utility of LGE and NT-ProBNP in Patients with 
Defibrillators 
 
 102 
outlined in the ESC HF guidelines rely on the use of LVEF (which is subject to wide 
variation when measured using standard two-dimensional echocardiography) and NYHA 
FODVVZKLFK LV VXEMHFWLYH EDVHG RQ ERWK WKH SDWLHQW¶V DQG GRFWRU¶V LQWHUSUHWDWLRQ RI WKH
patients symptoms (McMurray et al., 2012). These can be somewhat blunt tools when 
making the decision to implant these costly devices. The average annual rate of appropriate 
shocks in clinical trials is only 5.1% and as many as two thirds of patients may never use 
their ICD after implantation. (Moss et al., 2004, Stecker et al., 2006, Bardy et al., 2005). 
Therefore, it would be useful to find newer, more accurate methods to improve the 
identification of individuals who may not be likely to benefit from ICD implantation 
despite meeting conventional criteria such as NYHA class 2-4 and reduced ejection 
fraction are needed.  
 
The presence of LGE is associated with a higher risk of all-cause mortality, sudden cardiac 
death, appropriate ICD activation and admissions for heart failure in HF patients with both 
ischemic cardiomyopathy (ICM) and dilated cardiomyopathy (DCM) (Bernhardt et al., 
2011, Gao et al., 2012, Iles et al., 2011, Kwong et al., 2006, Scott et al., 2011a, Wu et al., 
2008, Assomull et al., 2006). I have also demonstrated this relationship in Chapters 3 and 
4.  
 
B-type natriuretic peptide (BNP) and N-terminal pro-B type natriuretic peptide (NT-
proBNP) are easily measured biomarkers which are presently primarily used in diagnosis 
of HF. These biomarkers have also been explored as a potential marker of risk in those 
receiving a primary prevention ICD and predictors of sudden death in HF patients. (Scott 
et al., 2011b, Biasucci et al., 2012, Berger et al., 2002).  
 
As both LGE and NT-proBNP have been shown to be markers of risk in patients receiving 
ICDs, it is possible that they may be useful in stratifying high and low-risk patients. The 
aim of this study was to assess the prognostic utility of LGE and NT-proBNP for 
prediction of death or appropriate ICD activation in individuals undergoing implantation of 
a primary prevention ICD. More specifically, I hypothesized that the two markers may be 
combined in order to predict a group of patients who may be at low risk of ventricular 
arrhythmia and ICD activation.  


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



157 consecutive patients referred to our tertiary centre for implantation of primary 
prevention ICD or CRT-D and were referred for a pre-implantation CMR were evaulated. 
Patients with both ICM and DCM were included. The diagnosis of ICM was made 
confirmed on the basis of either computed tomography coronary angiography or invasive 
coronary angiography in conjunction with CMR results. If patients were found to have a 
small area of late gadolinium enhancement in an ischemic distribution that was felt not to 
be significant enough to cause the degree of left ventricular systolic impairment seen they 
were classified as DCM; conversely, in some patients there was a definite regional wall 
motion abnormality in conjunction with a history of significant stenosis on invasive or CT 
coronary angiography (>70%) ± these patients were classified as having ICM (figure 5-2). 
All patients referred for a secondary prevention ICD and those with renal impairment 
unable to be given gadolinium contrast (eGFR<30) were excluded. 
 
Figure 5-2. Typical LGE Patterns. 
 
 
Typically in ICM enhancement is subendocardial or transmural (left), while in DCM 
enhancement is midwall or absent (right). 
 


All patients underwent a simplified standardised CMR protocol including cine imaging and 
LGE. Sequences were performed as described in Chapter 2. Briefly, cine images were 
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obtained using an SSFP sequence in three long axis planes (2-chamber, 3-chamber, 4-
chamber) and in short axis slices through the left ventricle. LGE imaging for myocardial 
infarction was acquired 10 minutes after intravenous gadolinium injection. CMR was 
performed within a mean of 3±1 day of defibrillator insertion. 
 
All analysis was performed using Argus as described in Chapter 2. Left ventricular 
diameter, volumes and function were derived from the short-axis slices using manual 
tracing of the endocardial contours including papillary muscles as part of the ventricular 
volume. The presence of LGE was assessed by identification of areas of myocardium with 
a signal intensity of >5SD above normal myocardium. Quantification of LGE was 
measured using manual planimetry in short-axis and taking this area as percentage of the 
total left ventricular area measured in short-axis. 
 


Serum NT-proBNP was obtained within 2±1 weeks of defibrillator implantation and 
analysed in our local laboratory, the methods and reproducibility of which have been 
previously described (Gardner et al., 2007). Blood samples were collected in 
ethylenediamine-tetraacetic acid-containing tubes before being centrifuged at 3000rpm for 
10 minutes at 0°C before measurement of NT-proBNP using a chemiluminescent 
immunoassay kit (Roche Diagnostics, Basel, Switzerland) on a Elecsys 2010 analyzer. 
Normal values are <125pg/mL in patients aged less than 75 years and <450pg/mL in 
patients over 75. All participants were stable outpatients ensuring that haemodynamic 
status at the time of sampling was similar to status at the time of CMR. 



All patients had an ICD or CRT-D device implanted using standard techniques. Choice of 
device was at the discretion of the operator.  
 

 
The pre-defined primary outcome was death or appropriate ICD therapy, which was either 
shock for ventricular fibrillation/tachycardia or anti-tachycardia pacing for ventricular 
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tachycardia. All patients were followed up at 3-6 month intervals using computerized 
record linkage for death and admissions for ventricular arrhythmias causing appropriate 
ICD activation. Information about appropriate ICD activation not leading to hospital 
admission was obtained by searching the records of routine local hospital ICD 
interrogations. These as performed as a routine out-patient appointment on a 6 monthly 
basis. Additionally, if the patient experiences an ICD activation for which they are not 
admitted to hospital, they can also attend hospital for ICD interrogation on an ad-hoc out-
patient basis. An independent observer blinded to the CMR analysis and NT-proBNP 
results adjudicated events (N.T.). No patients were lost to follow-up. 
 


As described in Chapter 2, continuous variables are expressed as mean ± SD and 
categorical variables are expressed as a number and percentage. Differences between 
groups were tested using t-tests or the chi-squared tests as appropriate. As the distribution 
of NT-proBNP was skewed it was log-transformed and geometric means calculated.  
 
Kaplan-Meier and Cox proportional hazards survival analysis was used to examine the 
association between baseline variables, CMR variables and NT-proBNP and the primary 
outcome. Percentage LGE and NT-proBNP were most strongly associated with the 
outcome as assessed by the Chi-squared statistic and were explored further. As NT-
proBNP was not normally distributed (log) NT-proBNP was initially evaluated, however 
to provide clinical relevance the inverse log was then calculated to provide an optimal NT-
proBNP value. Multivariable analysis was performed using significant univariable 
predictors of the primary outcome (p<0.05). The type of device (ICD versus CRT with 
ICD) was also included to adjust for the potential mortality and morbidity benefits of CRT 
(Bristow et al., 2004). Correlation between percentage LGE and NT-proBNP was assessed 
XVLQJ3HDUVRQ¶VFRUUHODWLRQFRHIILFLHQW 
 
To evaluate optimal discriminatory level of percentage LGE and NT-proBNP for 
identification of a population at low-risk of death or ventricular arrhythmia, both DCM and 
ICM cohorts were divided into groups based on percentage of LGE and NT-proBNP. Best 
cut-off values were identified using ROC curves to obtain the optimal sensitivity and 
specificity. This allowed stratification of patients by LGE percentage and NT-proBNP into 
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low and high-risk groups. For all analyses a p value <0.05 was considered statistically 
significant and all p values are two-tailed. 
 




157 patients were included in this study, 60 patients with ICM and 97 patients with DCM. 
Baseline characteristics of each group are summarized in Table 5-1.  
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Table 5-1. Baseline clinical and CMR characteristics of the cohort stratified by 
aetiology. 
 
 Dilated 
cardiomyopathy 
(n=96) 
Ischemic 
cardiomyopathy 
(n=61) 
p value 
Age (years) 46.0 ± 13.4 57.7 ± 11.2 <0.001 
Male 75 (78.1%) 48 (78.6%) 0.69 
AF 18 (18.8%) 17 (27.9%) 0.15 
Hypertension 14 (14.6%) 13 (21.3%) 0.24 
Smoker 19 (19.8%) 23 (37.7%) 0.010 
Diabetes 6 (6.3%) 8 (13.1%) 0.13 
Prior 
Revascularisation 
6 (6.3%) 32 (52.5%) <0.001 
LBBB 32 (33.3%) 19 (31.1%) 0.86 
NYHA Class 
1 
2 
3 
4 
 
15 (15.6) 
38 (39.6) 
38 (39.6) 
5 (5.2) 
 
0 (0.0) 
24 (39.3) 
36 (59.0) 
1 (1.6) 
0.006 
ACEI/ARB 75 (78.1%) 54 (88.5%) 0.044 
Beta-blocker 79 (86.8%) 50 (82.0%) 0.76 
Spironolactone 46 (47.9%) 46 (75.4%) <0.001 
Furosemide 52 (54.2%) 45 (73.8%) 0.007 
(Ln) NT-proBNP 7.06± 1.24 7.46± 1.05 0.018 
LGE present 24 (25) 61 (100) <0.001 
Mean LGE (%) 2.1 ± 6.0 24.8 ± 16.2 <0.001 
LVEF (%) 27.2 ± 16.3 28.5 ± 12.9 0.71 
AF ± atrial fibrillation; LBBB ± left bundle branch block; ACEI ± angiotensin-converting 
enzyme inhibitor; ARB ± angiotensin II receptor blocker; LVEDD ± left ventricular end-
diastolic diameter; Ln ± natural logarithm; LGE ± late gadolinium enhancement; LVEF ± 
left ventricular ejection fraction 
Data are presented as mean ± SD if continuous or number (%) if categorical. 
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Differences between the groups reflected typical risk factors - the ICM cohort was older 
with more smokers and was more likely to have undergone prior revascularisation. The 
ICM group was more likely to have LGE on CMR and with a higher mean volume of 
fibrosis (24.8% vs. 2.1% respectively for ICM vs. DCM patients, p <0.001). The use of 
evidence-based therapy for heart failure was high in both groups (total on beta-blockers 
82.2%; ACE-inhibitors 82.2%; spironolactone 58.9%). The majority of patients had mild 
to moderately symptomatic heart failure (86.6% NYHA class 2-3 heart failure) and low 
ejection fraction by CMR, thus meeting the ESC criteria for ICD or CRTD therapy. 
 

 
The median follow-up time of the cohort was 915 days (2.5 years). During the follow-up 
period 32 patients (20.4%) died or had appropriate defibrillator therapy. There were 12 
cardiac deaths (10 due to end-stage heart failure and 2 due to myocardial infarction), 14 
appropriate defibrillator shocks and 6 episodes of appropriate anti-tachycardia pacing. The 
differences between the groups stratified by outcome are summarised in Table 5-2.  
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Table 5-2. Clinical and CMR characteristics stratified according to occurrence of the 
primary outcome. 
 
 Primary Outcome 
(n=32) 
Without Primary 
Outcome (n=125) 
p value 
Age (years) 51.6 ± 16.8 50.2 ± 13.2 0.64 
Male 27 (84.4%) 96 (76.8%) 0.35 
ICM 18 (56.2%) 43 (34.4%) 0.024 
Diabetes 5 (16.7%) 9 (7.1%) 0.058 
LBBB 8 (26.7%) 43 (33.9%) 0.84 
NYHA Class 
1 
2 
3 
4 
 
1 (3.1) 
19 (59.4) 
11 (34.4) 
1 (3.1) 
 
14 (11.2) 
43 (34.4) 
63 (50.4) 
5 (4.0) 
0.11 
ACEI/ARB 18 (60.0%) 111 (87.4%) 0.059 
Beta-blocker 18 (60.0%) 111 (87.4%) 0.001 
Spironolactone 13 (43.3%) 79 (62.2%) 0.33 
Ln NT-proBNP 7.79 ± 1.09 7.02 ± 1.19 0.005 
Presence of LGE 19 (59.3) 53 (42.4) 0.015 
Mean LGE (%) 18.8 ± 17.7 7.4 ± 13.4 0.01 
LVEF (%) 26.2 ± 12.8 27.9 ± 12.8 0.67 
Data are presented as mean ± SD if continuous or number (%) if categorical. 
ICM ± ischaemic cardiomyopathy; LBBB ± left bundle branch block; ACEI - angiotensin-
converting enzyme inhibitor; ARB ± angiotensin II receptor blocker; Ln ± natural 
logarithm; LGE - late gadolinium enhancement; LVEF ± left ventricular ejection fraction 
 
 
ICM patients were more likely to suffer the primary outcome, and overall had a higher 
mean percentage of LGE (18.8% vs. 7.4%, p=0.01). The patients who suffered the primary 
outcome were also had a higher NT-proBNP (p=0.005). 
 
Patient characteristics associated with the primary outcome in a univariable analysis are 
shown in Table 5-3. 
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Table 5-3. Hazard ratio and 95% confidence interval for the association between 
clinical and CMR characteristics and death or ICD activation. 
 
Variable Death/Appropriate ICD 
Activation (n=32) 
Appropriate ICD Activation (n=20) 
 Univariable HR 
(95% CI) 
p 
value 
Univariable HR (95% CI) p value 
Age 1.02 (0.99-1.04) 0.26 1.02 (0.99-1.05) 0.21 
Male 1.27 (0.48-3.37) 0.64 0.79 (0.25-2.52) 0.70 
ICM 2.42 (1.19-4.90) 0.015 2.63 (1.07-6.50) 0.035 
Diabetes 2.14 (0.82-5.58) 0.12 2.75 (0.91-8.29) 0.07 
LBBB 1.46 (0.64-3.31) 0.37 1.98 (0.72-5.45) 0.19 
NYHA Class 
3-4 
2.33 (0.92-5.93) 0.08 3.03 (0.82-11.17) 0.10 
ACEI/ARB 0.82 (0.36-1.87) 0.64 1.58 (0.47-5.28) 0.46 
Beta-blocker 0.53 (0.25-1.13) 0.10 0.66 (0.24-1.82) 0.42 
Spironolactone 1.06 (0.51-2.20) 0.87 2.97 (1.01-8.72) 0.047 
Ln NT-
proBNP 
1.71 (1.22-2.39) 0.002 1.84 (1.17-2.88) 0.008 
Presence of 
LGE  
3.77 (1.48-9.58) 0.005 3.30 (1.05-10.42) 0.042 
LGE (per 1% 
increase) 
1.05 (1.02-1.07) <0.001 1.05 (1.02-1.08) 0.002 
LVEF (%) 1.00 (0.97-1.03) 0.73 1.01 (0.98-1.05) 0.50 
All hazard ratios (HR) adjusted for device type (ICD/CRTD). 
ICM ± ischaemic cardiomyopathy; ICD ± implantable cardioverter-defibrillator; Hr ± 
hazard ratio; LBBB ± left bundle branch block; ACEI - angiotensin-converting enzyme 
inhibitor; ARB ± angiotensin II receptor blocker; Ln ± natural logarithm; LGE - late 
gadolinium enhancement; LVEF ± left ventricular ejection fraction 
 
ICM (HR 2.42; 95% CI 1.19-4.9, p=0.015), the presence of LGE (HR 3.77; 95% CI 1.48-
9.58 p=0.005) and the percentage of LGE (HR per 1% increase 1.05; 95% CI 1.02-1.07, 
p<0.001) were all associated with the primary outcome. Ln NT-proBNP was also a 
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significant predictor of the primary outcome (HR 1.71; 95% CI 1.22-2.39, p=0.002). 
Percentage of LGE, (ln) NT-proBNP and aetiology of cardiomyopathy (ICM or DCM) 
were entered into the multivariable model, again with adjustment for device type (ICD or 
CRTD). Both LGE percentage (HR 1.04; 95% CI 1.02-1.07 p=0.001) and ln NT-proBNP 
(HR 1.69; 95% CI 1.15-2.47 p=0.007) remained significant predictors of the primary 
outcome (table 5-4). 
 
Table 5-4. Mulitvariable analysis for the prediction of death or appropriate ICD 
activation. 
 
Variable Death/Appropriate ICD 
Activation (n=32) 
Appropriate ICD Activation 
(n=20) 
 HR (95% CI) P value HR (95% CI) P value 
LGE (per 1% 
increase) 
1.04 (1.01-1.07) 0.001 1.04 (1.01-1.07) 0.004 
Log NT-proBNP 1.69 (1.15-2.47) 0.007 1.81 (1.09-3.03) 0.023 
Ischemic 
Cardiomyopathy 
1.01 (0.32-3.16) 0.99 1.39 (0.33-5.89) 0.66 
All hazard ratios (HR) adjusted for device type (ICD/CRTD). 
LGE ± late gadolinium enhancement; HR ± hazard ratio; ICD ± implantable cardioverter-
defibrillator 
 
There was no significant correlation between LGE and ln NT-proBNP (Pearson correlation 
co-efficient = 0.14, p=0.22).  
 
Based on the combination of LGE percentage and NT-proBNP the cohort could be 
stratified into 2 groups as follows: low-risk (DCM: 20 patients, LGE=0%, NT-proBNP 
<545pg/mL; ICM: 11 patients, LGE <23%, NT-proBNP <898 pg/mL) and high-risk 
(DCM: 76 patients, LGE >0%, NT-SUR%13SJP/ ,&0 SDWLHQWV /*(
NT-SUR%13SJP/7DEOH-5).  
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Table 5-5. Hazard ratio and 95% confidence interval for the association between 
optimal discriminatory level of late gadolinium enhancement and NT-proBNP and 
death or ICD activation. 
 
Group Aetiology LGE 
(%) 
NT-
proBNP 
(pg/mL) 
Number 
of 
Patients 
Death/Appropriate 
ICD Activation (%) 
Appropriate 
ICD 
Activation 
Low-
Risk 
DCM 
 
ICM  
0 
 
<23 
<545 
 
<898 
20 (20.8) 
 
11 (18.0) 
 
1 (3.1) 
 
0 (0) 
High-
Risk 
DCM 
 
ICM 
>0 
 
 
 
 
 
76 (79.2) 
 
50 (82.0) 
 
31 (24.6) 
 
20 (15.9) 
DCM ± dilated cardiomyopathy; ICM ± ischaemic cardiomyopathy; LGE ± late 
gadolinium enhancement; ICD ± implantable cardioverter-defibrillator 
Both groups had similar numbers of patients from each aetiology (p=0.67). In the low-risk 
group, the primary outcome only occurred in 1 (3%) of the patients (event rate of 1.5% per 
year). The occurrence of the primary outcome in the high-risk group was 24.6% 
(occurrence in 31 patients), giving an event rate of 12.3% per year. With the low-risk 
group as the reference, patients in the high-risk group had a higher risk of the primary 
outcome and appropriate ICD activation alone (high-risk group HR 9.12; 95% CI 1.24-
66.82, p=0.03) (figure 5-3).  
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Figure 5-3. Kaplan-Meier curves of the association between the combination of LGE 
and NT-proBNP for prediction of the primary outcome. 
 
 
 
 
When analyzing ventricular arrhythmias only, appropriate activation occurred in 20 
patients. Both LGE percentage (HR 1.04; 95% CI 1.01-1.07, p=0.004) and ln NT-proBNP 
(HR 1.81 95% CI 1.09-3.03, p=0.023) remained multivariable predictors of outcome (table 
5-4). Patients in the high-risk group had a higher risk of the appropriate ICD activation 
(figure 5-4). Only one patient in the low-risk group had an appropriate ICD activation over 
the follow-up period, an event rate of 1%/year, in comparison to the high-risk group where 
the event-rate was 10.1%/year. 
 
  



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Figure 5-4. Kaplan-Meier curves of the association between the combination of LGE 
and NT-proBNP for prediction of appropriate ICD activation alone. 
 
 
 

 

 
This study was one of the largest studies to date examining patients undergoing 
implantation of an ICD or CRTD. A number of important associations were identified:  
 
x LGE and NT-proBNP predict adverse cardiac outcomes in patients with ICDs.  
x The increasing burden of myocardial fibrosis (scar) as measured by percentage of 
LGE was associated with death or appropriate ICD activation independent of HF 
aetiology (ICM or DCM).  
x Finally, this study is the first to show that in primary prevention patients, the LGE 
percentage and NT-proBNP can be combined to identify a population at 
significantly increased risk of adverse cardiovascular outcome, and also a 
population at lower risk in whom (potentially) ICD implantation may not be 
mandatory, providing extra information on risk stratification. 
 



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
 
While current guidelines for implantation of ICDs and CRTDs are relatively clear, the 
clinical decision to implant these devices may not be as straightforward as it appears on 
paper. As described, many patients who currently meet criteria for implantation will never 
use their device, with the subsequent financial and personal implications (such as potential 
for device lead infection and the risk of inappropriate shocks). Additionally, there will be 
some patients who do not meet the criteria for device implantation who could potentially 
have their lives saved by an implantable defibrillator who may presently be denied this 
(Stecker et al., 2006). 
 
There is a recognition that both echocardiographic assessment of LVEF and the NYHA 
classification (table 5-6) can be subject to observational bias, and so there is still a drive to 
identify further markers that might improve risk stratification and help the clinician make a 
more informed decision for their patient. 
 
Table 5-6. The New York Heart Association (NYHA) Classification for HF 
Symptoms. 
 
NYHA Class Symptoms 
I Cardiac disease, but no symptoms and no limitation in ordinary physical 
activity, e.g. shortness of breath when walking, climbing stairs etc. 
II Mild symptoms (mild shortness of breath and/or angina) and slight 
limitation during ordinary activity. 
III Marked limitation in activity due to symptoms, even during less-than-
ordinary activity, e.g. walking short distances (20±100 m). 
IV Severe limitations with symptoms at rest.  
 
 

 
LGE during CMR identifies areas of myocardial fibrosis. The link between the 
pathological presence of fibrosis and ventricular arrhythmias leading to sudden death is 
well established, as the areas of fibrosis form an arrhythmogenic substrate (Bernhardt et 
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al., 2011, Bolick et al., 1986). Several recent studies have identified the utility of LGE to 
predict adverse outcomes including ICD activation in both ICM (Kwon et al., 2009, Roes 
et al., 2009, Scott et al., 2011a, de Haan et al., 2011) and DCM (Wu et al., 2008). This 
study not only added this evidence, but also further adds that risk increases in proportion 
with the volume of LGE and that this may provide additional prognostic information than 
the presence of LGE alone. Two small studies have reported that scar size is associated 
with adverse outcome in patients with ICM (de Haan et al., 2011, Scott et al., 2011a). Gao 
et al (Gao et al., 2012), studied 124 patients with ICM and DCM and reported that LGE 
mass was the most significant univariable predictor of their primary outcome (ICD 
activation, sudden death or survived cardiac arrest), though it was not included in 
multivariable analysis. This study shows (in a larger cohort) that this association persists 
regardless of the HF aetiology and additional to NT-proBNP, which is a consistently 
strong marker of prognosis in heart failure (Pocock et al., 2006). A small retrospective 
study by Scott et al (Scott et al., 2011a) also described a similar relationship in 64 patients 
with ICM. 
 

 
NT-proBNP is secreted by the ventricles in response to increased cardiomyocyte stretch 
caused by pressure and volume overload (Pocock et al., 2006). It has been shown to be 
useful as both a diagnostic and a prognostic biomarker in HF (Maisel et al., 2008, Wedel et 
al., 2009, Masson et al., 2008). Several studies have also examined its utility in predicting 
adverse outcomes in patients with ICDs. A meta-analysis of 8 studies by Scott et al 
(enrolling a total of 1047 patients) (Scott et al., 2009) found that NT-proBNP (or BNP) 
levels above the study median increased risk of occurrence of death or ventricular 
arrhythmia in patients with or without an ICD. Another large study by Verma et al 
evaluated 345 consecutive patients undergoing primary or secondary prevention ICD 
implantation and found that BNP was the only significant multivariable predictor of death 
or appropriate ICD activation (Verma et al., 2006). Finally, in a large multi-centre study, 
Biasucci et al evaluated 300 patients with ICM undergoing primary prevention ICD 
implantation (Biasucci et al., 2012). The main aim of this study was to examine the 
potential of C-reactive protein as a marker of risk, however the authors also found that NT-
proBNP was also a significant predictor of adverse outcome. Nevertheless, the combined 
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use of NT-proBNP and percentage of LGE have not been prospectively evaluated in one 
cohort before.  
 

 
I hypothesised that because LGE and NT-proBNP are markers of different pathological 
processes, they may be associated with death or ICD activation via different pathways, and 
that their use in combination would lead to a powerful evaluation of risk. I found that they 
are both strong predictors of risk in HF patients and that their combination provided 
additional prognostic information. This is the first study to demonstrate that both markers 
are able to identify a group of patients at higher risk of adverse outcomes and that the 
association is present in a cohort of patients with ICM and DCM. Perhaps of more clinical 
relevance, these two markers can also be combined to identify a group of patients at low 
risk of events who might not benefit from ICD implantation. This may be important given 
the social and psychological implications of a defibrillator, and an estimated complication 
rate of around 4% (Lee et al., 2010). 
 
Wu et al demonstrated the incremental prognostic utility of a combination of imaging and 
a biomarker in patients with chronic heart failure for prediction of death and arrhythmic 
events (Wu et al., 2012). The authors found that the combination of LGE and C-reactive 
protein was able to identify a cohort at very low risk of adverse cardiovascular outcome. 
Interestingly, the authors also noted that patients with the primary outcome had a higher 
NT-proBNP, although they did not explore this further.  
 
Another important finding from this study is that even after adjusting for the presence of 
each other, percentage of LGE and NT-proBNP levels were still associated with adverse 
outcomes. This is particularly important given the wider availability of serum NT-proBNP 
testing and its ease of use and interpretation compared to CMR which is perhaps not as 
widely available. Importantly, the primary outcome occurred in a number of without LGE. 
Although LGE appears to be an important predictor of adverse outcome, this finding 
highlights the value of a multi-marker model of risk. Furthermore, NT-proBNP may be of 
benefit in patients unable to undergo CMR, for example in those with contrast allergy or 
renal impairment.  However, in centres with the access to CMR, the combination of these 
LGE and NT-proBNP may provide the clinician with further confidence. There may also 
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be advantages to identifying a group of lower risk patients in which the clinician is unsure 
as to whether to proceed to ICD insertion, perhaps for example in those with LVEF around 
35% and in NYHA class 1/2. LVEF can fluctuate over time while NYHA class can be 
fairly subjective and these limitations may account for some of the current reduced cost-
effectiveness of ICDs. There is an increasing recognition however that risk stratification 
for ICD implantation may be further refined by using other markers such as LGE and NT-
proBNP, hence more studies of this type are required to optimize patient selection and 
improve outcomes. 
 

 
Although this is the largest study to date to examine this area with a cohort of 157 patients, 
this is still a single-centre study with a relatively small cohort. Nevertheless, a larger multi-
centre study is needed to validate our findings. The overall death rate in this study cohort 
(8.3%) was lower than reported in MADIT-II (14.2% in 20 months) while the rate of 
appropriate ICD therapies is also lower than larger multi-centre trials (Moss et al., 2002, 
Germano et al., 2006). Larger studies might be able to identify the optimal cut-off points 
for these markers, allowing them added to clinical guidelines to be used as risk stratifiers 
in order to avoid ICD implantation.  
 
I used a threshold of >5SD between remote myocardium and fibrosed myocardium, rather 
WKDQRWKHUPHWKRGVVXFKDV!6'RUWKH³IXOOZLGWK-half-PD[´):+0PHWKRG$OHYHO
of >5SD has been shown to be more accurate than 2SD and as accurate as FWHM for 
quantification of fibrosis by LGE (Flett et al., 2011). Additionally, LGE, unlike T1 
mapping, does not identify diffuse fibrosis, which may also be of prognostic importance.  
 


In a population of patients with ICM and DCM both percentage of LGE and NT-proBNP 
were both associated with poorer outcome. Used in combination, both markers are able to 
discriminate of risk of death or ICD activation in patients undergoing implantation of a 
primary prevention ICD. The use of both markers allows identification of a group at low 
risk for future adverse events in whom ICD implantation may potentially be deferred. 
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Larger studies should be conducted in order to identify the optimal levels of LGE and NT-
proBNP in order for these markers to be incorporated into clinical guidelines. 
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6. Can Advanced CMR Parameters Help To 
Differentiate Between Early Dilated Non-Ischaemic 
Cardiomyopathy and Physiological Myocardial 
Adaptation To Exercise? 
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

In the last chapter I explored the potential role of CMR in solving a diagnostic dilemma in 
patients with severe DCM. Another diagnostic dilemma is in making the correct diagnosis 
in patients with a mildly reduced LVEF, which could potentially represent an early 
manifestation of cardiomyopathy. Many healthy people can demonstrate changes that 
might be consistent with early DCM such as left ventricular cavity dilatation and 
consequently mildly reduced LVEF. These changes occur particularly in people who 
undergo strenuous physical training, including in middle-aged marathon runners (Zilinski 
et al., 2015)7KHVHP\RFDUGLDODGDSWDWLRQVDUHFRPPRQO\NQRZQDV³DWKOHWH¶VKHDUW´ (La 
Gerche et al., 2009, Maron and Pelliccia, 2006). There could potentially be diagnostic 
SUREOHPV LQ WKHGLIIHUHQWLDWLRQRIHDUO\'&0DQGDWKOHWH¶VKHDUW&RUUHFWGLDJQRVLV LVRI
vital importance for future prognosis and management. 
 
In many patients, history, examination and basic imaging can provide a clear answer. For 
example, in patients with a family history of cardiomyopathy, a significantly dilated left 
ventricle and moderate to severely reduced LVEF, it is most likely that this phenotype 
represents DCM. There is however a grey zone, in which these more simple parameters are 
not able to give a clear diagnosis (Figure 6-1). This is particularly so in middle-aged and 
older patients, in whom the pre-test probability of cardiomyopathy is probably higher. This 
is compounded by the fact that an increasing number of older adults are taking up more 
intense exercise.  
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Figure 6-7KH*UH\$UHD%HWZHHQ$WKOHWH¶V+HDUWDQG'&0 
 
 
Adapted from (Maron et al., 1995). 
 
LGE (particularly the typical midwall pattern of fibrosis) has the potential to add 
diagnostic confidence and provide prognostic information, allowing the identification of 
specific etiologies of DCM (Mahrholdt et al., 2005a), (McCrohon et al., 2003) (Assomull 
et al., 2006, Gulati et al., 2013) 1HYHUWKHOHVVKHDOWK\SDWLHQWVZLWKDWKOHWH¶VKHDUWFDQDOVR
have midwall LGE present, which might again cause some diagnostic uncertainty 
(Mohlenkamp et al., 2008) . 
 
More advanced CMR techniques for assessment of myocardial function and tissue 
characterization include tagging (for assessment of global and regional strain) (Ibrahim el, 
2011) and T1 and T2-weighted imaging (for tissue characterization) (Puntmann et al., 
2013, Dass et al., 2012). A reduction in circumferential (GCS) and longitudinal strain 
(GLS) has been noted in heart failure patients (Kraigher-Krainer et al., 2014). 
Echocardiographic assessment of GCS and GLS has been shown to be indicator of adverse 
prognosis in DCM patients (Cho et al., 2009, Stanton et al., 2009). T1 and T2-mapping 
techniques have been shown to identify diffuse myocardial disease in patients with DCM 
which may occur prior to the development of more focal changes (Puntmann et al., 2013, 
Dass et al., 2012). 
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The purpose of this study was to evaluate the utility of CMR tagging, T1 and T2 mapping 
in differentiation of athletes and patients with mild DCM, potentially allowing for 
improvement in diagnostic confidence where assessment of LVEF and LGE may still leave 
some diagnostic uncertainty. 




 
Three separate cohorts of male patients were included in this study. The first cohort, who 
acted as the control group, consisted of 21 healthy control patients without any history of 
cardiovascular disease and normal electrocardiograms. The second group consisted of 21 
males with a history of regular aerobic exercise and mildly impaired or borderline LVEF 
XVLQJ HFKRFDUGLRJUDSK\ /9() XVLQJ 6LPSVRQ¶V ELSODQH -50%). All patients in this 
group undertook over 6 hours of intensive aerobic exercise per week. These patients also 
had no history of cardiac disease and were on no medications. The final group consisted of 
16 patients with confirmed DCM (LVEF 40-50% by echocardiography) and without a 
history of engagement in significant aerobic exercise. All of these patients had also 
undergone comprehensive evaluation to exclude ischemic cardiomyopathy with invasive or 
CT coronary angiography or SPECT imaging (modality chosen at the discretion of their 
clinician). 
 


All patients underwent a systematic CMR protocol including cine imaging, T1 and T2 
mapping, tagging and LGE as described in Chapter 2. Briefly, cine images were obtained 
using an SSFP sequence in three long axis planes (2-chamber, 3-chamber, 4-chamber) and 
in short axis slices through the left ventricle. Then 3 matched short-axis slices were taken 
to represent the basal, mid and apical levels of the left ventricle using T1 and T2 mapping. 
These 3 slices were also repeated using tagged CMR, and an additional 4-chamber image 
acquired for assessment of GLS. Intravenous gadolinium was then given. T1 mapping was 
repeated after 10 minutes, and LGE imaging was performed immediately after.  
 
Chapter 6: The Potential of CMR WR'LIIHUHQWLDWH%HWZHHQ$WKOHWH¶V+HDUWDQG'LODWHG
Cardiomyopathy 
 
 124 
All analysis was performed using Argus, other than analysis of tagged CMR images which 
was performed using Diagnosoft HARP as described in Chapter 2. To assess myocardial 
T1 and T2 times, as wide a region of interest as possible was drawn within the septum of 
the basal and mid-ventricular slices, taking care to avoid blood pool signal. The average of 
the two values was taken in order to have as representative value of the myocardium as 
possible. The apical slice and the lateral walls were excluded as these areas were more 
likely to be affected by artefact. Once the region of interest was drawn, T1 and T2 times 
were automatically displayed on the workstation. On T1-weighted images a large 
representative region of interest was also drawn within the blood pool.  
 
Post-contrast T1 mapping allows calculation of the extracellular volume (ECV) of the 
myocardium within the region of interest chosen. This is known to represent a marker of 
diffuse fibrosis and corresponds well with histological measurements of fibrosis (Miller et 
al., 2013). Calculation of ECV relies on knowledgHRIWKHSDWLHQW¶VKDHPDWRFULWWKHUHIRUHD
blood sample was taken immediately prior to CMR scanning to analyse the full blood 
count. The haematocrit was obtained, allowing for calculation of ECV using the equation: 
ECV = (1-KDHPDWRFULWîǻ5myocardium/ǻR1blood) (Arheden et al., 1999). 
 
Tagged images were analysed offline. End-diastole was automatically selected while end-
systole was manually selected. Endocardial and epicardial contours were drawn for 3 
short-axis slices to allow automatic tracking of the myocardial tags. Each frame was then 
adjusted individually to ensure correct tracking and GCS was derived. The same process 
was followed for the long-axis image in order to obtain GLS. 
 


As described in Chapter 2, continuous variables are expressed as mean ± SD and 
categorical variables are expressed as a number and percentage. Comparisons between 
multiple groups were carried out using a one-way ANOVA with Bonferroni correction 
applied for multiple group testing. Binary logistic regression was used to identify 
significant predictors of the diagnosis of cardiomyopathy. Sensitivity and specificity using 
receiver-operator characteristic (ROC) curves, in order to obtain the area under the curve 
(AUC). For all analyses a p value <0.05 was considered statistically significant and all p 
values are two-tailed. 
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

       

 
Myocardial T2 times were significantly correlated with both native T1 times (r=0.43, 
p<0.001) and ECV (r=0.44, p<0.001). There was a strong correlation between native T1 
and ECV (r=0.63, p<0.001) and a strong correlation between LVEF and GCS (r=-0.73, 
p<0.001). There were modest but significant correlations between GCS and native T1 
(r=0.30, p=0.003) and ECV (r=0.29, p=0.005).  
 
LVEF was also strongly correlated with both native T1 (r=-0.40, p<0.001) and ECV (r=-
0.43, p<0.001). T2 signal was not significantly correlated with either LVEF or GCS. 
 
Strain was significantly reduced in patients with LGE present compared to those without 
(GCS: -10.76% vs. -13.90, p=0.01; GLS: -11.00% vs. -14.83%, p<0.001 respectively).  



In total 58 males were evaluated ± 21 with a history of aerobic exercise, 16 with mild 
DCM and 21 age-matched healthy controls. The average age of the cohort was 47.9 ± 14.5 
years. Comparisons between the three groups are shown in table 6-1.  
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Table 6-1. Baseline clinical and CMR characteristics. 
 
 Controls 
(n=21) 
Exercisers 
(n=21) 
DCM 
Patients 
(n=16) 
p value 
Age (years) 47.9 ± 16.0 45.9 ± 10.7 46.1 ± 13.6 0.79 
LV Mass (g/m2) 60.7 ± 12.7 84.3 ± 28.2* 68.8 ± 15.5 0.001 
LVEF (%) 64.5 ± 4.1 51.2 ± 5.9*+ 48.1 ± 4.8*+ <0.001 
LVEDV (ml/m2) 78.6 ± 12.4 102.2 ± 36.0+ 101.2 ± 21.2+ <0.001 
LVESV (ml/m2) 28.0 ± 5.9 49.5 ± 16.2+ 52.6 ± 12.2*+ <0.001 
GCS (%) -17.33 ± 2.30 -12.87 ± 
3.61*+ 
-13.05 ± 
4.37*+ 
<0.001 
GLS (%) -16.53 ± 2.44 -14.91 ± 2.18+ -13.90 ± 3.00+ <0.001 
LGE Present 
(%) 
0 (0) 7 (33.3)+ 5 (31.3)+ <0.001 
Native T1 (ms) 952 ± 31 958 ± 30+ 1017 ± 42*§ <0.001 
ECV (%) 26.2 ± 2.8 26.4 ± 6.8+ 31.2 ± 4.1*§ 0.002 
T2 (ms) 52.9 ± 3.3 52.8 ± 3.2 55.9 ± 4.4*+ 0.024 
*p<0.01 vs. healthy controls; +p<0.01 vs. severe DCM patients; §p<0.01 vs. athletes. 
DCM ± dilated cardiomyopathy; LVEF ± left ventricular ejection fraction; GCS ± global 
circumferential strain; GLS ± global longitudinal strain; LGE ± late gadolinium 
enhancement; ECV ± extracellular volume 
Data are presented as mean ± SD if continuous or number (%) if categorical. 
 
Both exercisers and DCM patients had significantly increased left ventricular volumes and 
reduced LVEF compared to controls. Exercisers also had an increased LV mass compared 
to both controls and to DCM patients. 
 
DCM patients were more likely to have LGE than both controls and exercisers (p=0.027). 
There was no subendocardial LGE in any group to suggest prior myocardial infarction.  
 
Both native T1 and ECV were significantly different between athletes and DCM patients 
(native T1: 957 ± 32 ms vs. 1017 ± 42 ms, p<0.001; ECV: 26.3 ± 3.6% vs. 31.2 ± 4.1%, 
p<0.001 respectively). Athletes had a similar native T1 and ECV to controls. T2 relaxation 
time was also similar between controls and athletes (52.9 ± 3.3 ms vs. 52.8 ± 3.2 ms 
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respectively) and significantly lower than in DCM patients (55.9 ± 4.4 ms, p=0.024 
between all three groups). Figure 6-2 shows examples of the CMR finding while figures 6-
3 and 6-4 show the differences between the three groups in T1 mapping parameters. 
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Figure 6-2. Typical Patterns using T1 Mapping and Tagging in a Healthy Control 
(left) and a Patient with DCM (right). 
 
 
Row 1: Cine imaging; Row 2: Native T1 mapping; Row 3: LGE; Row 4: Post-contrast T1 
mapping; Row 5: Global circumferential strain using tagging. 
Left: A 52 year-old healthy male control with a normal sized left ventricle (end-diastolic 
diameter 5.6 cm) and preserved left ventricular ejection fraction (57.8%) (Row 1). Septal 
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native T1 was 924.9 ms (Row 2) and there was no LGE (Row 3) or significant diffuse 
fibrosis (post-contrast T1 467.1 ms, ECV 27%, Row 4). GCS was -15.68% (Row 5). 
Right: A 58 year-old DCM patient with a dilated left ventricle (end-diastolic diameter 6.7 
cm) and mildly impaired left ventricular ejection fraction (45.4%) (Row 1). Septal native 
T1 1017.8 ms (Row 2). There was midwall LGE row 3; arrow) also reflected by the 
reduced post-contrast T1 and ECV (post-contrast T1 429.8 ms, ECV 35%, Row 4; arrow). 
GCS was -5.15% (Row 5). 
 
Figure 6-3. Comparison of Native T1 Times. 
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Figure 6-4. Comparison of ECV. 
 
 
 
 
Using multivariable logistic regression analysis, native T1 was the only independent 
discriminator between exercisers and DCM patients (OR 1.05; 95% CI 1.01-1.10, 
p=0.015). Using ROC analysis, the AUC for differentiation between exercisers and 
patients with DCM was 0.91 (95% CI 0.82-1.00, p<0.001), which was significantly better 
than ECV (AUC: 0.82; 95% CI 0.67-0.98, p=0.002) (figure 6-5).  
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Figure 6-5. Receiver-operator Characteristic for Differentiation of Exercisers and 
DCM Patients. 
 
 
 

 

 
This study identified two important findings: 
 
x Both CMR tagging and T1 mapping identify changes in the myocardium in patients 
with DCM.  
x Native T1 might be a novel parameter that could be used to differentiate between 
patients with healthy myocardial adaptation to exercise and patients with early 
DCM, potentially providing a new tool to help in a diagnostic dilemma. 
  

 
The screening of athletes and the identification of early cardiomyopathy remains a difficult 
diagnostic and therapeutic challenge. When exposed to aerobic exercise the myocardium 
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undergoes changes which are similar to early DCM, particularly in those who 
predominantly partake in endurance training. This can pose problems for these patients, as 
they may potentially be excluded from sport, incorrectly, in order to reduce risk (Pelliccia 
et al., 2005). Conversely, in athletes in whom potential cardiomyopathy is not recognised, 
the first manifestation of this may be sudden death (Maron et al., 1995). Currently, simple 
echocardiographic measurements of left ventricular dimensions and ejection fraction may 
not be enough to differentiate between normal athletic adaptation and cardiomyopathy, 
while a period of observation without exercise may not be palatable to people who 
regularly undertake exercise, therefore more parameters are still required to allow 
confident discrimination between the two phenotypes (La Gerche et al., 2009). 
 

 
Both T1 and T2 mapping have emerged as valuable tools in the CMR assessment of non-
ischemic cardiomyopathies (Kramer et al., 2013, Parsai et al., 2012). T2 mapping identifies 
myocardial edema secondary to acute myocardial injury (Nishii et al., 2014). Native T1 
times reflect both interstitial and myocyte signals, hence the high correlation between 
native T1 and T2 times. Finally, the assessment of T1 values after the administration of 
intravenous gadolinium (which shortens tissue T1 time) allows the measurement of diffuse 
fibrosis and the ECV. Similarly to other studies, this study shows that these parameters are 
associated with the presence of DCM and are correlated with adverse remodeling in this 
condition (Dass et al., 2012, Puntmann et al., 2013). This study also shows, for the first 
time, that these parameters can provide diagnostic confidence at the 1.5T field strength 
which is more commonly used in routine clinical practice (Antony et al., 2011) . 
 
Puntmann et al studied 27 patients with DCM (included in a cohort with 25 HCM patients) 
and found that native T1 times were longer in DCM patients compared to controls, while 
post-contrast T1 values were lower and ECV was higher (Puntmann et al., 2013). The 
authors found that native T1 was the best predictor of cardiomyopathy. In another study by 
Dass et al, the authors evaluated 18 DCM patients (along with 28 HCM patients) and again 
found that native T1 values were increased in DCM patients compared to controls and 
were significantly correlated with GCS (Dass et al., 2012). In this study I also found that 
native T1 was significantly higher in patients with DCM.  
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Numerous myocardial adaptations occur in endurance-trained athletes (La Gerche et al., 
2009, Utomi et al., 2014). These include an increase in end-diastolic diameter, volume and 
mass, leading to a reduction in LVEF (Abergel et al., 2004). These findings were also 
reflected in this study. LV mass tends to increase in both endurance and strength trained 
athletes, but also increases in DCM due to the increase in left ventricular size, potentially 
causing diagnostic difficulty (Pluim et al., 2000). This has important clinical implications, 
particularly in the differentiation between the normal cardiac adaptations to exercise and 
athletes in whom the changes in myocardial structure and function are actually the early 
signs of DCM. The finding that native T1 mapping seems to be able to differentiate 
between athletes and patients with early DCM might provide an extra parameter to support 
the diagnosis in these difficult cases. 
 

 
In this study, both GCS and GLS were significantly correlated with LVEF, but were not 
able to differentiate between athletes and sedentary patients. Circumferential shortening is 
mostly mediated by midwall fibers while longitudinal shortening is mediated by 
subendocardial and subepicardial fibres (Buckberg et al., 2008). Using echocardiography, 
strain has been shown to correlate well with areas of fibrosis seen using LGE (Saito et al., 
2012). The finding that GCS but not GLS was significantly lower in both athletes and 
sedentary patients compared to controls might be related to the fact that any fibrosis may 
often be midwall in these patients, thus affecting circumferential shortening more. I found, 
similarly to echocardiographic studies, that both GLS and GCS were reduced in patients 
with LGE present. It may be however that T1 mapping identifies different changes in the 
myocardium to tagging. The finding of lower GCS and GLS compared to controls in this 
study could also simply be a reflection of the fact that it specifically only included athletes 
with a mildly reduced LVEF, whereas the majority of previous studies examining 
myocardial deformation in athletes include athletes with normal ejection fractions. 
 
Studies measuring strain using speckle tracking echocardiography have reported 
conflicting results (Utomi et al., 2014, Nottin et al., 2009, Simsek et al., 2013, Richand et 
al., 2007). Richand et al. evaluated 29 professional soccer players using speckle-tracking 
echocardiography and found that GLS was significantly reduced in these athletes 
compared to controls (Richand et al., 2007). Exercise has also been shown to reduce GLS 
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and GCS in athletes compared to pre-exercise deformation measurements (Nottin et al., 
2009). A more recent study by Utomi et al. however found that there was no difference in 
GLS and GCS between endurance-trained athletes and controls (Utomi et al., 2014). On 
the other hand, a further study by Simsek et al. including 22 marathon runners found 
increased GLS compared to controls (Simsek et al., 2013). All of these studies are limited 
by small numbers, but it is possible that strain in athletes is not significantly different 
compared to sedentary patients with similar ejection fractions, hence these conflicting 
results. Larger studies are needed to explore this, but the finding in this study that there 
was no significant difference between strains measured using CMR tagging (the current 
non-invasive gold standard) in exercisers and DCM patients with similarly reduced 
ejection fractions might support this. 
 

 
The importance of these findings is perhaps their potential use in identification of athletes 
at risk of sudden death, in whom the first presentation of any cardiac abnormality is that of 
SCD. Vigorous exertion can act as a substrate for ventricular arrhythmias in people with an 
underlying abnormal myocardium (Maron and Pelliccia, 2006). One theory for this is that 
repeated myocardial injury (reflected by troponin release) leads to fibrosis and scarring, 
which may be identified using LGE (Whyte et al., 2007, Waterhouse et al., 2012). These 
areas of fibrosis lead to an increased susceptibility to ventricular arrhythmias. ECV 
evaluation using T1 mapping may also identifies these areas, however whether T1 
mapping is valid also in athletic hearts remain to be established pathologically. 
Nevertheless, many athletes (and patients with DCM) do not have fibrosis that can be seen 
using LGE or ECV imaging. Native T1 mapping appears to identify other processes that 
are not purely related to fibrosis, for example myocardial inflammation represented by 
edema (also seen using T2 mapping, for which there is a strong correlation in our study) 
(Ugander et al., 2012). Speculatively, native T1 mapping may also identify early changes 
in myocardial function and metabolism, although large studies are awaited to understand 
the mechanisms and their clinical impact (Dass et al., 2012). 
 



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
 
This study does have some limitations. First, it is a single-centre study with a relatively 
small cohort, although to the best of my knowledge, this is the largest cohort studied in this 
area. Nevertheless, larger studies are required to confirm its findings and identify any 
potential prognostic benefit.  
 
Secondly, the lack of histological correlation in this study is a limitation as this could have 
provided further information. This does however reflect the decreasing use of 
endomyocardial biopsy in routine clinical practice. Also, biopsy itself is limited by 
sampling error.  
 
Thirdly, although measurement of T1 and T2 times in the septum is accepted in the current 
literature as being an adequate surrogate for the whole myocardium, both sequences still 
need to be optimized to allow accurate quantification in the lateral wall and apex without 
artifact. Only males were included in this study as T1 parameters show gender specific 
variation (Liu et al., 2013, Piechnik et al., 2013). This study would need to be repeated in 
order to validate the findings in females. Additionally, T1 mapping values can also be 
affected by LGE. Measurement of T1 times in different areas of the myocardium may have 
been changed by the presence or absence of LGE and so could have yielded different 
results. 
 
Finally, post-contrast T1 imaging was carried out at one time point only, 10 minutes after 
gadolinium administration. The optimal time for post-contrast T1 mapping has yet to be 
validated, although 10 minutes is potentially the most accurate for determination of ECV 
(Puntmann et al., 2013). In order to maintain consistency, I adhered to imaging at 10 
minutes for all patients in our protocol. 
 


Both CMR tagging and T1 mapping parameters can independently predict the presence of 
DCM. Native T1 mapping could potentially have the ability to both differentiate between 
patients with early cardiomyopathy and healthy athletes. 
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7. Comprehensive Dobutamine Stress MRI versus 
Dobutamine Stress Echocardiography in the 
Assessment of Patients with Left Bundle Branch 
Block and Suspected Coronary Artery Disease 
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

So far, I have looked at the prognostic value of CMR in patients with cardiomyopathies, 
and the diagnostic value of CMR in patients with suspected or potential cardiomyopathy. 
In scanning patients with cardiomyopathies, the presence of ECG abnormalities is 
relatively common (Baig et al., 1998, Grunig et al., 1998). One of the commonest I came 
across was the presence of left bundle branch block (LBBB). Its presence can alert the 
clinician to the potential presence of a cardiomyopathy. Significant coronary artery disease 
(CAD) can be a cause of LBBB, and the presence of LBBB can pose a challenge in the 
non-invasive diagnosis of CAD. 
 
In this chapter, in an extended introduction, I shall describe the clinical problem, and 
outline why current diagnostic methods are unsatisfactory, and how CMR could potentially 
provide a solution. This will lead on to the clinical study, in which I shall compare 
dobutamine stress CMR (DSCMR) against dobutamine stress echocardiography (DSE). 
 

 
While conventional invasive coronary angiography (ICA) remains the gold-standard for 
identification and treatment of CAD, most pathways for diagnosis and management of 
chronic stable angina caused by obstructive CAD include a non-invasive test to risk stratify 
patients and identify those in whom invasive management would be beneficial, particularly 
in those patients at low to intermediate risk of CAD (Montalescot et al., 2013). Either 
anatomical or functional imaging can be used. Common non-invasive tests include 
exercise stress testing (treadmill or bicycle), nuclear perfusion imaging, stress 
echocardiography, multislice CT coronary angiography and stress CMR. 
 
The presence of LBBB on the resting ECG in patients with suspected angina presents a 
diagnostic challenge. Common causes of LBBB are aortic stenosis, dilated 
cardiomyopathy, acute myocardial infarction, pre-existent coronary artery disease, older 
age and hypertension. Of course, the cause cannot often be identified from the ECG. 
Prevalence in the general population is estimated to be 0.43% in men and 0.28% in women 
while incidence is 3.2 per 10,000 per year in men and 3.7 per 10,000 per year in women 
(Hardarson et al., 1987). Despite the numerous causes of LBBB, CAD accounts for the 
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majority of cases. Indeed, the estimated prevalence of CAD in patients with LBBB has 
been between the range of 30-52% (Hardarson et al., 1987, Mulcahy et al., 1968). 
 
While acute LBBB accompanied by chest pain remains an indication for immediate 
primary percutaneous coronary intervention, identifying the presence of CAD in patients 
with chronic LBBB remains challenging. Each non-invasive cardiac imaging modality has 
its own pitfalls as well as benefits. The aim of this review is to look at techniques for non-
invasive investigation of CAD, specifically in patients with LBBB, and to identify their 
advantages and disadvantages. 



The presence of LBBB has been associated with adverse prognosis, including sudden death 
(Rabkin et al., 1980). In the Framingham study, 48% of patients with LBBB developed 
CAD or heart failure, while after 18 years of follow-up only 11% of patients with LBBB 
were free of any cardiovascular disease (Schneider et al., 1979). Despite this, in patients 
with LBBB but without any clinically significant manifestation of cardiovascular disease, 
mortality is only slightly increased compared to the general population (Francia et al., 
2007). Given this, the presence of LBBB often prompts referral to the cardiologist for 
further evaluation. With the most common cause being CAD, investigations will often be 
directed towards the exclusion of significant CAD. 
 
The presence of LBBB causes a number of changes in myocardial function which have an 
important impact on non-invasive testing for angina. The most obvious is the delay in 
electrical activation of the left ventricle, recognised as the wide QRS complex on the ECG 
(>120ms) (figure 7-1) (Mehdirad et al., 1998). This manifests itself as abnormal 
contraction of the interventricular septum, leading to dysynchrony in comparison to the 
posterior wall during systole. These features impact on both assessment of ST segment 
changes on the ECG during exercise and on assessment of regional wall motion 
abnormalities (RWMA). The delay in activation of the septum can make it appear as 
though there is a RWMA, particularly in inexperienced hands. 
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Figure 7-1. The typical electrocardiographic pattern of left bundle branch block.  
 
 
Note the wide QRS complex, the QS complex in V1 and the rSR in V6. 
 
In an experimental model of LBBB, the induction of LBBB caused impaired septal systolic 
thickening and an increase in intramyocardial pressure, leading to a relative reduction in 
myocardial perfusion and glucose uptake within the septum compared to the lateral wall 
(Ono et al., 1992). This phenomenon was actually found to be related to hyperperfusion of 
the lateral wall, which was also found in patients with permanent pacemakers (who were 
paced from the right ventricle, causing an LBBB equivalent), and was also exacerbated by 
exercise (Koepfli et al., 2009). In this study, the authors explained the presence of lateral 
hyperperfusion by the delay in lateral wall contraction, causing a reduction in workload in 
the septum and reduced oxygen demand compared to the lateral wall. During exercise, this 
phenomenon would be further increased as the lateral wall does more work, causing a 
more pronounced hyperemic response. This could potentially cause the misrepresentation 
of septal perfusion defects as indicative of significant coronary stenoses. 
 
The early septal contraction also means that the septum appears thinner at end-systole. As 
described above, this may cause difficulty with the interpretation of wall motion 
abnormalities. It may also cause difficulties in the interpretation of perfusion at systole if 
the spatial resolution of the technique is not high, known as a partial volume effect. In a 
cohort of LBBB patients without significant CAD examined using positron emission 
tomography and CMR, the thinned septum had reduced deformation and reduced glucose 
metabolism in comparison to the lateral wall (Mahrholdt et al., 2005b). 
 
The combination of these myocardial features specific to LBBB may cause difficulties in 
the use of non-invasive imaging to assess for the presence of CAD, as I shall now describe. 
 


Chapter 7: Dobutamine Stress CMR vs. Dobutamine Stress Echo in LBBB. 
 
 140 


This refers to the recording of the electrocardiogram with the patient exercising to achieve 
a predefined target heart rate (adjusted by age). This is achieved either by exercise on a 
treadmill or on a bicycle. The level is gradually increased in stages, with ECG monitoring 
carried out continuously. The test can be considered diagnostic if the patient reaches 85% 
of their maximum predicted heart rate or if typical symptoms are brought on. Commonly, 
LIHLWKHURIWKHVHSRLQWVLVUHDFKHGDW³ORZZRUNORDG´HJOHVVWKDQPLQXWHVRQH[HUFLVH
treadmill test using full Bruce protocol), patients can then commonly go on to have ICA. 
 
The principal diagnostic endpoint on the ECG is of horizontal or downsloping ST-segment 
depression. In LBBB however, due to the resting ECG abnormality, it is very difficult to 
interpret any changes in the ECG during exercise.  
 
Although the exercise ECG may provide some additional diagnostic and prognostic 
information regarding exercise tolerance, heart rate and blood pressure response and 
symptoms, the exercise ECG is not presently recommended as a routine investigation in 
patients with LBBB (Fihn et al., 2012, Montalescot et al., 2013). Given this, imaging 
modalities must be used in the evaluation of patients with LBBB. 
 


Nuclear imaging, most commonly performed using single positron emission tomography 
(SPECT) is one of the most validated techniques for assessment of stable angina. 
 
Intravenous technetium-99 is most commonly used, with thallium-201 less favored due to 
its increased radiation dose (Baggish and Boucher, 2008). The myocardium is stressed 
either using exercise (bicycle or treadmill) or pharmacologically (vasodilator ± adenosine, 
dipyridamole; or inotropic ± dobutamine +/- atropine). Current recommendations are that 
exercise should be used whenever possible in order to provide a physiological response, 
with pharmacological stress only being used in patients unable to exercise. Vasodilator 
VWUHVV ZRUNV RQ WKH SULQFLSOH RI FRURQDU\ DUWHU\ ³VWHDO´ $W UHVW WKH VWHQRVHG FRURQDU\
artery is vasodilated in order to maximize blood flow to its supplied territory (i.e. its 
coronary vasodilator reserve has been utilised). When a vasodilator such as adenosine or 
dipyridamole is given, the non-diseased arteries dilate, increasing coronary blood flow to 4 
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to 5 times above normal. The diseased artery however is unable to dilate further, resulting 
in relative hypoperfusion distal to the coronary stenosis. Conversely, when dobutamine is 
used as stressor the aims are to mimic exercise by increasing the myocardial contractility 
and heart rate. The contractility of areas of ischaemic myocardium initially improves with 
low dose dobutamine, however at higher doses the blood supply is unable to match 
demand and wall motion abnormalities become more obvious. 
 
Whatever means of stress is used, there is relative hypoperfusion ± NQRZQDV WKH ³VWHDO
SKHQRPHQRQ´- of myocardial areas subtended by stenosed coronary arteries and therefore 
there is a relative decrease in radioactive tracer uptake, suggesting significant CAD. The 
presence of transient left ventricular dilatation and reduced ejection fraction at stress are 
also suggestive of the presence of significant CAD. 
 
Nuclear medicine has been the most studied imaging modality. In general nuclear medicine 
has been shown to be relatively robust in the assessment of CAD in the general population. 
In the general population with suspected obstructive SPECT has a sensitivity of 87% and 
specificity of 73% (Salerno and Beller, 2009). It is recognised that in LBBB however 
SPECT does suffer some limitations, predominantly explained by the impact of LBBB on 
the myocardium described earlier in this chapter; because of these several early studies 
found a high rate of positive test results in the LAD territory with inducible perfusion 
defects being seen in patients without CAD on angiography (Inanir et al., 2001, Higgins et 
al., 2006).  
 
There are technical reasons that cause an apparent decrease in perfusion in the septum. It 
has been observed that resting septal radionuclide counts are lower compared to the lateral 
wall ± this is accepted as the lateral wall is closer to the gamma camera, while the partial 
volume effect also causes an apparent decrease in perfusion due to the limitations of spatial 
resolution (Prinzen et al., 1995). Despite this, there is also evidence that there is a definite 
reduction in septal perfusion in patients with LBBB that is picked up during SPECT 
imaging not caused by significant CAD on invasive coronary angiography. As described 
earlier, it has been noted that there is a relative hyper-perfusion of the lateral wall, which 
may cause perfusion in the septum to appear abnormal, due to its decreased workload 
compared to the lateral wall (Koepfli et al., 2009).  
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Other mechanisms for a true decrease in perfusion include impairment of diastolic 
coronary blood flow caused by the abnormal septal post-systolic motion leading to 
compression of the septal perforators, the phenomenon known as phasic flow (Skalidis et 
al., 1999) and reduced septal endothelial function and reduced coronary flow reserve 
leading to microvascular dysfunction, reduction in the length of diastole in LBBB 
(worsening during exercise, leading to reduced perfusion) (Masoli et al., 2000). 
 
Several methods have been used to overcome these problems. The widespread adoption of 
ECG-gated SPECT has improved the accuracy of technique. Specifically, viewing gated 
SPECT images at end-diastole has been found to be the most accurate method of 
identifying CAD. Demir et al studied 25 patients with LBBB, none of whom had 
angiographically proven CAD. Non-gated SPECT revealed a 20 septal perfusion defects, 
gated SPECT with images at end-systole ten and gated-SPECT at end-diastole five, the 
lowest number of false positives (Demir et al., 2003). These results have been replicated in 
other studies, suggesting that ECG gating with acquisition in diastole might provide some 
extra diagnostic confidence in this group of patients (Sugihara et al., 1997, Inanir et al., 
2001). Gated SPECT also allows assessment of left ventricular volumes and function 
which have been shown to have prognostic value in patients with LBBB (America et al., 
2007, Jeevanantham et al., 2009, Evangelista et al., 2012). 
 
Algorithms for assessment of septal perfusion defects have also been suggested to improve 
the diagnostic accuracy of SPECT. By only counting patients with apical defects in 
addition to septal defects as being positive there seems to increase diagnostic accuracy 
(Higgins et al., 2006). This appears to be logical, given that the LAD supplies the apex and 
so patients without significant LAD disease should have normal apical perfusion on 
SPECT as the apex will not be thinned or dysynchronous. Doing this appears to increase 
the diagnostic accuracy of SPECT to a similar level to that of dobutamine stress 
echocardiography (Tandogan et al., 2001). Correlating the perfusion defect with any wall 
motion abnormality may also prove useful; indeed if there is normal septal wall motion 
and thickness but abnormal septal perfusion this lends more weight to the result being a 
true positive. With these caveats, the performance of gated SPECT is more than 
satisfactory. 
 
Several of the effects mentioned that may lead to false positives are caused by the increase 
in cardiac inotropy and chronotropy and so vasodilator stress is preferred to exercise or 
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pharmacological in patients with LBBB (Burns et al., 1991, O'Keefe et al., 1993, 
Vaduganathan et al., 1996).  2¶.HHIHHWDOUHSRUWHGDVSHFLILFLW\RIGLDJQRVLQJVHSWDO&$'
of 82% using adenosine compared to 42% with exercise stress (O'Keefe et al., 1993). A 
large retrospective analysis focusing on this was conducted by Vaduganathan et al 
(Vaduganathan et al., 1996). The authors looked at 383 patients recruited over a 5-year 
period who had been referred to their unit for myocardial perfusion scintigraphy. Of those, 
206 patients were stressed with exercise, 127 had adenosine and in 50 dobutamine was 
used. They found that all 3 stress modalities performed fairly equally in diagnosis of 
circumflex (sensitivity and specificity 74% and 96% for exercise; 50% and 100% using 
dobutamine; 63% and 91% with adenosine) and right coronary artery disease (96% and 
86%; 82% and 91%; 79% and 100% respectively). Sensitivity in LAD disease was also 
acceptable (88%, 79% and 100%, respectively) however, specificity and positive 
predictive value in diagnosing LAD disease was rather disappointing with exercise 
compared to pharmacological methods (36% and 51% for exercise, 81% and 85% for 
adenosine and 80% and 90% for dobutamine respectively). Therefore, in patients with 
LBBB it may be recommended to perform a gated-SPECT study with adenosine or 
dipyridamole. Two drawbacks with this large study are that only 40% of patients 
underwent invasive coronary angiography (ICA) and the retrospective nature of the study 
calling therefore for caution in interpreting the results. 
 
Positron emission tomography (PET) scanning is another nuclear imaging technique that 
can be used for assessment of ischaemia. Generally speaking, it is slightly more accurate 
than SPECT (Bateman et al., 2006). It is however not widely available and is more 
expensive than SPECT. It does however provide the ability to quantify absolute blood 
flow, however, PET does seem to be afflicted with the same problems as SPECT (Zanco et 
al., 2000). Indeed, PET scanning has shown the lateral wall hyperperfusion during stress 
(Koepfli et al., 2009, Lindner et al., 2005). 



Stress echocardiography is also well validated for identification of CAD. Again, all forms 
of stress (exercise, vasodilators and inotropes) can be used. Unlike SPECT, rather than 
perfusion, stress echocardiography (most commonly) looks for the presence of inducible 
regional wall motion abnormalities during stress (figure 7-2).  
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Figure 7-2. Dobutamine Stress Echocardiography in LBBB.  
 
 
DSE revealing an inducible wall motion abnormality at peak stress in the RCA territory 
(basal inferoseptal; B, D - arrows) confirmed on ICA (E - arrow). 
 
Sensitivity in the general population is around 74-97% for exercise echocardiography, 61-
95% for dobutamine and 61-81% for dipyridamole/adenosine while specificity is 64-86%, 
51-95% and 90-94% respectively (Marwick, 2003). Again, exercise echocardiography is 
preferred to pharmacological stress if feasible. 
 
There have been mixed results with use of stress echocardiography in patients with LBBB. 
The main problem lies with the abnormal septal motion seen in LBBB which is aggravated 
by tachycardia. Nevertheless, several studies have found that stress echocardiography had 
 
 

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a better diagnostic accuracy than SPECT for detection of CAD (Schartl et al., 1997, 
Mairesse et al., 1995, Tandogan et al., 2001). Some more recent studies have improved this 
slightly, perhaps suggesting that more familiarity with the techniques has improved 
diagnostic accuracy, however, the fact that echocardiography mainly relies on wall motion 
analysis means that its accuracy, especially in diagnosis of LAD disease is reduced. In a 
retrospective review of 60 patients who underwent stress echocardiography, Lewis et al 
found that the technique had a poor specificity (64%) despite a sensitivity of 100% (Lewis 
et al., 2007). Positive predictive value was poor at around 40% for patients with or without 
prior MI. 
 
Dobutamine stress echocardiography has shown some good results in other studies 
however. Yanik et al studied 30 patients with LBBB and left ventricular dysfunction and 
found that dobutamine stress echocardiography had a sensitivity of 82%, specificity 95% 
and an overall diagnostic accuracy of 90% (Yanik et al., 2000). One of the largest studies 
employing stress echocardiography was a prospective evaluation of 64 patients in a multi-
center study by Geleijnse et al. (Geleijnse et al., 2000). All patients had been referred for 
ICA for suspected CAD. They all underwent dobutamine/atropine stress echocardiography. 
Significant CAD was confirmed angiographically in 19 patients. Sensitivity for the 
detection of CAD was 68% while specificity was better than what had been previously 
measured by SPECT at 91%. Diagnostic accuracy overall was 84%. Similar to SPECT, the 
authors found that the lowest level of diagnostic accuracy was in patients with abnormal 
septal wall thickening at rest, which made it difficult to diagnose LAD disease correctly. 
Given that septal abnormalities are the highest cause of false positives, it is of concern that 
this area provided so much diagnostic uncertainty. 
 
Prognostically, stress echocardiography has been shown to be helpful. A large study by 
Bouzas-Mosquera et al. identified 618 patients with LBBB who underwent exercise 
(treadmill) echocardiography. They found that patients who developed ischemia had 
almost double the 5-year mortality rate and major adverse cardiac event rate to patients 
who did not (24.6% vs. 12.6% and 18.1% vs. 9.7% respectively) (Bouzas-Mosquera et al., 
2009). Similar prognostic information has been shown using dobutamine stress 
echocardiography (Supariwala et al., 2014) and in patients over the age of 80 (Innocenti et 
al., 2011).  
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The use of advanced echocardiographic techniques can also be used to further improve the 
diagnostic accuracy of stress echocardiography. The quantification of long-axis shortening 
using tissue Doppler appears to be more accurate than simple wall motion scoring for 
differentiation of patients with and those without CAD undergoing dobutamine stress 
echocardiography (Duncan et al., 2003). Badran et al evaluated the addition of tissue 
Doppler analysis in 62 patients undergoing dobutamine stress echocardiography 6 weeks 
prior to ICA. As well as standard wall motion analysis, post-systolic shortening velocity, 
post-systolic peak velocity and peak early and late diastolic velocities were measured. 
Using these techniques they were able to obtain a sensitivity of 90% and specificity of 87% 
(Badran et al., 2007). The use of vector velocity imaging to assess strain and strain rate has 
also been shown to add additional prognostic information in prediction adverse 
cardiovascular events in patients with LBBB (Shan et al., 2009). 
 
The use of myocardial contrast echocardiography (MCE) may also improve diagnostic 
accuracy of stress echocardiography. The use of contrast not only allows clearer 
endocardial border definition, but also allows assessment of myocardial perfusion. Given 
that the development of perfusion defects are earlier than wall motion abnormalities in the 
ischaemic cascade, in theory the assessment of perfusion might increase the diagnostic 
accuracy of stress echocardiography. Karavidas et al. compared adenosine stress 
echocardiography against SPECT and ICA (Karavidas et al., 2006). This study was 
prospective, with 47 patients suspected of having CAD undergoing SPECT, then MCE 1-3 
days later before having ICA within 1 week. In the study MCE outperformed SPECT 
significantly. Sensitivity was 73% vs. 91%, specificity 72% vs. 92%, positive predictive 
value 44% vs. 77% and negative predictive value 90% vs. 97% respectively. Overall, 
diagnostic accuracy was 72% for SPECT and 97% for MCE. The authors also found that 
MCE maintained its high performance in the diagnosis of LAD disease. Similar figures 
were found by Hayat et al, who took 83 patients, reporting a sensitivity of 92% and 
specificity of 95% using MCE, which significantly outperformed SPECT (Hayat et al., 
2008).  
 
Dobutamine stress echocardiography, in experienced hands, appears to perform at least as 
well as SPECT in diagnosis of CAD in patients with LBBB. The use of more advanced 
techniques such as tissue Doppler imaging, speckle tracking and myocardial contrast 
echocardiography could potentially increase diagnostic accuracy.  
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

Given the limitations with techniques reliant on wall motion and that the gold standard 
they are compared with is ICA, it would perhaps be hoped that an anatomical non-invasive 
imaging technique ± multislice cardiac computed tomography angiography (MSCT) - 
might overcome some of these problems. 
 
In current guidelines, MSCT is usually recommended in patients with a low pre-test 
probability of CAD (typically less than 15%) to exclude the presence of CAD 
(Montalescot et al., 2013). The diagnostic accuracy for CTCA in detecting CAD in this 
group is very good (sensitivity >95%, specificity ~80%) (figure 7-3) (Budoff et al., 2008, 
Meijboom et al., 2008). But for the majority of patients who fall within an intermediate 
pre-test probability of CAD, functional imaging is usually recommended to assess whether 
the coronary artery lesions are functionally significant. 
 
Figure 7-3. Computed Tomography in LBBB.  
 
 
CT coronary angiography correctly identifies an RCA lesion (left, arrow), with 
confirmation on invasive coronary angiography (right, arrow). 
 
While the presence of LBBB in itself does not cause technical problems with CTCA, given 
the prevalence of co-morbidities in patients with LBBB, most of these patients will have at 
least an intermediate pre-test probability of CAD. Despite this fact, one large study 
comparing MSCT against ICA reported extremely favourable results. Ghostine et al. 
looked at 66 patients with LBBB but no prior history of CAD using 64-slice CT and found 
that on a per-patient basis MSCT had a sensitivity of 97%, specificity of 95% and positive 
predictive value of 93% compared with ICA (Ghostine et al., 2006). Sensitivity did drop to 
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72% however when analyzing CAD per AHA segment. The performance of MSCT was 
also reduced in patients with more than one coronary artery stenosis (multivessel disease). 
MSCT does certainly appear to be a viable option in patients with low pre-test probability 
and LBBB (Perrier et al., 2006). 
 
Newer techniques such as CT stress myocardial perfusion imaging and non-invasive 
measurement of fractional flow reserve have shown some improvement in diagnostic 
accuracy in the general population, with the ability to provide some functional information, 
however these have not yet been studied in patients with LBBB (Ko et al., 2012b, Koo et 
al., 2011). 


 
CMR can use a combination of sequences to evaluate both inducible wall motion 
abnormalities and perfusion defects and can be performed using either dobutamine or 
adenosine stress. Typical CMR sequences for the assessment of CAD are cine imaging for 
measurements of chamber size and function and assessment of wall motion, T2 weighted 
imaging for edema, first pass perfusion imaging at rest and stress using dobutamine, 
dipyridamole or adenosine and LGE for assessment of myocardial fibrosis (for example in 
prior infarcts) (Schmid et al., 2010, Karamitsos et al., 2011).  
 
Both DSCMR and adenosine stress CMR appear to have good diagnostic accuracy, 
especially when combination techniques are used, such as LGE. In the general population 
DSCMR seems to be at least equal to SPECT and stress echocardiography ± it has been 
shown to have a sensitivity of 83-89% and a specificity of 84-86%. Prognostically it has 
also been shown to be useful, with a 96.2% 2-year survival rate in patients with suspected 
ischemia but a negative DSCMR (Nandalur et al., 2007). Perfusion imaging with 
adenosine is perhaps more commonly carried out clinically, and two large trials have also 
confirmed its diagnostic accuracy, and suggest it may be better than SPECT, with 
additional prognostic value. It has also been shown to have reasonable accuracy in 
diagnosis of patients with CAD (Schwitter et al., 2012, Pilz et al., 2008, Greenwood et al., 
2012). 
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CMR seems to have some potential to overcome the limitations of other non-invasive 
functional techniques for investigation of suspected CAD in patients with LBBB, but as of 
yet there have been no studies evaluating its diagnostic accuracy in this group of patients. 
 


Obstructive CAD is common in patients with LBBB, however all common non-invasive 
imaging techniques do appear to suffer some limitations, which are summarised in table 7-
1.  
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Table 7-1. Summary of Advantages and Disadvantages of Non-Invasive Techniques 
For Investigation of CAD in LBBB. 
 
Investigation          Advantages          Disadvantages 
Exercise ECG x Cheap 
x Easily available 
x Too unreliable for 
regular use 
Nuclear Imaging x Most studied 
x Widely available in many 
areas 
x Large number of centres 
and expertise 
x Prognostic data available 
x High rate of false 
positives in the 
septum 
x Radiation exposure 
Stress 
Echocardiography 
x Readily available in many 
centres 
x Prognostic data available 
x No radiation exposure 
x Safe 
x Cheap 
x Can make non-coronary 
diagnoses 
 
x Perhaps a lower rate 
of false positives 
than nuclear testing, 
but high variability 
between operators 
x Can be limited by 
poor windows 
Cardiac CT x Excellent anatomical 
definition 
x Can deliver extra-cardiac 
diagnosis 
x Addition of perfusion 
allows functional analysis 
x Not as useful in 
patients with high 
probability of 
coronary artery 
disease 
x High radiation dose 
(especially if 
perfusion added) 
x High calcium may 
not correlate to 
significant stenosis 
Stress CMR x 1RW OLPLWHGE\³ZLQGRZV´ x Not widely available 
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unlike echocardiography 
x Allows functional testing 
x Able to make non-
coronary diagnoses 
x Improvement in 
angiographic techniques 
may allow anatomical 
diagnosis 
x No ionising radiation 
x More technically 
challenging 
x Claustrophobia 
x Expensive 
x Not as validated as 
SPECT or stress 
echocardiography 
 
Both SPECT and stress echocardiography have reduced diagnostic accuracy in this group 
of patients, while although MSCT and stress CMR may hold some promise, large studies 
and prognostic data are still lacking for these techniques in LBBB. Important note must be 
made of the difficulties in diagnosis of significant LAD territory disease. 
 
It is important to mention some caveats with studies of imaging techniques. Firstly, many 
of these studies do suffer from post-test referral bias, as with many studies in diagnostic 
testing. That is, in most studies, patients with positive results are preferentially referred on 
for angiography. This means that the number of false positives is much higher than the 
number of true negatives, thus giving potentially (artificially) lower test specificity 
(Hachamovitch and Di Carli, 2008). Also, physicians may preferentially refer high-risk 
patients for angiography without imaging. This may mean that the patients included in 
studies might be lower risk and not wholly representative of the general population, 
especially relevant in patients with LBBB where there is a high prevalence of CAD. 
 
The other important point to note is that most studies have defined the presence of CAD on 
the basis of angiographic stenosis of greater than or equal to 50%, often based on visual 
assessment, or at best quantitative coronary angiography. It is now accepted that lesions of 
this size (or larger) are not always functionally significant, and that lesions that appear 
smaller might actually be so. Again, this (at least theoretically) may artificially lower the 
sensitivity and specificity noted in non-invasive imaging. No studies have been done 
specifically in patients with LBBB to compare non-invasive imaging modalities with 
invasive function assessments such as fractional flow reserve. 
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At present, it would be preferable that non-invasive imaging of patients with LBBB should 
be performed wherever possible to avoid unnecessary angiography. Selection of the 
technique used probably should come down to physician preference, confidence and 
perhaps more importantly, an awareness of the limitations of each technique and methods 
to overcome these. Gated SPECT and vasodilator stress echocardiography are probably the 
most widely available techniques, however, stress CMR might be able to provide a 
solution to this difficult clinical problem. I shall now go on to test this hypothesis in a 
study comparing dobutamine stress CMR against dobutamine stress echocardiography in a 
group of patients with stable angina and LBBB. 
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 

So far in this chapter I have described the difficulties posed to the clinician in the non-
invasive assessment of LBBB. Because of the prevalence of CAD in patients with LBBB 
(Eriksson et al., 1998, Hardarson et al., 1987), initial investigation of patients with this 
ECG abnormality is often directed to the exclusion of significant CAD, particularly when 
the history is suggestive. 
 
It appears that non-invasive techniques that use a combination of parameters to assess 
ischaemia appear to hold the best promise in accounting for the limitations of individual 
techniques, for example the difficulty in assessing wall motion, or the presence of 
perfusion defects unrelated to the presence of significant obstructive CAD (Badran et al., 
2007, Karavidas et al., 2006). 
 
Dobutamine stress CMR (DSCMR) can assess both wall motion and perfusion, and this 
perhaps has the ability to overcome some of the disadvantages of other non-invasive 
investigations (Charoenpanichkit and Hundley, 2010). DSCMR allows confident diagnosis 
of stress-induced wall motion abnormalities with excellent differentiation of the 
myocardial border, while the use of gadolinium contrast allows visualisation of myocardial 
fibrosis caused by the presence of CAD. Additionally, the visualisation of myocardial 
perfusion during the first pass of gadolinium at rest and stress also provides another 
potential tool for diagnosis of CAD. Nevertheless, the utility and potential superiority of 
DSCMR in this setting has not yet been established. 
 
The aim of this study was to compare a comprehensive DSCMR examination including 
wall motion analysis, perfusion and LGE imaging with dobutamine stress 
echocardiography (DSE) compared to the gold-standard of invasive coronary angiography 
(ICA). Two aspects of DSCMR were evaluated ± firstly, the diagnostic accuracy of CMR 
wall motion analysis alone (analogous to DSE), and then the additional diagnostic value of 
the addition of perfusion and LGE imaging. 

 
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



82 consecutive patients with LBBB who were referred for assessment of suspected CAD 
were recruited. All patients underwent DSE, DSCMR and ICA. All tests were performed 
within 14 ± 8 days by observers blinded to results of the other tests. The study is 
summarized in figure 7-4. 
 
Figure 7-4. Study Summary 
 
 
 
Currently, it is recommended that non-invasive functional imaging for investigation of 
stable angina should be used in patients with intermediate probability of CAD 
(Montalescot et al., 2013, Skinner et al., 2010) and therefore no patients of low or high risk 
were chosen (<10% or >80% pre-WHVWSUREDELOLW\7RHQVXUHWKLVDOOSDWLHQWVZHUHDJH
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years and had typical features of angina (exertional chest pain or dyspnoea) with one or 
more risk factors. In addition to the standard CMR exclusion criteria (described in Chapter 
2), patients with uncontrolled hypertension (baseline systolic BP of >190 mmHg or 
diastolic BP of >100 mmHg), those with atrial fibrillation with fast ventricular response 
were also excluded.  Patients were allowed to continue their anti-anginal medications, 
including oral beta-blockers, calcium channel blockers and nitrates, before DSCMR. For 
DSCMR, DSE and ICA analysis was performed by two observers blinded to the results of 
the other investigations. All patients provided written informed consent to undergo 
DSCMR, DSE, ICA. 
 


Two-dimensional transthoracic DSE was carried out in all patients using an IE33 scanner 
(Philips, Amsterdam, Netherlands). All patients were scanned in the left lateral position 
and with continuous ECG monitoring employed. All patients were pharmacologically 
VWUHVVHG XVLQJ GREXWDPLQH VWDUWLQJ DW D UDWH RI  ȝJNJPLQ DQG LQFreased at 3-minute 
LQWHUYDOVE\LQFUHPHQWVRIȝJNJPLQWRDPD[LPXPRIȝJNJPLQ,IWDUJHWKHDUWUDWH
(85% of 220 - DJHZDVQRWUHDFKHGDWȝJNJPLQRIGREXWDPLQHLQWUDYHQRXVEROXVHVRI
atropine sulphate were also given (0.25-0.5 mg aliquots up to a maximum total dose of 2 
mg) to increase the heart rate response. Standard echocardiographic views were taken 
(parasternal long and short axes, apical 2, 3, 4 and 5 chamber and subcostal views). Images 
were acquired at rest and peak stress. The dobutamine infusion was stopped were: the 
patient reaching target heart rate (i.e. 85% of predicted for age), occurrence of a new wall 
motion abnormality, development of significant symptoms (e.g. chest pain, dyspnoea) or 
significant ECG changes such as arrhythmias. In order to improve endocardial border 
definition intravenous contrast was used for all patients during at both rest and stress. The 
DSE protocol is summarised in figure 7-5. 
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Figure 7-5. DSE Protocol 
 
 
 


DSCMR was performed using the same scanner as before. The order of sequences is 
summarized in Figure 7-6. 
 
Figure 7-6. DSCMR Protocol 
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All patients underwent HASTE and cine imaging as previously described. Following this, 
dobutamine was infused at progressive 3-minute stages of 10, 20, 30, and 40 mcg/kg/min, 
analogous to DSE. Again, intravenous boluses of atropine sulphate were used at 30 or 40 
PFJNJPLQ VWDJHV LQ WKH FDVH RI DQ LQDGHTXDWH KHDUW UDWH UHVSRQVH $W ȝJNJPLQ
dobutamine stress (intermediate dose), intravenous gadolinium-DOTA (0.1mmol/kg) was 
injected and first-pass myocardial perfusion images were acquired at 3 short-axis slices 
(representing the basal, mid and apical levels of the left ventricle) and the 4-chamber long-
axis view. This dose was selected as there was concern that at higher doses of dobutamine 
the increase in myocardial contractility and heart rate might cause difficulty interpretation 
of first-pass perfusion images. There is evidence to suggest that this dose can cause 
adequate vasodilatation and augmentation of blood flow to allow assessment of myocardial 
perfusion equivalent to perfusion imaging using adenosine (al-Saadi et al., 2002, Bartunek 
et al., 1999, Severi et al., 1995). Following stress perfusion imaging and stress wall motion 
analysis and return to resting heart rate, a further dose of intravenous gadolinium was 
given and rest perfusion images acquired using the same views as at peak stress. 10 
minutes after this second dose of gadolinium LGE imaging was performed.  
 
7ZRH[SHULHQFHGUHDGHUVEOLQGHGWRSDWLHQWV¶FOLQLFDOKLVWRU\DQGRXWFRPHLQWHUSUHWHGWKH
dobutamine-CMR images. The presence of regional wall motion abnormalities (RWMAs) 
each stage was analyzed according to the standardized American Heart Association 17-
segment model (Cerqueira et al., 2002). At each dobutamine stage segments were graded 
as 1 = normal, 2 = hypokinesia, 3 = akinesia, and 4 = dyskinesia. An inducible RWMA 
was defined as the presence of wall motion grade >1 and absence of wall thickening during 
progressive dobutamine stress, apart from the progression of segmental akinesia to 
dyskinesia which was considered non-specific. Segmental RWMAs had to be present in 
both short and long axis views to be considered true ischaemic defects. 
 
For perfusion imaging, the 3 slices were qualitatively analysed for the presence of 
perfusion defects. The left ventricular myocardium was segmented into 6 sectors at the 
basal and mid ventricular slices and 4 sectors at the apical slice, again following the 
American Heart Association model.  Each myocardial segment was qualitatively 
interpreted as having normal perfusion or abnormal hypoperfusion (reduction in signal). 
Ischemia by myocardial perfusion imaging was defined by any persistent segmental 
reduction in signal in absence of delayed hyper-enhancement by delayed imaging or, in 
patients who had evidence of prior MI on LGE imaging, the presence of peri-infarct 
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ischemia was also counted as a positive perfusion defect. In detecting coronary stenosis, 
myocardial ischemia by WMI or MPI was only considered true positive if the myocardial 
segment was in the same territory of a significant stenosis. Using CMR cine imaging 
alone, CMR was judged to be positive if an inducible regional wall motion abnormality 
(RMWA) was seen. In the comprehensive DSCMR examination, the test was adjudged to 
be positive if either there was LGE present in a distribution typical of infarction 
(subendocardial or transmural) with evidence of peri-infarct ischemia; or if there was no 
LGE, if there was an inducible perfusion defect which corresponded to an inducible 
RMWA. 
 
Infarcted myocardium was quantitated by semiautomatic detection of any region with 
signal intensity 5 standard deviations above the mean signal intensity of the remote 
myocardium as previously validated. The presence of LGE was only counted as positive if 
it was present in a sub-endocardial or transmural distribution typical of CAD (other 
patterns such as midwall LGE were excluded). 
 
Using CMR cine imaging alone, the test judged to be positive if an inducible RMWA was 
present. In the comprehensive DSCMR examination, the test was ruled positive if either 
there was LGE present in a distribution typical of CAD, with or without evidence of peri-
infarct ischemia. If no LGE was present, only the presence of an inducible perfusion defect 
corresponding to an inducible RMWA was ruled as a positive test. 
 


ICA was performed in all 82 patients. All angiograms were performed by experienced 
operators at the Golden Jubilee National Hospital. The operators were blinded to both DSE 
and DSCMR findings. To improve the accuracy of the assessment of the significance of 
coronary stensoses quantitative coronary angiography analysis (QCA) was performed 
using GE automated edge detection software, which calibrates using the coronary guide 
catheter as its reference diameter (Centricity Cardiology CA1000, GE Healthcare, 
Dornstadt, Germany). In order to ensure that significant, ischaemia causing stenoses were 
LGHQWLILHGVLJQLILFDQWVWHQRVHVZHUHGHILQHGDVOXPLQDOQDUURZLQJLQWKHPRVWVHYHUH
YLHZ  IRU OHIWPDLQ VWHQRVLV 3DWLHQWVZHUH FODVVLILHG DVhaving 1, 2 and 3-vessel 
disease. 
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
 
In addition to the statistical methods described in Chapter 2, several other analyses were 
conducted. Sensitivities, specificities, positive predictive and negative predictive values, 
chi-square statistic and the area under the curve (AUC) of DSE, CMR cine imaging and 
the complete DSCMR examination for detection of significant CAD (> 70% coronary 
artery stenoses) were calculated. Comparisons between diagnostic techniques were made 
with the McNemar test. The AUC between the tests was calculated using the method of 
DeLong et al (DeLong et al., 1988). 
 




All 82 patients underwent all 3 investigations without any complication. Image quality was 
satisfactory in all patients. The mean peak dose of dobutamine given was 35.4 ± 5.7 
ȝJNJPLQ DQG PHDQ SHDN KHDUW UDWH DWWDLQHG ZDV  EHDWVPLQXWH 3DWLHQW
characteristics are summarized in table 7-2 while hemodynamic parameters are 
summarized in table 7-3.  
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Table 7-2. Baseline characteristics of the cohort. 
 
 All Patients 
(n=82) 
CAD 
(n=34) 
No CAD 
(n=48) 
p value 
Age (years) 56.5 ± 7.8 57.2 ± 9.2 56.0± 6.6 0.50 
Male 53 (64.6) 23 (67.6) 30 (62.5) 0.63 
QRS duration (ms) 133.0 ± 8.1 134.5 ± 7.0 132.2 ± 8.7 0.19 
Hypertension 38 (46.3) 21 (61.8) 17 (35.4) 0.018 
Diabetes Mellitus 19 (23.2) 11 (32.4) 8 (16.7) 0.10 
Peripheral Arterial Disease 17 (20.7) 7 (20.6) 10 (20.8) 0.98 
Chronic Obstructive 
Pulmonary Disease 
12 (14.6) 6 (17.6) 6 (12.5) 0.54 
Hyperlipidaemia 39 (47.6) 14 (41.2) 25 (52.1) 0.33 
Smoker 33 (40.2) 12 (35.3) 21 (43.8) 0.44 
Alcohol excess 9 (11.0) 3 (8.8) 6 (12.5) 0.73 
Family History 37 (45.1) 13 (38.2) 24 (50.0) 0.29 
Aspirin use 22 (26.8) 9 (26.5) 13 (37.1) 0.34 
Beta-blocker use 13 (15.9) 6 (17.6) 7 (14.6) 0.71 
Oral Nitrate use 4 (4.9) 0 (0.0) 4 (8.3) 0.14 
Statin use 32 (39.0) 13 (38.2) 19 (39.6) 0.90 
Calcium Channel 
Antagonist use 
25 (30.5) 14 (41.2) 11 (22.9) 0.08 
Angiotensin-Converting 
Enzyme Inhibitor use 
31 (37.8) 16 (47.1) 15 (31.3) 0.15 
Data are presented as mean ± SD if continuous or number (%) if categorical. 
CAD ± coronary artery disease 
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Table 7-3. Haemodynamic data for DSCMR. 
 
 
 
Resting HR (bpm) 71 ± 9 
Maximal HR (bpm) 143.3 ± 10.0 
Resting Systolic BP (mmHg) 132 ± 20 
Peak Systolic BP (mmHg) 162 ± 10 
Resting Diastolic BP (mmHg) 72 ± 9 
Peak Diastolic BP 71 ± 11 
Peak Dose of Dobutamine (mg) 35.4 ± 5.71 
Number reaching target HR (85% 
of predicted) (%) 
82 (100)  
Atropine Given (%) 79 (96.3) 
Data are presented as mean ± SD if continuous or number (%) if categorical. HR ± heart 
rate; bpm ± beats/minute; BP ± blood pressure 
 
There was no significant difference in mean age between patients with CAD compared to 
those without significant CAD (57.1 ± 8.9 years vs. 55.9 ± 6.6 years, p=0.50). As would be 
expected in a cohort of patients with an intermediate pre-test probability for CAD, a 
significant proportion had CAD risk factors. The commonest risk factors within this patient 
population were hypercholesterolaemia, hypertension, smoking and a family history of 
CAD. The presence of hypertension was the only significant difference between the two 
groups (61.8% in patients with CAD vs. 35.4% in patients without CAD; p=0.018). 
 


Based on the results of quantitative analysis of ICA, 34 patients were deemed to have 
significant CAD. For assessment of inducible wall motion abnormalities DSCMR cine 
imaging and DSE had the same sensitivity (70.6%), however cine imaging had improved 
specificity (87.5% vs 72.9%), and consequently higher diagnostic accuracy (80.4% vs. 
72.0%). Positive and negative predictive values for wall motion interpretation by DSCMR 
cine imaging were 80.0% and 80.8% respectively while for echocardiography values were 
64.9% and 77.8% (Table 7-7).  
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Table 7-4. Per-patient diagnostic performance of DSE and DSCMR. 
 
 Sensitivity 
(%) 
Specificity 
(%) 
Accuracy 
(%) 
PPV 
(%) 
NPV 
(%) 
AUC 
DSE 70.6  72.9 72.0  64.9  77.8  0.72 
DSCMR Cine 
Imaging 
70.6  87.5  80.4  80.0  80.8  0.79 
First Pass 
Perfusion 
70.6  93.8  84.1  88.9  81.8  0.82 
LGE 41.5  100  72.0  100  67.6  0.66 
Comprehensive 
DSCMR 
82.4  95.8  90.2  93.3  88.5  0.89* 
PPV - positive predictive value; NPV - negative predictive value; AUC - area under the 
curve; DSE - dobutamine stress echocardiography; DSCMR - dobutamine stress 
cardiovascular magnetic resonance imaging 
* p<0.05 between comprehensive DSCMR and DSE 
 
There was an incremental improvement in diagnostic accuracy following the addition of 
stress perfusion imaging and LGE results, outlined in table 8-3. 11 patients had an 
ischaemic pattern of LGE. Sensitivity of the comprehensive DSCMR exam was 82.4% 
while specificity increased to 95.8%, leading to an improved overall diagnostic accuracy of 
90.2%. Using the receiver-operator characteristic, the area under the curve was greatest for 
a comprehensive DSCMR examination and was significantly better than DSE (AUC 0.89 
vs. 0.72 respectively, p<0.05). Examples of typical findings using DSCMR are shown in 
figures 7-7 to 7-9. 
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Figure 7-7. An example of a patient correctly identified with CAD using DSCMR. 
 
This patient had an inducible inferior RWMA seen using cine imaging (top, arrows). 
Perfusion imaging showed a stress-induced defect in the inferior wall (middle, arrows), 
with subendocardial LGE typical of CAD in this area (bottom left, arrow). ICA confirmed 
the presence of a right coronary artery stenosis. 
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Figure 7-8. An example of a patient with a septal wall motion abnormality typical of 
LBBB correctly identified with CAD using DSCMR. 
 
This patient had an inducible septal RWMA seen using cine imaging (top, arrow). 
Perfusion imaging showed a stress-induced defect in the septum and anterior wall (middle, 
arrow). There was no LGE present (bottom left). ICA confirmed the presence of a left 
anterior descending artery stenosis. 
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Figure 7-9. An example of a false positive septal wall motion abnormality for CAD 
using DSCMR cine imaging only but correctly identified as not having significant 
CAD using the comprehensive DSCMR examination. 
 
 
This patient had an inducible septal RWMA seen using cine imaging (top, arrow). There 
was no perfusion defect seen (middle) and no LGE present (bottom left). ICA confirmed the 
absence of any significant CAD. 
 
Of the 34 patients with diagnosed with CAD by invasive angiography, 14 had left anterior 
descending (LAD) stenoses, 14 had circumflex (Cx) disease, 5 had right coronary artery 
disease (RCA) disease and one had two-vessel disease. Table 7-8 summarises the 
respective performance of DSE and DSCMR for in correctly identifying the affected 
coronary artery. 
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Table 7-5. Percentage of patients correctly identified per vessel by echocardiography 
and CMR. 
 DSE DSCMR Cine Imaging  Comprehensive DSCMR 
No CAD 72.9 (35/48) 87.5 (42/48) 95.8 (46/48) 
LAD 64.3 (9/14) 57.1 (8/14) 71.4 (10/14) 
LCx 64.3 (9/14) 78.6 (11/14) 92.9 (13/14) 
RCA 100 (5/5) 80.0 (4/5) 80.0 (4/5) 
2-Vessel 
Disease 
100 (1/1) 100 (1/1) 100 (1/1) 
CAD ± Coronary Artery Disease; ICA - invasive coronary angiography; DSE - 
dobutamine stress echocardiography; DSCMR - dobutamine stress cardiovascular 
magnetic resonance imaging 
 
In two coronary artery territories, comprehensive DSCMR had improved sensitivity in 
comparison to DSE and DSCMR cine imaging (LAD: 71.4% vs. 64.3% vs. 57.1%; LCx: 
92.9% vs. 64.3% vs. 78.6% respectively). Sensitivity for the left-sided circulation was 
DSE: 64.2%, CMR cine imaging: 67.9% and comprehensive DSCMR: 82.1%. Both CMR 
techniques failed to identify one RCA lesion that was correctly identified by DSE. All 
three techniques correctly identified the presence of 2-vessel disease in one patient. 
 




This study was the first prospective evaluation using a comprehensive DSCMR 
examination of patients with LBBB for the diagnosis of CAD.  
 
x Regarding the primary hypothesis, DSCMR cine imaging proved to have higher 
diagnostic accuracy than DSE.  
x Additionally, there was an incremental benefit in diagnostic accuracy in using a 
comprehensive exam including cine imaging, first pass stress perfusion and LGE 
over wall motion analysis using DSCMR cine imaging alone. 
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

LBBB becomes more prevalent with age (around 17% of people at age of 80 in a Northern 
European population) and it is known to confer an adverse prognosis, at least in part due to 
the risk of cardiac death (Hardarson et al., 1987, Eriksson et al., 2005, Eriksson et al., 
1998). The prevalence of CAD in patients with LBBB is thought to be between 30-50% 
therefore, given the poor prognosis of LBBB it would be beneficial to identify those who 
may benefit from revascularization to alleviate some of the risk of cardiovascular mortality 
and morbidity (Schneider et al., 1981). 
 
Despite improvements in non-invasive imaging, diagnosis of CAD in patients with LBBB 
remains difficult. Functional non-invasive tests (exercise ECG, SPECT and stress 
echocardiography) are all affected adversely by LBBB as described in chapter 7 (Gibbons 
et al., 1997, DePuey et al., 1988), (Geleijnse et al., 2000). MSCT has been shown to have 
good diagnostic accuracy in LBBB, however in patients with intermediate pre-test 
probability of CAD, such as the population in our study, current guidelines suggest the use 
of a functional rather than anatomical imaging as first-line (Ghostine et al., 2006, 
Meijboom et al., 2007, Skinner et al., 2010). Due to these limitations and the consequent 
diagnostic uncertainty, many patients may end up undergoing ICA, which may indeed be 
unnecessary and exposes them to the risks of this invasive procedure. 
 
The limitations of current non-invasive imaging techniques for the diagnosis of CAD mean 
that the ideal non-invasive imaging technique has not yet been found for patients with 
LBBB. The improved diagnostic accuracy of DSCMR in this study is therefore 
encouraging and perhaps offers a potential solution to this clinical problem. 
 

 
DSCMR has been shown to have good diagnostic accuracy in patients with suspected 
CAD, with several studies reporting good sensitivity and specificity (Charoenpanichkit and 
Hundley, 2010). In one of the largest studies using DSCMR for detection of significant 
CAD, using cine imaging alone, Gebker et al. evaluated 455 patients and reported a 
sensitivity of 85% and a specificity of 82%, with an increase in sensitivity to 91% with the 
addition of first pass perfusion, at the cost of a decrease in specificity to 70% (Gebker et 
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al., 2008). The authors suggested that this was due to the fact that perfusion defects tend to 
occur before RWMAs and therefore may be caused by less significant CAD (figure 7-10).  
 
Figure 7-10. The ischaemic cascade and the consequences for diagnostic accuracy of 
non-invasive imaging techniques. 
 
 
The ischaemic cascade (top). Perfusion defects are the earliest sign of ischaemia caused 
by CAD, which eventually causes the clinical symptoms of angina. Wall motion 
abnormalities occur later on in the ischaemic process. This leads to consequences in the 
accuracy of diagnostic techniques, where techniques that identify perfusion defects have 
increased sensitivity at the cost of specificity, with the converse true for techniques reliant 
on wall motion (bottom). 
 
The difficulty in assessing RWMAs in patients with LBBB would explain the lower 
sensitivity seen in this study compared to others using DSCMR (in patients without 
LBBB). The reduced sensitivity of DSCMR cine imaging alone was also shown in a study 
by Paetsch et al, who reported a sensitivity of 78.2% and specificity of 87% (Paetsch et al., 
2006). The sensitivity and specificity for DSE in this study corresponds well to a study of 
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64 patients by Geleijnse et al., who reported sensitivity of 68% and specificity of 91% 
(Geleijnse et al., 2000). The number of false negatives may be due to the difficulties in 
knowing whether any abnormal septal motion seen is due simply to the presence of LBBB 
or rather is truly representative of significant CAD. The higher specificity of DSCMR cine 
imaging (reduced false positives) compared to DSE may be due to the increased spatial 
resolution and clearer endocardial blood pool definition, allowing easier and more accurate 
wall motion analysis. In this respect our results correspond fairly well to those of Nagel et 
al in patients without LBBB, who also proposed that the improved diagnostic accuracy 
using CMR cine imaging alone was due to the increased spatial resolution of CMR (Nagel 
et al., 1999).  
 

 
Given the reduced sensitivity of DSCMR due to the resting myocardial abnormalities in 
LBBB, I hypothesized that the addition of first-pass stress perfusion and LGE imaging 
would enhance the diagnostic accuracy of the CMR exam, which was proven to be correct. 
The incremental value of perfusion imaging in addition to wall motion analysis was shown 
in a study by Lubbers et al. in which the authors found that the addition of first pass 
perfusion imaging during dobutamine stress reduced the number of false positives. Indeed, 
in their study, all four patients that had an inducible wall motion abnormality with no 
perfusion defect had LBBB, giving some early evidence that this might be technique that 
could be used in this group of patients (Lubbers et al., 2008).  
 
The addition of first pass stress perfusion and LGE increased diagnostic accuracy 
markedly. Cine, perfusion and LGE imaging are 3 techniques that can each independently 
diagnose CAD, hence an examination combining the 3 gives greater diagnostic confidence. 
Of clinical importance is the improved performance of the comprehensive DSCMR exam 
in left-sided coronary disease, which poses particular difficulties in patients with LBBB. 
Sensitivity increased from 64.2% with DSE to 82.1% with comprehensive DSCMR. 
Speculatively, this may lead to some prognostic benefit in improved identification of 
patients who need invasive management. This has been shown in a general population of 
patients with suspected CAD (Bingham and Hachamovitch, 2011). Similarly to other 
studies, we have shown that a comprehensive CMR exam can be performed relatively 
safely in routine clinical practice (Bingham and Hachamovitch, 2011). 
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The additional value of LGE appears to be in its increased specificity/positive predictive 
value, although this may only apply to a cohort with typical anginal symptoms and an 
intermediate pre-test probability of CAD. An associated inducible perfusion defect along 
with the presence of LGE may indicate peri-infarct ischemia. In other groups of patients, 
such as those without anginal symptoms, this may not apply as the presence of LGE may 
be more indicative of a cardiomyopathy, especially if not in a typical coronary distribution, 
obviating the need for invasive angiography (Mahmod et al., 2012). The increase in 
sensitivity found by using the comprehensive examination is probably due to the strict 
criteria for a positive result, which mean that a patient must have either LGE (with or 
without a perfusion defect) or an inducible RWMA and a perfusion defect, meaning that 
the criteria are more strict. This combination lead to the overall improved diagnostic 
performance of the comprehensive DSCMR exam. 
 
Performing first pass perfusion at an intermediate dose of dobutamine appears to provide 
adequate diagnostic confidence for the assessment of inducible perfusion defects by direct 
comparison against ICA. Prior studies suggest that the majority of the increase in 
myocaUGLDOEORRGIORZDQGYDVRGLODWDWLRQFDXVHGE\GREXWDPLQHRFFXUVDWȝJNJPLQ
beyond this there is simply an increase in heart rate and contractility, which may make it 
more difficult to identify the presence of perfusion defects (al-Saadi et al., 2002, Bartunek 
et al., 1999, Severi et al., 1995). Furthermore, the false positive perfusion defects seen in 
SPECT are most often due to the fast heart rate at peak stress ± the rate of false positives 
reduces significantly in patients with LBBB when vasodilator stress is used rather than 
dobutamine (Iskandrian, 2006). 
 

 
Although this study is the first prospective evaluation of DSCMR in patients with LBBB 
using CMR, there are some limitations. Firstly, although all patients in our study were 
referred for ICA and this reduced post-test referral bias, the use of quantitative analysis of 
coronary stenoses as the gold standard was not ideal. The importance of the functional 
impact of coronary stenoses has been well established and it is known that visual 
assessment of angiographic stenoses is not optimal (Tonino et al., 2009). Results may have 
been different if DSCMR had been compared to a functional invasive test such as 
fractional flow reserve. In order to combat this limitation, stricter criteria than usually used 
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were used to define the presence of significant CAD (stenosis severity over 70% by QCA 
rather than 50%, which is most often used).  
 
Secondly, this study was also conducted in a single centre with high volumes of both CMR 
and angiography hence may be difficult to reproduce these results in lower volume centres.  
Thirdly, the number of patients in this study is relatively small. Further information could 
be gained by larger, multi-centre trials with the potential for obtaining prognostic 
information. 
 
Finally, additional echocardiographic techniques, which have been shown to improve 
diagnostic accuracy of DSE such as strain analysis, were not used (Badran et al., 2007). 
 


DSCMR is a feasible, safe non-invasive investigation for the exclusion of CAD in patients 
with LBBB that outperforms DSE. The addition of perfusion and LGE sequences to 
DSCMR cine imaging improves sensitivity, specificity and overall diagnostic accuracy. 
Comprehensive DSCMR provides a viable non-invasive functional investigation for with 
LBBB and suspected CAD and may overcome some of the disadvantages of DSE in this 
group. 
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8. Discussion 
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

The aim of this thesis was to demonstrate the clinical utility of CMR by demonstrating its 
potential ability to answer clinical dilemmas that have previously not been answered but 
might have clinical significance to patients. The main findings of this thesis were: 
 
x The two main advantages of CMR, namely its accuracy in measurement of left 
ventricular function, and its ability to characterise the presence of myocardial 
fibrosis using gadolinium contrast, provide incremental prognostic significance for 
prediction of adverse cardiovascular events when added to baseline clinical 
variables in a general cohort of patients. 
x In patients with a history of prior MI, the presence of fat within the infarct scar, 
known as lipomatous metaplasia, is a predictor of mortality and ventricular 
arrhythmias. 
x In patients being considered for implantable cardioverter-defibrillators, the 
combined use of a cardiac biomarker (NT-proBNP) and a marker of structural 
myocardial injury (LGE) prior to device implantation is able to further stratify risk 
into groups of patients who may or may not benefit from these devices. 
x In patients with mild left ventricular systolic impairment, characterisation of the 
myocardium using T1 mapping may help differentiate between those with early 
cardiomyopathy and those without. 
x In patients with LBBB and suspected CAD, dobutamine stress CMR has improved 
diagnostic accuracy compared to dobutamine stress echocardiography for the 
identification of significant coronary artery stenoses identified by invasive coronary 
angiography. 
 


As a relatively new technique, CMR has not yet been included as a mainstay in most 
clinical guidelines. Echocardiography and nuclear imaging remain the predominant non-
invasive imaging techniques in use, both in the UK and worldwide, mainly due to 
increased operator experience with these modalities, cost and the undoubted breadth and 
depth of evidence validating both techniques in various conditions. 
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For CMR to become more widely adopted, and perhaps even part of clinical guidelines, 
more evidence needs to be gathered showing that CMR can change clinical management 
and make a difference to patient prognosis, as well as potentially providing cost savings to 
clinical services. Harking back to Chapter 1, there is still a relative paucity of evidence in 
CMR to suggest that it has patient and societal outcome efficacy, and also diagnostic 
efficacy in some conditions. The studies in this thesis aim to add to the literature and 
provide further evidence of the efficacy of CMR. 
 
In Chapter 3 I demonstrated that CMR assessment of LVEF, strain and LGE provide 
additional prognostic information in addition to baseline clinical variables in a large 
unselected cohort of patients. While LGE is well-established as a clinical predictor (Parsai 
et al., 2012), the utility of strain assessment has not been as well-validated, with only one 
large study in asymptomatic patients (Choi et al., 2013). In this study, I extended the 
findings to patients with symptoms and those with reduced ejection fractions, and also 
showed the additional value of strain in combination with LGE and LVEF. These findings 
might suggest that there is a role for CMR in identifying patients who might have a worse 
prognosis than at first thought when echocardiography is used alone. 
 
The incremental prognostic utility of CMR was expanded on in Chapters 4 and 5. In 
Chapter 4, I showed for the first time, the prognostic significance of lipomatous metaplasia 
in patients with a prior history of MI. The ability to non-invasively identify LM is specific 
to CMR and CT, and so this may provide a new prognostic marker. CMR has the 
advantages of being able to be repeated without radiation exposure and the ability to 
provide functional information, perhaps making it a more favourable technique than CT. 
The suggestion that LM could provide a substrate for arrhythmias could also provide a new 
therapeutic target which could improve patient outcomes. 
 
In Chapter 5, I showed that CMR could be used, in combination with biomarkers, to 
predict death and defibrillator use in patients with ICDs. We know that many patients who 
meet the current criteria for ICD implantation never use their device, and conversely, many 
patients who would benefit from an ICD do not meet the current criteria for one. The use 
of CMR might help in clinical decision-making, potentially identifying a group at higher-
risk who might benefit from these devices and identifying a lower-risk group who might 
not need an ICD. This might lead on to societal benefits in cost savings, as well as 
avoiding potentially needless device implantation. 
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In Chapters 6 and 7, I explored the diagnostic utility of CMR in two areas that pose 
difficulties to clinicians. In Chapter 6, I showed that the use of the novel T1 mapping 
sequence might help differentiate between normal myocardial adaptation and early 
cardiomyopathy in patients with mildly reduced LVEF. The clinical implications of this 
finding are potentially very important. Early diagnosis of cardiomyopathy may allow early 
introduction of disease-modifying therapies. The ability to reassure patients by diagnosing 
DWKOHWH¶VKHDUWZRXOGSURYLGHKXJHSDWLHQWEHQHILW3URIHVVLRQDODWKOHWHVPLJKWDOVREHDEOH
to be reassured and continue competitive sport. 
 
The final study, in Chapter 7, utilised dobutamine stress CMR to potentially offer another 
solution to another clinical problem, namely the diagnosis of significant CAD in patients 
with LBBB. The main benefit of any stress test is the ability to rule out prognostically 
significant CAD, avoiding the need for invasive coronary angiography. The presence of 
LBBB tends to mitigate this, exposing patients to the risks of an invasive procedure. The 
enhanced diagnostic accuracy using DSCMR might allow improved selection of patients 
for invasive angiography. Furthermore, a patient with negative DSCMR study has an 
extremely low chance of having an adverse event (<1%/year) (Lipinski et al., 2013). If this 
finding was extrapolated to patients with LBBB, there would be likely to be significant 
benefits. 
 


In addition to the limitations relevant to each individual study described in each chapter, 
there are a number of limitations relevant to the thesis as a whole. The cross-sectional 
design of each study meant that I was unable to test further hypotheses about progression 
of conditions, with imaging only being carried out at one time point. This is particularly 
relevant to the studies in Chapters 3 (overall prognosis using CMR) and 4 (lipomatous 
metaplasia), where progression over time would have given further information on 
prognosis. 
 
A second limitation is that a number of the scans in these studies were analysed 
retrospectively, as they occurred before conception of the thesis. Nevertheless, the majority 
of patients were prospectively analysed, and events were prospectively recorded, reducing 
the potential limitations caused by retrospective analysis. 
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Finally, as CMR is not a routine standard of care in most conditions at present, the studies 
may have been subject to referral bias. This was hopefully minimised by studying 
consecutive patients, however the cohorts may not be completely representative of the 
general population as it may have included those in whom their clinician was more 
concerned than usual. 
 


These studies hopefully demonstrate the potential power of CMR and its ability to impact 
on clinical decision-making. Generally, larger, multi-centre studies are required to 
demonstrate the prognostic impact of CMR and its cost-effectiveness in order for it to 
become more widely adopted and be incorporated into clinical guidelines. 
 
Regarding the specific studies in this thesis, there are a number of further studies that could 
be performed to advance our knowledge: 
 
x A multi-centre study could be performed evaluating the role of multi-parametric 
CMR in assessing prognosis in patients referred for cardiological opinion compared 
to the routine standard of care (e.g. using echocardiography). 
x Serial CMR examinations could be performed in patients post-MI to clarify if the 
development of lipomatous metaplasia is indeed a condition that develops with 
time, and to identify the processes that influence its development. This could lead 
to identification of therapeutic targets to reduce adverse outcomes. 
x A large multi-centre study could be performed to assess the impact of a CMR-
guided strategy for ICD implantation in patients on cardiovascular outcome. This 
could be particularly relevant in patients who do not meet the current guidelines for 
ICD implantation. 
x The prognostic value of T1 mapping has yet to be assessed in a large cohort. This 
novel parameter could be a new biomarker and lead to new therapeutic directions. 
x The diagnostic accuracy of stress CMR has yet to be tested against the invasive 
gold-standard (fractional flow reserve) for the diagnosis of significant coronary 
artery disease. A large multi-centre study using adenosine stress CMR is currently 
recruiting patients with this gold-standard, however dobutamine stress CMR has 
not been evaluated in this way as yet (Hussain et al., 2012). The use of quantitative 
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wall motion and perfusion analysis using CMR could also improve its accuracy in 
LBBB. 
 



Cardiovascular magnetic resonance holds huge promise as a non-invasive imaging 
technique for a variety of conditions. The studies in this thesis demonstrate its diagnostic 
and prognostic utility, and add further evidence of the clinical utility of cardiovascular 
magnetic resonance. 
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Imaging using Analysis of MRI, CT and 
Echocardiography. 
REC reference: 14/WS/1052 
IRAS project ID: 146085 
 
Thank you for your letter of 4 August 2014 responding to the Committee¶s request for further 
information on the above research and submitting revised documentation. 
 
The further information has been considered on behalf of the Committee by the Alternate 
Vice-Chair.  
 
We plan to publish your research summary wording for the above study on the HRA website, 
together with your contact details. Publication will be no earlier than three months from the date 
of this opinion letter.  Should you wish to provide a substitute contact point, require further 
information, or wish to make a request to postpone publication, please contact the REC 
Manager, Mrs Liz Jamieson, wosrec3@ggc.scot.nhs.uk. 
 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above 
research on the basis described in the application form, protocol and supporting documentation 
as revised, subject to the conditions specified below. 
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  Conditions of the favourable opinion 
 
The favourable opinion is subject to the following conditions being met prior to the start of the 
study. 
 
Management permission or approval must be obtained from each host organisation prior to the 
start of the study at the site concerned. 
 
Management permission ("R&D approval") should be sought from all NHS organisations involved 
in the study in accordance with NHS research governance arrangements. 
 
Guidance on applying for NHS permission for research is available in the Integrated Research 
Application System or at http://www.rdforum.nhs.uk.   
 
Where a NHS organisation¶s role in the study is limited to identifying and referring potential 
participants to research sites ("participant identification centre"), guidance should be sought from 
the R&D office on the information it requires to give permission for this activity. 
 
For non-NHS sites, site management permission should be obtained in accordance with the 
procedures of the relevant host organisation.  
 
Sponsors are not required to notify the Committee of approvals from host organisations 
 
Registration of Clinical Trials 
 
All clinical trials (defined as the first four categories on the IRAS filter page) must be registered on 
a publically accessible database within 6 weeks of recruitment of the first participant (for medical 
device studies, within the timeline determined by the current registration and publication trees).   
 
There is no requirement to separately notify the REC but you should do so at the earliest 
opportunity e.g when submitting an amendment.  We will audit the registration details as part of 
the annual progress reporting process. 
 
To ensure transparency in research, we strongly recommend that all research is registered but for 
non clinical trials this is not currently mandatory. 
 
If a sponsor wishes to contest the need for registration they should contact Catherine Blewett 
(catherineblewett@nhs.net), the HRA does not, however, expect exceptions to be made. 
Guidance on where to register is provided within IRAS.  
 
It is the responsibility of the sponsor to ensure that all the conditions are complied with 
before the start of the study or its initiation at a particular site (as applicable). 
 
Ethical review of research sites 
 
NHS sites 
 
The favourable opinion applies to all NHS sites taking part in the study, subject to management 
permission being obtained from the NHS/HSC R&D office prior to the start of the study (see 
"Conditions of the favourable opinion" below). 
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Yours sincerely 
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Summary 
We plan to undertake analysis of scans carried out for clinical reasons in the Golden 
Jubilee from 2008 to 2012. 
 
Since 2012 there has been a cardiovascular imaging database, however consent for this 
does not cover scans acquired prior to this. 
 
During each scan there is a multitude of data acquired which is additional to that required 
for clinical purposes and therefore not analysed in detail. Over 2000 scans have been done 
in this period and so there is a lot of data that could provide useful information but has not 
yet been studied to show its utility such as: 
 
Regional dysfunction in patients using MRI 
Prognosis of scarring in patients undergoing ICD implantation combined with other 
markers 
Utility of stress MRI 
Arterial stiffness measured by MRI and CT 
Fat seen using MRI and CT in patients with prior myocardial infarction 
Inflammation and scarring in patients with cardiomyopathies 
Microscopic and diffuse fibrosis seen using MRI 
 
We wish to analyse prior scans anonymously for these parameters. We plan to search the 
radiology system (RIS) to identify patients (via CHI number) who have had a CT or MRI, 
and then analyse scans in the Golden Jubilee using the in-hospital workstations. If possible 
we would like to use computerised record linkage (e.g. Clinical Portal, SCI store, Cathi) to 
check for patient deaths/adverse events. 
 
This analysis will not require any further input from the patient (we will not be calling 
them or their family up), and will not impact on their care in anyway (all scans have been 
reported and analysed by members of the clinical team). 
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1.  Background 
The Golden Jubilee National Hospital, as the West of Scotland Regional Heart and Lung 
Centre, is in a unique position. Every year, thousands of scans are undertaken, specifically 
cardiac MRI scans. These are requested for clinical purposes to provide optimal patient 
care. 
As an academic centre, we are also at the forefront of new imaging techniques. Because of 
this, many of our imaging protocols and studies have parts that are not yet well validated 
for clinical purposes. Both these sequences, and more routine ones that we do report for 
clinical reasons, could provide a wealth of information which could be useful in patient 
care but we are not yet aware of their significance. 
Since 2011 there has been a cardiovascular imaging database in place, which allows for the 
prospective consent of patients undergoing clinically indicated scans for research analysis 
purposes. Of course, this does not cover the analysis of scans prior to this date, of which 
there are several hundred. We believe that not utilising and investigating this data would 
not only be a missed opportunity, but may also mean missing out on information which 
could help us (as clinicians) to provide optimal care to our patients.  
 
2. Aim 
To examine the potential clinical utility of cardiovascular MRI using the scans undertaken 
at the Golden Jubilee National Hospital since 2008. 
 
3.  Hypothesis 
 We hypothesise that advanced retrospective analysis of cardiac structure and 
function on MRI, with linkage to subsequent clinical outcomes will identify potential 
prognostic features that as yet are undefined.  
 
4.  Design and Methods  
 
Personnel 
All analysis will be undertaken by Dr Ify Mordi and Dr Niko Tzemos. 
Methods 
We wish to undertake analysis of MRI scans carried out since 2008. Using the radiology 
database, we will be able to identify (by name and CHI number) all patients who had 
undergone MRI scans. We will collate these details onto a database kept on the secure 
hospital intranet. 
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We will then recall these scans from the hospital MRI archive and load them onto the 
hospital MRI workstations, where we will undertake further analysis. This will include: 
 
Measurement of cardiac structure and function using both ejection fraction (from cine 
imaging) and strain (used tagged MRI) 
Measurement of areas of fibrosis (using both late gadolinium enhancement imaging and T1 
mapping) 
Arterial stiffness assessment (using phase contrast imaging) 
Measurement of areas of myocardial injury (using T2 weighted imaging).  
 
The results of this analysis will also be kept on this database. 
 
Furthermore, we wish to correlate the results of our analysis with outcome. Specifically, 
we will look at mortality (all cause and cardiovascular), hospital admission for 
cardiovascular reasons (e.g. heart failure, MI), coronary revascularisation, stroke and 
ventricular arrhythmias. To do this, we would like to use the patient details (CHI number) 
to search our computer systems (Clinical Portal, SCI Store etc.) to search for these events. 
The patients themselves will not be contacted and will not be required to partake in any 
further testing. We will not include any patients who have not consented to take part in the 
database. 
 
:HKRSHWKDWEHFDXVHZHDUHORRNLQJVSHFLILFDOO\DWWKHVHSDUDPHWHUVUDWKHUWKDQ³UH-
UHSRUWLQJ´WKHVWXGLHVWKLVZRXOGFDXVHQRIXUWKHULQFRQYHQLHQFHWRSDWLHQWVDQGDOVR
would reduce the possibility of any new clinically significant findings being discovered. 
 
We have a large cohort of patients. A recent paper by Gulati et al (JAMA 2013) examined 
the association of fibrosis measured by late gadolinium enhancement and adverse 
cardiovascular outcome in 472 patients with dilated cardiomyopathy and found that it 
provided independent prognostic information. The incidence of measured fibrosis was 
30%. This is one of the largest studies to date examining this, and provides a good guide 
for our analysis. Our number of patients is at least as extensive, and we expect should 
provide us with good results.  
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Data sharing 
Identifiable data will not be shared beyond the aforementioned staff (Drs Mordi and 
Tzemos) within the Golden Jubilee.  
All identifiable data, including the CHI number, are restricted to NHS computers in the 
Golden Jubilee National Hospital. Data which are moved from this environment will be 
de-identified. All identifiable data will only be kept for a maximum of 24 months after 
analysis to allow time for publication and dissemination of studies conducted. 
New or incidental findings 
A main concern regarding this type of analysis is of course the discovery of incidental 
findings on scans which may not have been originally noted. Despite this, all of scans will 
have been reported initially by the imaging experts in the Golden Jubilee at the time of 
scanning and the reports (and relevant actions, if any) communicated to the physician 
responsible for the patient. 
There is however the possibility that there may be a new discovery. In this case, we will 
discuss with the result with the clinician who initially requested the scan, and following 
WKLVDUUDQJHDSSURSULDWHFRUUHVSRQGHQFHZLWKWKHSDWLHQW¶V*3QRUPDOO\E\WKHUHTXHVWLQJ
clinician). The patient will not be directly contacted. 
Protection of Patient Identity  
All data will be stored on password-accessible NHS computers. Any data to be moved 
outside of an NHS network can only be done after anonymisation.  
Arrangements for Governance 
Governance 
The Database Management Group (DMG) is directly responsible to the R&D Steering 
Group, the Caldicott Guardian of the National Waiting Times Board and the West of 
Scotland Research Ethics Committee. The DMG will generate a quarterly report to list the 
Project Requests received and approved, number of patients recruited, and also mention 
feedback on active projects as appropriate. This report will be submitted to the R&D 
Steering Group and to the NHS West Cardiovascular and Metabolic Specialty Group. The 
DMG will provide an annual report to the Research Ethics Committee which will 
summarise the information in quarterly reports. 
Patient representation 
The design of this project has been discussed with patients who have been treated in our 
hospital. In addition, the Lay Member of the R&D Steering Group will have access to the 
project information through this group.
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